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The menopause is associated with many symptoms, but 
surTeys have shown that bot flushes, insomnia, and 
psychological symptoms are especially common in the peri-
menopausal years. Menopausal symptoms are often treated 
by hormone replacement therapy beoause the menopause is 
associated with changeing hormone levels, but the value 
of treatment has not been conclusively proven. 
The aim of my study was to determine the effect of 
oestrogen treatment on sleep, mood, anxiety, and hot 
flushes in perimenopausal women. Patients in the study 
were women aged 45-55, with at least three months 
amenorrhoea and symptoms of insomnia, depression, anxiety, 
and hot flushes. The study was 4 ouble blind and controlled, 
with half of the patients receiving six weeks placebo 
followed by eight weeks piperazine oestrone sulphate 
3 m·g/day, and half remaining on placebo throughout the 
study. Sleep was recorded electrophysiologically on one 
night per week, the first two nights being for adaptation 
purposes only, the next four in the baseline placebo 
period, the next four in the first treatment month, and 
the remaining four in the second treatment month. Patients 
rated their sleep quality, mood, anxiety levels, and hot 
flush :severity daily us ing visual analogue scales, and 
recorded their daily hot flush count. Hamilton observer 
rating scales of depression and anxiety were completed at 
intervals during the study. 
ii. 
There were 17 patients in each group1 and the two 
groups were similar in terms of age and duration of 
amenorrhoea. Electropbfaiologioal sleep recording showed 
that during the first month of active treatment, the aaount 
of wakefulness interrupting periods of sleep decreased aore 
in the oestrone group than the placebo group. In the 
second treatment month, the oestrone group showed a further 
decrease in the aaount of intenening wakefulness, a decrease 
in the frequency of waking, and an increase in their aaount 
of REM sleep, all of which were significant when compared 
with the changes shown by the placebo group. The lea• 
sensitive visual analogue soales failed to differentiate 
between the groups. Koo4 and anxiety improved, aDd the 
number and severity of hot flushes decreased to a siailar 
extent in the two groups. 
Six patients in each group attended on two extra nights, 
when blood samples were taken at 20 min intervals while 
recording sleep to investigate their nocturnal plasma hormone 
levels. In all oases, plasma oestrone and oestradiol con-
centrations fluctuated rapidly and widely, but the mean 
levels of both hormones ware low on placebo. The four 
patients studied after four weeks of oestrogen treatment 
showed an increase in their mean oestrone levels, but only 
two bad higher mean oestradiol levels. Prolactin secretion 
increased after sleep onset in all cases, and oestrogen 
treatment bad no consistent effect on prolactin secretion. 
Free and total plasma tryptophan levels were measured in 
three patients on placebo, and in each case a highly signi-
ficant correlation was found between total plasma oestrogen 




It ia impossible to carr.y out sleep research which 
involves the recording of hundreds of nights unaided, and 
I am grateful to m:r assistant, Krs. Mary Cherry Gray, whose 
oheertulnesa and good nature contributed so Dl\loh to the 
auocess of the project, and to the friends and colleagues 
who have helped ••• Dr. Vlasta B'f-ezinovt is espeoiall¥ 
to be thanked for her advice on computer programming and 
statistics, ·and Prof. Ian Oswald for his encouragement and 
advice. 
Oestrogen and tryptophan assays were carried out by 
Dr. Mansel Aylward and Mr. Jettrey Maddock at Sim.bec 
I.&bora,toriea, Merthyr Tydtil, and prolactin asaaya by 
Drs. Alan McNeillY and ·Michael Thorner at st. Bartholomew's 
Hospital, London, and I am grateful to them and to their 
technicians. 
Mrs. Angela Waters and her colleagues in the Psychiatry 
Dept. Library have helped .m.e greatly in my search through 
the literature, and the manuscript was typed with speed 
and ettioiency by :Mrs. R1 ta Keane. 
I must also thank rq husband, whose unfailing support 
and understanding made this work possible. 
This work was carried out while I was employed as 
Abbott Research Fellow in the Dept. of Psych1atr.r, Edinburgh 
University, and I am grateful to A'bbottlaboratories tor 
their support. 





List ot Tables vi 
List ot Figure• ix 
Intrq4uotios ap4 Rev111 of tht L1ttratQrt 1 
Introduction 1 
Historical Review 2 
Physiology 10 
Social Problema ot Middle Age 22 
Attitudes and Caltural Influences 24 
EPidemiology of Kenopauaal Symptoms 25 
Insomnia 32 
Hormones and Sleep 35 
Psyohologioal Symptoms 42 
Vasomotor Symptoms 49 
Treatment ot Menopausal Symptoms 52 
(a) Psychotherapy 55 
(b) T.ranquillisers and Antidepressants 56 
( o) Hormone Therapy 58 
Subjects Materials and Methods 69 
Neuroendocrine Studies 82 
Results 86 
Patients 86 
Subjective Sleep Quality 87 
Electropbysiologioal Recording of Sleep 87 
(a) Sleep La tenoy 87 
(b) Sleep Duration 90 
( o) Intervening Wakefulness 91 
(d) Arousals to Wakefulness 96 
. -
< • 
OONTENTS oon td. !!!&!. 
(e) Stage 1 Sleep 100 
(f) Stage 2 Sleep 103 
(g) Slow Wave Sleep (Stages 3 a 4) 106 
(h) RDl Sleep 107 
(1) Rlld Latency 108 
Mood 109 
Aaxiet1 113 
Bot llushea 117 
Jeuroendoorine St\14iea 122 
Sleep Results 123 
Oestrogen Levels - oestrone 125 
- oestra4io~ 128 





Psychological Syaptoma 164 
Hot lluahes 172 







I. Hamilton Rating Scales ot Depression and 
Anxiety 224 
II. Conversion Factors S.I. to Traditional Units 229 
III. Reprints of Published Papers 230 
v i , 
LIST OJ' WLES 
Pase 
!ABLI la Xeaa plasma oestrone aad oestradiol levels 
in poa~enopauaal woaea - review of the literature. 16 
!ABLE 21 Results of epidemiological surveys of 
ayaptoms of pertmenopausal women in the general 
population (% reporting each s~tam). 27 
TABLE )a Duration of amenorrhoea (years) of patients 
in the oestrone and placebo gr~pa. 
TABLE 41 Sleep latency (min) in the oestrone an4 
placebo groupe in the baseline period, first 
87 
treataent month, and aeoond treataent month. 89 
TABLE 51 Sleep duration (min) 1n the oes trone and 
placebo groups in the baseline period, first 
treatment month, and second treatment month. 91 
TABLE 6t Intervening wakef\llnesa (min) in the whole 
night 1n the oestrone and placebo groupe in the 
baseline period, first treatment. month, and 
second treatment month. 
TABLE 7a Intervening waketulneas (min) 1n the first 
six hours of sleep in the oestrone group and the 
placebo group in the baseline period, firat 
92 
treatment month, and second treatment month. 95 
TABLE Sa The number of arousals to wakefulness in 
the oestrone and placebo groups in the three 
periods of the study. 97 
TABLE 9• The number of arousals to wakefulness in 
the first six hours of sleep in the oestrone and 
placebo groups in the three periods of the studJ• 100 
TABLE lOa The amount of stage l sleep (min) in the 
whole night and the first six hours of sleep in 
the oestrone and placebo groups in the three 
periods of the study. 101 
LIST OF TAB_LES contd. Page 
TABLE lla The number of shifts to stage 1 sleep in 
the whole night and the first six hours of sleep 
in the oestrone ana placebo groups 1n the three 
period~ of the siud7. lOl 
TABLE 121 The amount of stage 2 sleep (min) in the 
whole night and the first six hours o! sleep in 
the oestrone and placebo groups in the three 
periods of the stu47• 104 
TABLB 131 !he number of shifts to stage 2 sleep in 
the whole night and the first six hours of sleep 
in the oestrone and placebo groups in the three 
periods of the s~dy. 105 
TABLE 141 !he amount of slow wave sleep {llin) in the 
whole night and the first six hours of sleep in 
the oestrone and placebo groups in the three 
periods of the stud7. 106 
TABLE 151 !he amount of RDI sleep (min) in the -whole 
night and first six hours o! sleep in the 
oestrone and placebo groups in the three periods 
of the atuay. 108 
TABLE 161 REM onset latency (min) in the oestrone and 
placebo groups in the three periods of the study. 108 
TABLE 171 Age and duration of amenorrhoea of patients 
in the neuroendocrine study. 
TABLE 181 Sleep onset latency, sleep duration, and 
the amount of eaoh sleep stage (min) on the two 
12) 
blood nights and the night preceding each. 124 
TABLE 19a Mean noo~na1 plasma oestrone concen-
trations (pmo~l) ! standard error of the mean. 127 
TABLE 20s Mean nocturnal plasma oestradiol concen-
trations (pmo~l) ! standard error of the mean. 130 
TABLE 211 Mean oestroneaoestradiol ratios. 134 
v i :.i ·. 
J IST Of TABLES contd. Past 
TABLE 221 Mean nocturnal plasma prolactin concen-
trations (mlD/l) % standard error of the mean. 1l5 
fABLE 2)1 Peak noc'turnal plaua prolactin 
concentrations (miU/1) 138 
!ABLE 241 Total plasma tr.yptopball con centra tiona 
(Jlllol/1) % s'tandard error of the mean in three 
periods of the night. . 147 
TABL! 251 Mean free plasma t.r,yptophan concentration• 
(paol/1) t etandard error of the mean in three 
period e ot the night. 14 7 
TABLE 261 !rhe relationship between free plasma 
tr,rptopban oonoentrationa and plasma oestrQgen 
and p~laotin oonoentrationa. 
TABLE 271 The rela tionah1p between ·~ tree plaaa 






LIST QF FIGUR~ 
PIG. la Soh..atio representation of the obangea in 
aerwa Iii, PSH, progesterone, and oestradiol 
during the normal menstrual cycle in woaen. 
J'IG. 2a lrequency of complaints of insomnia in 
pertmenopausal women. 
J'IG. 3• The average annual incidence of onset of 
mental illness in women. 
PIG. 4t The Kupperman menopausal index. 
PIG. 5t The position of eleotrodea tor eleotro-
p~s1olog1oal reoording of sleep. 
FIG. 6a Sleep reoord during wakefulness. 
FIG. 7 a Sleep record ahowlq s'tage 1 sleep 
(drowaineaa). 
PIG. 81 Sleep record during stage 2 sleep. 
FIG. 9t Sleep record duriz).g stage 3 sleep. 
FIG. lOa Sleep record during stage 4 sleep. 
FIG. lla Sleep record during RIM sleep. 
FIG. l2a Visual analogue rating soale of mood. 
FIG. 131 Visual analoBUe scale of sleep quality 
results expressed as the weekly mean difference 
in millimetres from the mean baseline score in 
the two groups. 
FIG. 141 Mean OUDl\llative intervening wakefulness in 
the first six hours of sleep in the oestrone and 















treatment month, and second treatment month. 94 
FIG. 151 Owmulative mean number of awakenings in the 
first six hours of sleep in the oestrone and 
placebo groups in the baseline period, first 
treatment month, and second treatment month. 99 
·LisT OF FIGURE§ contd. 
FIG. 161 Xean Hamilton depreaeion rating soale 
eooree in the oestrone and plaoebo group•• 
FIG. 171 Visual analogue aoale of mood results 
expressed as the weekl7 mean 41f'f'erenoe in 
millimetres from the baseline mean soore in the 
oestrone and placebo gr~pa. 
FIG. 181 Mean Hamilton anxiet7 rating soale soorea 
of the oestrone and plaoebo groups. 
FIG. 191 Visual analogue soale of anxiev resul te 
expressed as mean weekl7 difference in JliU1-
metrea from the baae1~ne mean soore in the 
oestrone and placebo groups. 
FIG. 201 Mean weeklJ hot flush count of the ·oestrone 
and placebo groupe. 
FIG. 211 Bot flush severity rating expreseed ae 
mean week]¥ difference in m1111metrea from the 
baseline mean score in the oestrone and placebo 
groups. 
FIG. 221 Nocturnal plasma oestrone levels (pmol/1) 
in Oaae 10 on placebo (a1ght l) and after one 







sulphate 3 mg/da7 (Night 2). 126 
FIG. 23a Jooturnal plasma oestradiol concentrations 
(pmol/1) in Case 10 on placebo (Night 1) and 
after one month of treatment with piperazine 
· oestrone sulphate 3 mg/d&l' (Night 2). 129 
FIG. 241 The relationship between the duration of 
amenorrhoea and the mean plasma oestradiol 
concentration on the first night of the study. 131 
FIG. 25: Nocturnal plasma. prolactin concentrations 
{mi0/1) in Case 7 on placebo (Night 1) and after 
one month of treatment with piperazine oestrone 
sulphate 3 mg/day {Night 2). 137 
LIS± OF FIGQRi§ contd. 
FIG. 261 Hourly mean plasma prolactin concentrations 
(mlU/1) in relation to sleep onset in the 
placebo group. 
J'IG. 271 Hou.rl3 mean plasma prolactin concentrations 
(ai0/1) in relation to sleep onset in the 
oC~strone group. 
FIG. 281 Nocturnal plasma prolactin concentrations 
(miU/1) in Case 10 on placebo (Night l) an4 after 




sulphate l ms/d~ (lfisht 2). 142 
JIG. 291 Nocturnal tree plaeu t17ptopban conoen-
tra tiona ywol/1) in Case 1 on Night 2 (on 
plaoebc) and in Cases 4 and 5 on Ript 1 · 
(on plaoebo). 145 
J'IG. )01 Roo~l to~l plasma tr.yptopban ooncen• 
tration• (Juaol/l) in Case 1 on Nisht 2 (on 
placebo) and in oases 4 and 5 on Night 1 
(on placebo). 146 
FIG. 311 Total plasma oestrogen conoentrationa 
(pmol/1) and ~ tree plasma tryptophan in case 1 
during Night 2 (on placebo). 149 
FIG. 321 Total plasma oestrogen concentrations 
(pmol/1) and ~ free plasma tryptophan in case 4 
during Night 1 (on placebo). 150 
FIG. 331 Total plasma oestrogen concentrations 
(pmol/l) and ~ tree plasma tryptophan in Case 5 
during Night 1 (on placebo). 151 
l. 
ll!TROW CTION 
The menopause is defined aa the ttae of the last 
menstrual period, but in current usage it is synonymous 
with the climacterium, the ttae when reproductive function 
declines aDd is lost. It is a normal, physiological 
event of middle age for women, yet for many it is a source 
of anxiet7, as they fear it will bring physical or mental 
upset, or that they will age rapidly after it. Most women 
experience some symptoms around the t~e of the menopause, 
and even minor sfJAPtOJIS such as hot flushes can be tiresome 
and U&baraasins, so it is not surprising that many women 
request hormone replacement therapy, in the hope that it · 
will not only relieve their symptoms but also prolong their 
youth and attractiveness. 
Oestrogen treataent ia not without risk, as Coope et al 
(1975) have ahon that it can affect blood clotting mechan-
isms in pos~enopausal women, and ~ increase the risk of 
·thromboembolic disease, and Smith et al (1975) and Ziel 
and Finkle (1975) have reported that it may increase the 
risk of endometrial carcinoma, so this treatment should not 
be used indiacr1m1natel1• We believe . that oestrogen will 
relieve atrophic vaginitis and osteoporosis, but other 
than this little is known about the effect of oeatrogens 
on the symptoms of the menopause. Indeed, little is known 
about the symptoms of the menopause, and perusal of the 
literature will show that almost every symptom, physical 
or mental, which can be experienced by a middle aged woman 
haa at some time been attributed to the menopause. 
HISTORY 
The view that the female reproductive organa are 
associated with mental disorder dates back to the second 
oenturr A.D., when the Oappadocian physician, Are~eus, 
clailled that b7steria was due to wandering of the woab in 
th~ body. The menopause was known. in those days, and 
had been described by Soranus in his textbook of gynaecology 
written around 100 AD, but was not considered to be a 
cause of either pb7sioal or aental ill health. Of course, 
life expectancy at that tille was abort, and since few 
women can baTe lived to experience the menopause, it ia 
unlikely to have been a ma~ or prob lea. 
The first knownraference in the medical literature to 
a aenopausal complaint is the report by Willie in lo84 of 
a woman of 50 who developed •convulsions in the etoaaoh' 
aix months after the menopauae. Little interest was taken 
in the menopause until the 19th oentur,y when Tilt (1858) 
published a treatise on the change of life in which he 
reported that 90~ of women experienced •nervous irritability' 
during the menopause. Tilt also reported that 51% 
experienced hot flushes and 41% headaches, and he continued 
to list 135 less common symptoms, including such unlikely 
ones aa blind piles, boils in the seat, baemoptysis, aortic 
pulsation, ha.morrhage from the ears, and temporar,y deafness. 
Hegar (1878) added hyperaesthesia, prickling and burning 
sensations, uncertain gait, muscular weakness, insomnia, 
migraine and hallucinations, and Borner (188o) added 
personality change and quick temper to the growing list of 
'· 
3. 
menopausal symptoms. Later authors added to this growing 
catalogue of psychological ayaptou. Eyaer (1927) added 
scandal-JIOngering, untrutht1.\l.D.eaa, and forgettulneaa and 
Pappenheila (1930) addfd explosiTe affect, nightaarea, 
hypochondria, fear of madneaa, pyromania, and kleptomania. 
These authors all gave ane·cdotal accounts of their experience 
without att .. pting to separate cause and effect, and 1n 
1933 a survey was comaissioned by the Medical Women•• 
Federation to atteapt to determine which symptoms are 
comaonl7 associated with the menopause. This showed that 
hot flushea and nervous instability are indeed co .. on 
coaplainta aft•r the menopause, but neither thia nor sub-
sequent atudiea have d .. onatrated the existence of a meno-
pausal syndroae, nor shown which •1l1Ptoaa are caused by 
the aenopauae. 
The view that the menopause might be related to mental 
illness was first expresaed by Bri.re de Boiaaont (1842) 
when he obaerYed that the menopause waa often followed by 
aelanoholia~ Thia relationship was investigated by 
Merson (1876), who found a high percentage of new admissions 
to a psychiatric hospital showed a temporal relationship 
to the menopause, since in 69 oases the illness deTeloped 
just before, and 147 oases just after,oomplete cessation 
of menstruation. He described a variet,J of syndromes, 
including simple depression with nervous irritability, 
more severe depression with intellectual disturbance, and 
depression with hallucinations, depressive delusions, and 
delusions of suspicion or persecution. Merson did not 
4· 
blaae the menopause as the sole cause of psychotic illness, 
but reported that many women bad additional prcbl .. s such 
as bereaTement, physical illness, unhappy marriages, or 
financial problems which bad contributed to their illness. 
Other authors held conflicting Tiewa on the relationship 
between the menopause and mental illnese. Tilt (1858) 
co~aidered that the menopause might cure insanitJ, while 
Mau4aley (1867) stated that it caused a specific psychosis 
and Buclcbala (l888) and Cu.rrier (1898) denied that it ba4 
aUT role at all in the causation of .. mental illneaa. The 
aost widel-3 held view, however, was that expressed b7 von 
~fft-m»ing (1877), that the menopause could cause a wide 
variev of minor psJchiatric aymptou, and waa at tizaea a 
contributory cause of psychosis. He considered that 
sexual delusions and ideas of influence were typical ot 
psJohotic illnesses around the ttae ot the menopause. 
The relationship between involutional melancholia and 
the menopause baa also ~sed controvers7. Involutional 
melancholia ia a depressive illness occurring in the 
involutional period in both sexes, usually in people with 
a rigid, introverted, and obsessional premorbid personality, 
and its clinical tea tures include marked anxiety and 
agitation, hypochondriasis with bizarre somatic delusions, 
paranoid ideas, nihiliatic delusions, and feelings of 
unrealit.y. In 1896 Kraepelin classified it aa a discrete 
categor.y of functional psychosis because depression was 
unduly common in middle age, bad a prolonged course, and 
frequently terminated in dementia. He was criticised b7 
5· 
Dreyfus (1907) who re-exaaiD.ed Kraepelin' s aaterial aD4 
disagreed wi~h this cla•eitica~on, and in 1913 Xraepelin 
reversed his view that involutional melancholia was a 
discrete enti'Q', part}¥ because of this criticisa and 
partl-7 beoauae he bad realised that the inoreaae in 
depression in ~dle age is onl1 the start of a progreeaive 
increase in depreaaion whioh lasted into senescence, and 
which could be caused by dementia. Since then, opinions 
have been divided about the place of involutional melan-
cholia. Palaer and Sherman (1938) anc1 Kalaamd et al (1949) 
co~Q&red the symp~oas of a group of patients diagnosed aa 
involutional melancholia witn typical s~to .. of aaaio-
depresaive illness in a younger population, and concluded 
tbat involutional melancholia does exist aa a discrete 
entit7. Since it occurs in middle age, it was considered 
likelJ that involutional melancholia was related to the 
menopause in women. larrar and l'ranka (1931) found that 
the menopause and the onset of psychosis ocaurred within 
one year of each other in 60~ of t~eir oases, and Heaphill 
and Reiss (1940) even published tour endocrine patterns in 
involutional melancholia. However, more recent research 
has shown that it is unlikely to be due to hormonal factors, 
as Nedbailova (1962) showed that oestrogen secretion was 
normal in 14 out of 18 women with involutional melancholia, 
and Nikula-Baumann (1971) could find no difference in 
either oestrogen or gonadotrophin levels between cases 
and controls. Recent research bas shown that involutional 
melancholia is now rarely diagnosed. Tait et al (1957) 
6. 
found no evidence of the t,ypioal symptoms of involutional 
melancholia in 29 depressives admitted to hospital tor 
the first ttae between the ages of 40 and 55t and Rosenthal 
(1968) also noted the rari v of this syndrome and suggested 
that it J1J1q be due to early and effective treatment with 
antidepressants. Involutional melancholia is not now 
considered to be a specific illneaa, but ~erelf to be a 
depressive ps7ohosis such as occurs at all stages of lite, 
coloured bJ the lite events of middle age. 
The theor1 that menopausal s7JD.Ptoms are due to ovarian 
deticienct dates baok to the nineteenth centurJ, when 
oophorecto_, was used as a trea~ent tor n~sis and 
dJamenorrhoea. Hegar (1878) reported that oophorect~ 
is identical to the menopause and produces the eaae symptoms, 
and when treatment bJ organotherapJ was introduced b7 
Brown-s,quard in 1889 it seemed logical to treat menopausal 
symptoms with ovarian extract. Brown-Sequard (1889) 
claimed that injections of testiou.lar extract bad re-
juvenated h1Dl and in a later paper (1893) claimed that 
ovarian extract had a s1milar effect on women, and that 
his colleagu.e, Augusta Brown, had treated 60 old women 
with good effect. This treatment was heralded bJ the laJ 
press as the 'elixir of youth', a title which is used at 
times tor hormone replaceaent therapy in the l~ press to 
the present day. However, in the medioal world this 
treatment was leas popular, with some physicians claiming 
good results and others no effect at all. This may have 
been due to the varying potency of the treatments used, 
7-
since some used minced fresh ovaries, some desaioa~ed 
ovarian table~•• and sou extrac"s in water and in 
glycerine, &Dd it was ~ot un~il 1912 that it was discovered 
that the ac~ive substance coul4 be extracted using a lipid 
solvent. This purified extract was marke~ed as the.elin, 
and was widelt used in the 1930'•• In a olinioal trial, 
Pratt and Thomas (1937) failed to show that this product 
was more effeotive than the placebo in treatins aenopauaal 
aymptou but Hawkinson (1938) repo~ed excellent reaul ts 
in treating 1000 patienta, and ita use continu-ed. Theelin 
was also tried as a treataent for involutional melancholia 
in women. Werner et al (19341 1936) and Suckle and 
C.<».tesville (1937) fOUD.d tbat theelin was an effective 
~reataent, but their atwly designs were poor, and their 
results inconclusive, and Bowman and Bender (1932) and 
Shube et al (1937) found that it bad little effect. Since 
the results of trea~en~ of involutional melancholia on 
the whole were poor, oestrogen treatment was not widelr 
used, aDd with the discover,v of ao"ive antidepressant 
drugs waa ausperseded al~ogether. How.ver, ~he use of 
oea~rogens in the trea~ent of menopausal symp~oms continues, 
and wi~h the increase in knowledge of endocrinology i~ is 
now poaaible to give purified or SJD.*hetio horaonea orall.T 
as well as by in3ec~ion. This trea~men~ ia popular, bu~ 
is not yet completely evaluated. 
No~ all workers agree that menopausal symp~oms are 
due to hormonal cbangea. In the early twentieth centur,r 
in~erest was focussed on the psychodynamic schools of 
a. 
school of thousht. This was originated by lreud, who 
considered that neurotic syaptoaa were derived from sexual 
experiences in childhood. Preud hiaaelf bad little 
interest 1n the menopause• but later aaal7tic writers 
regard it as a pathogenic factor beoaua• of ita alJibolio 
eip.ifioance. Accordiug to psJchoaaal.7tic theoey, little 
girls experience a penis enT,J in childhood which ia 
resolved b7 identification with their mothers and the dia-
ooveq that the7 are able to bear children. !he aeno-
pause aeana the end of this biological function, and 
Deutsch (1945) described it aa a partial death followed b7 
a atng&le against decline, Benedek (1950) aa a time of 
des~lisation, and Pradoa (1967) •• a threatening, 
UD&Toidable lcse, and thq reaard conflicts about approachiq 
intertili t7 as a cause of maay ot the menopausal ayaptOJU. 
!he7 recommend paychoaaalytio paychotherapJ as treataent 
tor aenopausal ayaptoma, to enable the woman to adjust to 
the approaching lose, though Benedek also reooJIDlends the 
use ot hormone treatment since she considers that fallins 
production ot ovarian hormones decreases the egos oapaoit.y 
to loTe. 
Other workers have considered menopausal psychological 
symptoms to be due to a reaction to the social events of 
aiddle age. Greenhill (1946) suggested that they may be 
due to marital problems, and DeJkin et al (1966) described 
the 'empty nest syndrome• ot depression in the mother when 
the children have lett hoae. 
g. 
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Oona14er1ng the ~at litera~• which now exiata 
on the menopause, the ayaptoma aasoo1ate4 with it, an4 
their treataent, it 1a not surprising that eo m.uoh 
contusion exists in this field. Unoerta1Dt7 about the 
time oourae an4 sJmPtoaa baa led to clinical trials· that 
ba~e pro4uoe4 oontlictins reaulta by atudJiDB different 
a1Qtoaa and populations, and thia baa a44e4 to the . 
contusion. BYen the rationale for hormone replacement 
therap7 ia now in 4oubt, since a4vanoea in pbfaiologr 
baTe shown tba t the aaopaue ia tar troa a aiaple 
ovarian failure, but oausea ooaplex metabolic ob&Dgea. 
10. 
PliYSIOIDGT 
!broughout reproductive life women experience the 
aontblJ changes of the menstrual oyole. unleas they becoae 
pregnant. At the start of the eyelet sona4otrophins 
stt.nlate the deYelopaent of a follicle in the ovar,r, and 
an inoreaae in the secretion of ovarian oestrogena. At 
a14oyole there is a peak in aonadottophin secretion which 
causes OYUlation, and the ovarian follicle develops into 
the corpus lut.wa. IB the second part of the cycle, the 
secretion of oeetrogena increaaea, and progesterone too ia 
secreted b7 the OT&r,T• !heae hormonal changes of the 
menstrual cycle are ooaplex, as oan be seen froa li&• 1, 
and they are oontroll~ by a feedbaCk loop involving the 
b¥pothalam.ua, pi'tuitar.r, and the ovaries. '.rb.e pol.1Pep-
t1de luteinising horaone releasing horaone (LHBB) is 
produced by the bJpotbalamus and paasea via a portal blood 
system to the pituitar.y gland, where it proaotea the 
release of the gonadotrophins lutein1sing hormone (IB) and 
follicle stimulating hormone (PSH). These stimulate the 
production of oestrogens, and in the second part of the 
cycle progesterone, by the ovar,r, and after release into 
·-the bloodstream the oestrogen• bave a negative feedback 
effect on the hfpotbalamus and inhibit the release ofLHBH. 
There are three main oestrogens, oestradiol, oestrone, 
and oestriol. The moat potent is oestradiol, which ia 
secreted bt the ovar.y in premenopausal women, and its 
plasma l~el varies during the menstrual cycle from 128 
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Schematic representation of the changes in serum 
LH, FSH, progesterone, and oestradiol during the 
normal menstrual cycle in women. 
Oestradiol ia readilJ oxidised b7 the liver 'o oestrone, 
but this change is reversible and the conversion of 
oestrone to oestradiol ma7 be the main souroe of circulatiag 
oestradiol after 'he menopause. During the menstrual 
cycle the level of oestrone is lower than that of oestradiol, 
ransina froa 110 paol/1 (30 pg/111.) to 740 paol/l (200 pg/al) 
{Judd, 1976). The source of the cir011lating oestrone is 
complex in pr•enopauaal women, aa it ooaes partl3 fr011 
the oTa17, partly from the adrenal, and partly froa the 
oonTersion of oestradiol and androstenedione. Oestriol 
is the least potent of the three oestrogens, and is a 
peripheral metabolite pro4uoe4 b7 the bfdration of oestrone, 
and it ia present oDlJ in saall quantities in the blood. 
Treloar et al (1967) obsened that with 1ncreaa1nc 
age, the length of the aenatrual cycle shortens, aDd as 
the menopause approaches it becoaes irregular before 
menst~ation finally oeasea. !he cesaation of menstruation 
is a clearl¥ defined event, but the cballges leading up to 
it take place over a number of years. Gonadotrophin 
levels rise as the ovar.r beoo .. a resistant 'o gonadotrophic 
st~lation, and finally follicular development and 
oTUlation cease, causing a fall in the levels of the 
oestrogens and progesterone aDd cessation of menstruation. 
The high level of BOnadotrophins can be reduced b7 admin-
istration of oestrogen, so the feedback mechanism must 
still be working at the level of the ~pothalamus, but it 
is not possible to stimulate the ovar,r to produce oestrogen 
by the administration of gonadotrophin• after the aenopauae. 
!he oause of thia ovarian failure is unknotna. It 
was believed to be due to follicular exhaustion of the 
ove:q, but Blook (1952) found that there were atill a 
signifiO&Dt number of priaordial follicles in the ova:q 
... ~ ·-
' 
at the tiae of the menopawse, and Costoff and Kaheah (1975) 
reported that these folliolea aDd oYa appeared normal oa 
eleotroa microsoop7. Wb1 these follicles no long~r 
respond to gonadotrophic ati~lation after the menopause 
reuina a JQ'Siel7• 
the menopause aa7 also ooour as a result of aurse17, 
aa both a b7atereot~ aDd a bilateral oophoreotomT resa1t 
in the oeaaatioa· of menstruation. Oophoreoto~ leads to 
horaonal obangea airailar to those .ot the pb¥siologioal 
menopause, but it the oftriea are preserved intact at 
b7atereot~ the hormone changes mA¥ not ~e place till 
the tiae when the menopause would have oo~red spontaneou•lJ• 
!he aoat intenaivelJ a~died hormone change aasoo1ated 
with the menopause ia the tall in oestrogen levels. 
Oestrogen levels were first estimated ~7 vaginal oytologr, 
since oestrogen deficiency ia known to be aaaooiated with 
vaginal atroptq. .In this method, a vaginal auar ia 
examined and the proportions of aupert1c1al, intermediate, 
and parabasal cells determined. Oestrogen defic1enc7 1a 
associated with a decrease in the number of aupert1o1al 
cella and an increase in the nuaber of parabasal cella~ 
Randall et al (1957) carried out vaginal smears on 1768 
~oatmeno~ausal women and found that although 40% showed 
evidence of oestrogen deficiency within 5 years of the 
aeaopauae, a further 40~ did not show evidence of 
oestrogen deficiency after the age of 60, and Oh&piiAil 
et al (1976) obaerred atrophic saeara in woaen who were 
still menatruatiac• !his method of eatimatins oeatroseaio 
actin t,y ia oru4e and inaccurate, aDd baa been cri t~ciae4 
bJ llaauka• (1960) on the groUDda that the reaulta are 
distorted by D18DJ taotora auch as bleeding, illtection, 
prolapae, and the adainie ~ration of other homo nee, 
eapeciall¥ progesterone, and of drugs auoh aa cligi talia. 
It waa ahon. b,y Larraon-Cohll et al (1977) that there waa 
no correlation between T&Ciual epi theliwa appearance• aacl 
plasma oestrocea levels, aD4 althouch Ooope et al (1975) 
found ~bat the appearance of the Ta&inal aaear was aot 
related to the clinical state, and was of little .value 1B 
3wlging treatment outcome .. yaginal o,ytoloQ continues to 
be used in aoae oases in controlling oestrogen treatment. 
•ore recently methods bav• been deYised tor aaa&Jill& 
oestrogena and gonadotrophins in urine and plasma b7 ra41o-
t.aunoaaaaJ, and using these methods the horaonal changes 
ot th• peri- and postmenopausal periods have been iDYesti-
gated. Adamopoulos et al (1971) ~ried out aerial ass&7s 
of urinar,y PSH, LH, oestrogen, and pregnanediol. in 12 women 
approaching the menopause. In the pr~enopauaal phase, 
their PSH increased 3 times, and LH increased 7 tiaea above 
the normal levels of premenopausal women, while their 
oestrogen and pregnanediol levels were lower than those of 
y.oung women, . and only 3 ot the l2 cases showed hormone 
changes suggesting that ovulation had taken place. In 
15. 
aoae oaaea, hilh LH 1-.ela ooex1ated with b1&h l.vela of 
oea'U'oc•• aqgeatlJa& a 41a'tiu'banoe 1R the tee4-baok 
aeob&Dia• 
She~ et al (1976) a'hd1e4 plaaM horaone levela ill 
the perillenopauaal period. Ill reauJ.,arlJ meut:rutiDC 
perlanopaueal woaea, th., foWl4 elente4 lSB ln'ela ... 
low o"va41ol leYela tbroqhollt the OJ'Ole, w1 th a 4eonue 
1a the 1nterYal betweea aenat~tioa aa4 the a140JOle . 
aona4otroph1a peu. tbe7 atwtie4 two woua oTer a two 
7-.zt per1o4 dlll'iq .the .. opauaal tana1 tiOil &D4 obaerYe4 
o7olea of 'ft.J71DC leactb. Ia aou OJOlea, thq ehowe4 __ 
the honoul ohqpa aaaoo:l.ated with tolUcMlar utuat1oa 
&a4 ooJ:'pWI 1\\teaa tuotioaiq 1a the preeeaoe of hip IB 
&D4 lSB leYela, with nor..Al proceateroae -at 4eoreaael 
oeavactiol l"el.a. . I&tel'e aa t~e uaopaue appzaoaoheclt 
both oeatradiol aa4 progeeterone levela were low &D4 
anoftlatort blee41q ooourftdaa the oeatra41ol lnela fell 
without .., obaagea in proceeterone haTing ooourrect. 
KaDJ worken have atudie4 the pla- horaone ~eYela 
of poeuenopauaal woaen, aDd a1aoe aenopauaal. •J~~PtOIUI 
were bell"" to be 4ue to oeatrocn def1o1eno1• oeatroaa 
leTela baTe ben. studied aore tbaD thoae of other hononea. 
!able 1 ahowa the a.an pla..a oeatrone an4 oeatradiol 
l..,ela reported b7 ftl'ioue author•, and i i 0&11 be aeen 
troa tbie tbat their reaulta ~ troa Ter.J low leYela to 
leTela wllioh aight be expeotecl during the unstnal 07ole. 
Cqpbell (l976 a )aDcS Hutton et al (1978) reported oeatrona 
and oestradiol levels similar to thoae of the earlJ 
. 16. 
TABLE la Mean Plasma Oestrone and Oestradiol Level• in 
Postaenop~aal Women - Revi .. of the Literature 
Mean Jlean Age Authors Oestrone Oeatra4iol 
(pmol/1) (pmol/1) Bans• 
Baird and Guevara (1969) 263 48 7o-8g 
Xoreuan et al (1969) - 54 
TulobinakJ and Xorenman(l970) 148- - 48-60 
Longoope (1971) 92 24 74-89 
Rader et al (1973>" 152 48 31-82 
Abraham and Karoulis (1975) 222 48 
Oaapb ell (1976~) 168 137 
... 
Cbakr&Tarti et al (1976) 89 52 49-91 .!) 
Greenblatt et al (1976) ~ ~ 60., .,;. ~e 1~··  ..~·· 
Vermeulen (1976) 181 74 52-65 
httoa. et al (1978) 198 126 42-56 
Lind et al (1978) 98 85 
proliferative phase of the menstrual cycle, while all of 
the other authors reported much lower oestradiol levels, 
and Loqoope ( 1971) , Chakravani et al (1976) , and Lind 
et al (1978) also found auoh lower oestrone levels. Before 
the menopause, oestradiol is the main oestrogen, and the 
oestrone: oestradiol ratio is less than one, but after the 
menopause the proportions of the two oestrogen& change. 
All of the studies summarised in Table 1 have shown the 
oestroneaoestradiol ratio to be greater than 1, the lowest 
value being that of Lind et al (1978), who found a ratio 
of 1. 211 and t he highes t value being 5·5&1, reported by 
17. 
Vermeulen (1976). !here are m&Dl' possible causes tor 
these different results. There ma7 be differences tn 
the sensit1Y1~ of the aaaay methode in different labor-
atories, aDd it can be seen froa !able 1 that the n.rioua 
authors have studied different age groups, which ma, alao 
have infiuenoe4 the result. · 
Cbakraw.n1 et al. (1976) haTe· shown that oestrogen 
levels mAT change with time after the menopause. They 
studied the plasma hor.aone profiles of 60 poataenopausal 
women, taking two blood ... plea froa each and aaaaying the 
plasma tor oestrone, oestradiol, androstenedione, testoater-
one, lSB and IB. 
the hormone levels ex~eoted ~n the first 10 daya of the 
menatrual c7cle, and fouad that within one year of the 
menopauae the mean oeatrone, oestradiol, and an4roatene41one 
l.vela had fallen to 20; of these levels, while the con-
centration of FSH had increased by a factor of 13·4 and of 
LH by a factor of 3.0. Concentrations of the gonado-
trophins reached a peak between two and three yeara after 
the menopause, when PSH waa increased 18.4 ttaes, and LH 
3.4 times above the levels fouad 1n theearl.f proliferative 
phase of the menstrual c7c1e, but over the next three 
decades their levels graduallJ fell to halt the maxiaua 
value. Oestrone levels continued to fall after the 
menopause, but oestradiol levels began to rise again 10 yeara 
after the menopause, reaching in a few oases the lower 
normal levels of the menstrual cycle. They also noted a 
gradual tall in testosterone levels, contrary to the 
18. 
fincJ.iqa of Greeabla~~ e~ al (1976), who repor~ed tba~ 
tes~oa~erone le"Yels rose in women at~er the menopause. 
Oaapbell (1976a) a~died oestrone·, oestradiol, anc1 
oestriol levels at 2-hourlJ interY&la tor 24 houra in II 
poataenopaueal women. Their oestriol levels were coD-
aiatentlJ low, bu~ there was considerable T&riation in 
· their oestrone and oestradiol levels both between aaaplea 
and between sub~eots. !Yen where the patients bad lit~le 
difference between th .. in ter.s ·Of age or duration of 
amenorrhoea they could bave widelJ differina oestrogen 
le"Yels, an4 aoae patienta bad ver.y high leTels of oestrone, 
siailar to those f01Uld in the lu~eal pbase of the aeaa'b'aal 
CJOle, and high .levela of oestradiol, while others bad 
Ter, low leTela of both horaonea. If there is ao aoh 
T&riatioll 1n oestrogen 14.Yele, then a verr large. nUIIber 
of aub~ eota would be neoesaarr t .o give an aooura te refleo-
tion of the homone levels of postmenopausal women, a~ 
this is another possible oauae of the different results of 
the various stud 1ea. 
Hutton et al (1978)' oarriec1 out an even more intensive 
study, in which blood aaaplea were taken every 20 or 30 
minutes for between 4 and 24 hours from 26 poataenopauaal 
women. fhey too found no relation between age or duratioll 
of amenorrhoea and mean hormone levels. They found rapid, 
wide and irreBQlar fluctuation in eaoh patient i~ the 
levels of oestrone, oeatra41ol, and androstenedione, with 
no .relationahip between the changes in the levels of any 
of the three hormones. Both Campbell (1976a) and ~tton 
19. 
et al (1978) coaaented that aiDgle s-.ple atu.d1es of 
horaone levels ill postmenopausal women are invalid beoauae 
of this fluctuation in hormone levela. 
~he role of the ovar.y in ~ormone produc~ion after the 
menopause was inveatigated bJ Jud4 et al (1974), who fouad 
that the concentration of oeatrqen in the ovarian vein 
1n poat-aenopausal woaen ia little higher than that in 
peripheral blood, and they concluded that the ovariea aake 
little contribution to oeatroaen production after the 
menopause. This was oonfiraed b7 Vermeulen (1976) in a. 
atudt of the effect of ActH aD4 HOG stiaulation and 
d~etbaaoue suppression on the levels of aex horaonea in 
pos~aenopauaal women. He found tba~ AC~ increased all 
plaaaa steroid levels except oestra41ol; and dexaaetbaaoae 
aigaifioantl.J 4eorease4 all au: hormone levela, while HOG 
ati~lat1on eveatuall1 caused an increaae of borderline 
significance in testosterone, dehJdroepi&Ddrosterone and 
17-hfaroxyprogesterone levela. He oonolu4ed froa th1a 
tba t the adrenal cortex was allaost the sole source of 
plaau. oestradiol, oestrone, and progesterone, while the 
ovaries contributed 50~ of the testosterone and 30~ of 
the androatene41one in the peripheral blood, and tbat the 
ovaries are not influenced b¥ gonadotrophins after the 
menopauae. Heaaell at al (1974) showed that oestrone, 
the major oestrogen of post-menopausal women, arises 
aainly from peripheral conversion of androstenedione. 
EnS¥m88 to convert androstenedione into testosterone or 
oestrone, and both of these into oestradiol, are located 
=·-=----- -.. 20. 
in many tissues. Siiter1 and McDonald (1973) and Judd et 
al (1976) showed a positive correlation between the weight 
of the individual and the amount of androstenedione con-
verted to oestrone, and Nimrod and ~an (1975) have shown 
that adipose tissue plaJs an important part in this con-
Yersion. It does, however, seem that malT factors 
regulate the levels of these steroids, since Chakravarti 
et al (1976) and Hutton et al (1978) to~ no clear 
relationship between plasma androstenedione and oestrone 
levels. 
Both Vekemans and Robyn (l975a) and Lind at al (1978) 
found that prolactin levels were low in women after the 
menopause. Vekemans and Robyn observed that changes in 
prolactin levels in women paralelled changes in oestrogen 
levels and concluded that oestrogen must be involved in 
the control of prolactin secretion, but Lind disagreed 
with this view, as he found that the prolactin levels of 
his patients were unchanged by oestrogen treatment. 
Menopausal symptou are widely b'elieved to be due to 
the hormonal changes of the menopause. lor some years it 
was believed that high gonadotrophin levels caused the 
sjmptoms of the menopause, but this theory lost popularity 
when lluhman (1930) and Heller et al (1944) could find no 
correlation between gonadotrophin levels and the severity 
of menopausal symptoms. 
The most popular theory at the moment is that meno-
pausal symptoms are due to oestrogen deficiency, but 
there is again little proof that this is the case. Several 
21. 
workers baTe fail.ecl ~o show a correla~ion be~ween ur1Da17 
oes~rogen levels and the presence of menopausal aymp~oaa 
(Albrigh~, l.936J Shute 1939) or their eeYeri1J (PlubmiB 
and Kurpb3, 19391 -lAwrence and Kou.J.¥n, 1941) in poat-
menopausal women. However, Cooper at al·. (1974) reported 
that there was a oorrela~ioll be~•• plasu oestradiol . . 
levels and menopausal s~ptoaa,wi~h ayapto.a ocourrioa wheD 
the plasma oestradiol leYel tel.l. below 40 pg/ml, and be1ac 
relieved when it rose above this level. 
Jlore recen~ research baa been direo~ed at finding a 
relationship between oestrogen levels and specific 
I : '-
eymptoas, rather tban includiDC all of the •lll»toaa 
ex)erienoed, and this approach baa praYed more auccesatul. 
Chakravarti et al (1979) ·atudied ~he plaa-. hormone 
profiles ot women approaching the menopause who were •~111 
menatruatins, and reported that patients who coaplained of 
vasomotor symptoms bad a1gnifioantl1 lower plasma oestradiol 
level.s than those expected in daJa 1-10 of the menstrual 
cycle, and had gonadotrophin levels st.ilar to those of 
post-menopausal woaen. However, Campbell (1976a) &Ad 
Hutton et al. (1978) tailed to show any clear relationship 
between either the mean levels or aoute changes in plasma 
oestrogen concentration and hot flushes in post-menopausal 
women. Button also compared the oestrogen level.• of woaen 
with dyspareunia and atrophic vaginitis with those of o~her 
post-menopausal women, and found that the women with 
dyspareunia had significantly lower plasma oestradiol 
levels than symptomless women, but there was no difference 
in their oestrone levels. 
~---·· 
SOCIAL PROBL•s Ol lliDDLI AGI 
The mean age at which women experience 'the aenopauae 
has been shown to be about 51 (lrollller, 19641 Jassu.nn et 
al, 1969&1 Jlcteinlay et al, 197~) and around this age 
women experience mant sooial changes. Soae workers 
believe that mant ot the syaptou at-tributed to the aeno-
pause are due to aocial probleu rather tban to horaoD&l. 
changes (Greenhill, 19461 Pearl ·and Plots, 19641 Steiner, 
19'f)) and i't is generalq .agr.eed that these probleJU O&Jl 
exacerbate menopausal a)'lllptoaa. Ballinger (1976a) tOUD.4 
that mental disturbance in women in the perillenopauaal 
period was associated with baTing elderlJ and dependent 
parents, with children leaTiq home, and with b&Tins 
problema with the obildren. 
ln.derly' parents may be a great source ot anxiety, aa . 
they are likelf to be trail or eTen senile by the time 
their children are middle aged. Living with elderlJ 
relatives oan be difficult a~d distressing, yet it the7 
liTe alone the7 may be unable to look attar themaelvea, 
or have an accident, and 1t they are admitted to reaiden-
ti~l oare they feel unlOTed and rejec~ed, and their 
children feel guil~ and inadequate. !he death ot 
parents, while not unexpected, leads to feelings of grieft 
but illneaa and even death are not uncommon in middle age 
· in both man and women, and so m&Qt women are widowed &D4 
face problems ot loneliness and poverty in middle age. 
Around the age of the menopause the role of mother 
' 
comes to an end, as the children grow up and leave holle, 
" 
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ud the task• of oaring tor the faail-7 are no loqer 
necee&a!'f. !his means tbat women who bave spent .a l.arce 
.part of their lives bringing up children JBU.at develop a 
new life at,yle and interests in middle age, and Van Xeep 
and Xellerbals (1977) olatm that the higher social olasa 
woaan oopea better than the lower olaaa one with the 
menopause because she bas more alternatives at her dispo.-1 
in seeking ~ new life at,rle. !hey also state that the 
more strongly a woman identifies with the role of mother, 
the more likely abe is to become depressed, and Deykin 
et al (1966) haTe named thia &7ftdroiae of depreaaion after 
the children -haTe lett home the "eapty neat a1J14roae". 
Aa the ohildren leave home, the huebaa4 .and wife nee4 
to redefine their relationship. In maQJ oaaea thia ia 
sucoesaful, and D·eutaoher (1959) reported that 22 of the 
49 aiddle olaae oouplea he inteniewed aaid ·that they 
found the period from age 45 to 65 more aatiatactor,y tban 
their earlier married lite, since they ba4 more freedoa. 
HoweTer, LuokeJ aDd Bain (1970) found tbat couples who were 
dissatisfied with their marriage usually found their children 
to be a source, and sometiaea theil' only' source, of aatia-
faotion, so such couples are likely to separate when the 
children ~w up aDd leaTe home. 
llarital ·problema may of course be due to the probleas 
encountered by the husband in middle age, since men too aA¥ 
go through a mid-life crisis. It is often a time of 
stress fG~· m•n at work, and if a man loses his job at thia 
age he may have great difficulty in finding a new one.. ~en 
if he is at the peak of his success, his energies may be 
concentrated on fighting off the challenge of younger men, 
leaving little time or energy for his home life. This 
increase in the time spent at work often leads his wife to 
believe that she is no longer attractive, and since rapid 
ageing is one of the commonest fears of menopausal women, 
this can cause great distress. 
ATTITUDES AND CULTURAL INFWmCBS 
The effect of the menopause is likely -to be influenced 
by the woman's expectations, and if she is expecting to 
have probleas then this ~ make them more likelJ to occur. 
The attitudes of European women to the menopauae were 
investigated by the International Health Foundation in 
1970 in a surYey of 2000 women in 5 European oountriea. 
They found tba~ 69% of these women expected the menopause 
to cause a ph3sioal upset, and 57~ expeote4 it to be 
upsetting payoholosioallJ, but 72~ were glad to reaoh the 
menopause because they no longer had periods then, and no 
longer needed to fear pregnancy. The British women in 
this survey were more optimistic about the menopause than 
those of other countries, and only 13% of British women 
expected the menopause to impair their relationships with 
the opposite sex, and 9~ to lose their attractiveness to 
men. 
Maoz et a1 (1970) compared the attitudes of woaen of 
diverse ethnio origins in Israel, and found that over half 
of the Oriental and Arab women felt positive about the 
menopause, but only 2C>,t. . of the lhropean women. !hq 
commented that women only felt positive about the meno-
pause if the7 alreadJ had large families, but only worried 
about it if they had nothing else to worr, about. 
March& llint (1975) ~ested that the effect of 
the menopause depends on the change of status experiencecl 
by a woman at that time. She studied 483 Bajput women 
in Rajasthan, and found that few had &IJ¥ symptou at the 
menopause other than a change in their menstrual pa tt·em. 
Their status increased at the menopause, since tnt¥ no 
longer had· to remain in purdah, but were allowed to go 
out and to take part in the social activities of the men · 
after the menopause. She contrasted this with the 
situation in Alurioa, where youth and glaraour are at a 
premium, and the menopause is regarded as a tirae of loaa 
and i)unishment, and where menopausal complaints are common. 
She suggests that menopausa~ complaints must be cu.lturall7 
defined and engendered, and that a change in the role an4 
status of post-menopausal women could do much to reduce 
the frequency of menopausal symptoms in our sooie~. 
JRIDlWIOLOGY Ol KPOPAUS.A.L SW~IS 
Although ao m&IJ¥ ayaptoma occur aroUDd the time of 
the menopause, we still do not know which ayaptoaa coD-
atitute the menopausal syndrome. DonoY&n (1951) doubted 
whether there is such a ayndrome, and clataed tbat it 
could be an artefact of hiator.1 taking b7 ~JD&eoologiata. 
He studied 110 women diagnosed in a gynaecology clinic aa 
•. 
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haviq the menopausal syndrome, and found that 95~ of 
them bad a h1ato17 of decades of unexplained aomatio 
sfaPtoma and pbJsical illQesa. Their s~toma were 
relieved by histo17 taltilli alone, in moat cases, but · at 
the next interYiew they complained of different 8r-Ptoaa. 
However, these results cannot be generalise4 to all an.o-
- . . 
pausal women, as the population studied was high}3' eeleote4, 
and patients in a Qri.8.eoolog olinio are· not typical of 
menopausal women. Hawkinson (1938) and KoDowell aDS 
Paterson (1940) fCN.nd a Yeey- hi&h_ fl:'equeno7 of both 
physical and psyohologio~l &Japtoms i~ th• aeaopauaal 
patients of gynaeoolOCJ olinioe, and more reoent1J Balliacar 
(1977) fOWld that periU.nopausal women 1n a Qa&eool~l7 
clinic bad more severe psyOhiatrio symptoas thaD woaea 
of the saae age in the ·oo~~~~~miv, and were also more like~ 
to have a histor.y of psyohiatr1o referral. 
Many epidemiological sUrYeya have been carried out to 
determine which symptoms are associated with the menopauae. 
Their results are summarised in Table 2, and tr011 this it 
can be seen that they diff•r markedly in their findinga. 
All found that vasomotor srmPtoaa are coamon in peri-
menopausal women, but es tima tea of their frequency 'Y&r7 
from 35~ {Jaszmann et al, l969b) to 62% (Barrett et al, 
1933), and not all enquired about night sweata. E$t1matea 
ot th.e frequency of psychological· syaptou Yary wide}3', 
with the reported treque~oy of depression ranging troa 
20% (Jaszmann et al, 1969b) to 67~ (NeUgarten and Xrainea, 
196-5) and anxiety from 221 (leugarten and Krainea., 196·5) 
•. 
TABLE 2: Results of Bpideaio1ogical SurYqe of S,aptou of Perimeaopauaal Women 
in the General Population (~ reporting eaoh s7JlPtom). 
Symptom :Barrett Neugarten Jassmau I. H. F. fhOQSOil McK:ia.la7 1933 1965 1969b 1970 1973 1974 
.  
VASOKOTOR 
Hot fitlshes 62 48 35 55 48 50 
Night sweats - - - - - 41 
PSYCHOU>GICAL 
Depression 67 20 30 42 50 
Anxiety 22 - 41 - -
Irritabilit7 82 29 29 - -
Fatigue 80 45 43 )8 -
InsoJil'li& 46 28 32 31 36 
PHYSICAL 
Headaches 44 59 33 38 36 41 
Dizziness 40 .38 9 24 19 35 
.dheumatian 24 48 35 25 25 -
Palp-i~a tiona - 40 22 23 13 35 
No Syliptoms 16 - - 14 - 9 
Number of ~omen 1220 100 2956 2000 269 638 
Age Range 29-91 45-54 40-60 46-55 4o-60 45-54 
~ Postmenopausal 100 ? 61 54 64 52 
--------- -- -· ----
"' _. • 
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to 41% (International Health loUD.da tion, 1970 ).. !hie 
m&J of oourse reflect the difficulty in deciding which is 
normal and which pathological as anxiet1 and depression 
in a mild form are normal experiences, and even in a 
severe form may be appropriate responses to atreastul 
events. Insomnia ·Seema to be less common, with the lowest 
reported frequeno7 being 28% (Jaaaann et al, 1969b) and 
the highest being 46~ (Beugarten and Krainea, 19ft.). 
It is not surprising that the au.rYeJs have produced 
different results, as the7 bave each enquired about a 
different group of &Japtoma, and even where they have 
studied the aaae ayaptom, different wording of their 
questions may have given a different resu1t, e.g. b7 
asking about symptoms which are present now or including 
aymptoaa which were experienced in the past, and it is not 
clear in several of the surVe7s how the questions were 
phrased. As oan be seen from Table 2, the populations 
b.ad different proportions of pre- and postmenopausal women, 
and this is another possible cause of their differences. 
Barrett et al (1933) studied only postmenopausal women, 
and since they were aged up to go, then it is unlikelf 
tba t the7 would remember clearly wba t symptoms the7 had 
experienced at the menopause. 
It ia doubtful whether much can be learned about the 
symptoms of the menopause from this kind of study, since 
it gives no information on the frequency of the symptoms 
at other ages, and cannot show whether the symptoms are 
related to the menopause or to other causes. The only 
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study to includ~ women of all ages was that of Beugarten 
and Kraines (19o5) in which the prevalence of syaptoaa 
attributed to the menopause in 600 middle claaa American 
women aged between 13 and 65 was studied. They used a 
check-list of 28 eaotional and physical symptoms, aDd 
obtained a respondance rate of 85~· ln this s~dy, all 
&Jmptoaa were reported by a number ot patients in each age 
group, with the highest number ot psychological syaptoms 
occurring at adolescence, and the highest number of 
physical complaints at the menopause. Postmenopausal 
women bad a ver.y low incidence ot all complaints. However, 
the actual menopausal sia~s of the subjects in this a~dy 
is not clear, since they were asked to decide for themselves 
whether or not they were menopausal, and soae women who 
considered themselves menopausal were still menstruating, 
ao the signi!ioanoe ot these reeults is doubtful. 
The survey a of Jaaaann et al (1969b), Thompson et al 
(1973'), and McK1nla7 and Jeffreys (1974) included only 
middle aged women, but analysed their results in terms of 
menopausal age, i.e. pr~enopauaal if they were still men-
struating, menopausal if they bad experienced a change in 
their nan~trual pattern, and postmenopausal if they bad 
amenorrhoea for more than one year. Jaszmann et al (l969b) 
studied the point prevalence of symptoms by sending a 
postal questionnaire to all women aged between 42 and 62 
in the borough of Eae in the Netherlands. A total of 
4584 repli:~d, representing about 71% of the selected 
population, but Jaszmann gives only the results of the 
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2956 woaen who had undergone a physiological aeDopauae 
within the last 10 yeara. He stated tbat a true aeDo-
pauaal Complaint should be absent or rare before the meno-
pause, increase in frequenc,r at the time of the .. nopauee, 
and decrease thereafter. He found tbat 8hortnesa of 
breath and .. otional lability did not change in relation 
to m.enopauaal age, and that irritabiliV• fatigue, and 
depression were oo.aonest in women who were still men-
struating, but hot nuahea, night sweats, and inaouia 
showed a typical menopausal pattern. 
Thoapson et al (1973) and JloKinlay and Jefferys (1974) 
also surveyed the syaptoms of women in the ~eneral popula-
tion by means of postal questionnaires. thompson a~died 
291 women aged between 40 and 60 in Aberdeen, and obtained 
the surprisingly higb respondanoe rate of 92%, while 
McKinlay and J .efferya studied 955 women aged from 45 to 54 
in an area of London, with a respondanoe rate of o7~. All 
found a similar pattern in the frequency of hot flushes in 
relation to the menopause. Jaszmann found that the pre-
valance of hot flushes increased from 17% in women who 
were still menstruating to a peak of 65% in the first 
2 years after the menopause, and still affected 35% of 
women between 5 and 10 years after the menopause. Tnompson 
found that 11% of women were having hot flushes while still 
menstruating regularly, compared with 79~ two years after 
the menopause, and 20% between 7 and 9 years after the 
menopause, but that 93% of women experienced hot flushes at 
some time in the perimenopausal years. McKinlay and 
.... ... 
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Jeffer,ys obtained results ver,y like those of Jaasmaan et 
al (1969b)• The7 enquired whether their aub~eota bad 
experienced hot flu.shea in the previous year, and found 
that 18% of premenopausal women, 68~ of women between 4 and 
5 yeara after the menopause, and 29~ who bad undergone the 
menopause more than 9 years beforehand reported haTing 
hot tluahea. 
Their results agree lese closely on the frequency of 
insomnia. Jaazmann found that 20~ of middle aged woaen 
with reBUlar ael18ea ooaplained of ina omnia, rising to a 
peak frequency of 40~ in the period 2-5 years after the 
menopause, and reuinin& about 30" between 5 and 10 yeara 
after the menopa~e. The frequenCJ of insomnia in relation 
to the menopausal age ia not clear from the paper of 
!hoapaon et al (197 3) but KoXinl..a7 and Jefferys found that 
20~ of premenopausal women· complained of sleeplessness, 
and that the incidence of inaoania 1ncreaa•d after the 
menopause but ahowecl no clear pattern of change in relation 
to age, fluctuatiUB between 32 and 58". 
There is even lesa agreement on the frequencJ of 
depression. Jaszmann found that 20% of premenopausal 
women complained of this, 24~ of women with a changed 
menstrual pattern, and 15% between 5 and 10 years after the 
menopause. Thompson et al (197~) found that 33% of all 
age groups in their study complained of depression, and 
McKinlay and Jefferys found that the frequency of depression 
was 39% in premenopausal women, and increased to 55% 
immediately after the menopause, falling slightly to 45~· 
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between 2 and 4 years after the menopause, and then 
increasing to 61~ 7•9 7eara after the menopauae. 
fbeae ep1d .. 1olos1oal atu41es bave determined the 
pr41ftleaoe rather than tbe incidence of a,aptoaa, al'14 
although that bave shown tbat many &JQtODUI are co-on at 
this t1ae, theJ have not ahon whether the7 are clue to 
phJa1oloc1cal or P•toholog1oal cauaea, or even that the7 
......... 
are rela:te4 to the · unopauae. HoweTer, the tact that the 
pattern of occurrence of 1naoma1a, hot fluahea, and 
patchological ayaptoaa oh&Dc•• aroUDd the tiae of the meno-
pauae auggeata that the7 are related to the menopause, and 
I bave therefore investigated the effect of oestrogen 
treatment on theae az-ptoaa. 
INSOMNIA 
Sleep disturbance is common at the time ot the meno-
pause, and is usually described as difficulty in ge1ting to 
sleep associated with frequent waking. There are many 
possible causes for this symptom. Thompson et al (197 .~ 
suggested that insomnia might -be due to vasomotor ayaptoma 
such as night sweats, since many menopausal women coaplain 
.that they are wakened during the night by sweats, and the 
changes in the frequency of these complaints around the 
time o! the menopause are similar. Campbell (1976b) also 
thought that insomnia in menopausal women was due to vaso-
motor symptoms, since he found in his study of the effio&OJ 
ot oestrogen treatment that relief of insomnia was related 
to improvement. ot ·vasomotor symptoms. 
As• alone r1J&7 account for the increase in OOJIPlaints 
of insomnia at the menopauae, as McGhie aD4 ~saell (1962), 
who studied the frequenQJ of complaints of insoania in the 
general population in a questionnaire surve1 1 found that 
complaints of insomnia increased with age in both sex••· 
In men, this inareaae did not reach aignitioanoe till the 
age of 65 1 but in women the increase co .. enoecl in middle age, 
suggesting that aoae extra factor ia involved in oauaing 
sleep disturbance in aiddle aged woaen. Feinberg (1974) 
and Williams et al (1974) atudied the relation of sleep 
with age using eleotropbfaiological recording of sleep in 
all age groupa, and· theJ found that in older people aleep 
becoaes aore broken, with more frequent and prolonge4 
periods of waketulneaa, and leaa alow wave sleep thaD is· 
found in young people. 
Another posaibilitJ is that inaoania is due to psycho-
logical &1Jilptoma. KoGhie (1966) found that insomnia is 
a coiiUilon symptom in psychiatric illneaa, and Detre (1966) 
and Ward (1968) found that approximatel7 two thirds of 
patients admitted to a psychiatric hospital ooaplained of 
· sleep disturbance. The relationship between sleep dis-
turbance, psychiatric diagnosis, and mood ~s recently been 
investigated by Stonehill et al (1976) in a questionnaire 
survey of 375 new referrals to a payohiatrio out-patient 
clinic. They found a high incidence of complaints of 
insomnia in this population, and observed that anxiety was 
associated with delayed sleep and late waking, endogenous . 
depression with going to sleep early and waking earlf, and 
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neurotic depression with both initial insomnia and e&rlJ 
wald.q. Jla7er-Groee (1954) and Kiloh and Garai4e (1963) 
olaillecl that the pattern ot aleep disturbance was ot 
diagnostic significance in depressive dieordera in that 
patients with neurotic depresaion oomplairl of difficulty in 
getting to sleep while those with eDdogenoua depresaion 
complain of earl-7 moning waking, but other worker• baTe 
failed to show thia diohoto., (Hinton, 19631 Costello and 
Selby, 1965). Objective atQdiea using eleotrophyaiological 
recording of sleep have. failed to diatinsuiah between the 
two types of depreaeion (Hawkins and Mendela, 1966) and 
have ailhown that waketulneaa aotuall,y recurs throughout the 
night in endogenous depreaaion (Oawald et al, 1963). 
fhe relationship between subjective sleep dieorder, 
ps,yobi&trio diaturbanoe, aDd the menopauae baa been 1nTest1-
gated "by Ballinpr (1976b). She compared the patt•rn of 
sleep disturbance in women identified aa "payohiatrio : 
case... and in " non-oases" in her earlier survey (Ballinger 
1975). The frequenoy of ooaplaints of insomnia was con-
aid erabl.y higher in the "oases" than the "non-oasea" , but 
in both groups there was an increase in sleep disturbance 
due to increased diffioult.l in getting to sleep in the 
years after the menopause. The normal women also bad an 
increase in complaints of difficulty in staying asleep in 
the first six years after the menopause, with a subsequent 
fall, but neither group showed any significant difference 
in complaints of early morning waking in relation to meno-
pausal status. Ballinger concluded from these findings 
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that psychological disturbance alone would not account for 
the increased frequeno7 of insoa1a at the time of aeno-
pauae, and pointed out that the patten of frequeno7 of 
complaints of inaoania i• different from the pattern of 
peychological morbidity, which shows a peak in the pre-
menopauaal years. 
'the pattern of cb.aDge in the trequen07 of coaplaints 
of insomnia in relation to -.he menopa••• is ehown in 11g. 2, 
and it can be seen froa this that the incidence of insomnia 
increases ae oestrogen leTela tall aDd sonadotrophin leTele 
rise, so it is possible that insomnia is related to the 
noraonal changes of the aenopauee. This ia not of course 
scientific proof, &D4 the relationship between horaonea 
aad sleep at the menopause baa not yet been ob~eotiTelJ 
studied, but sinoe sleep and horaonea are known to be 
intiaatelJ related, it would not be surprising if changing 
horaone leTela brought about changes in sleep patte~. 
HOBMONES AND SLpP 
The relationship between sleep and hormones ie complex, 
and many hormones show a change in t heir secretion at 
night, either as part of a circadian rhythm or in response 
to sleep. This relationship bas been studied by aaapling 
blood at intervals while sleep is being recorded electro-
pbysiolo~ically, and the changes in hormone levels can 
then be compared with the sleep pattern. The electro-
encephalographic appearances of s leep may be divided into 
sleep stages 1, 2, 3 and 4 o! orthodox or NR::Ll sleep, and 
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•' \ 
3?. 
R]K or paradoxical sleep, according to recoBilisecl inter-
national criteria (Reohtaobaffen and Kales, 1968). Stages 
3 and 4 are known aa alow wave sleep, beoauae the E!U in 
these atagea ia obaracteriaecl by large slow waves, and the7 
occur mainly in the earlJ part of the night. Rll4 sleep 
periods recur throughout the night at 11lterYals of approxi-
mately 90 miDRtea. 
In aoae caaea the horaone leYela oh&Dge whether or not 
' 
the subject is asleep, e.g. corticosteroids, which are low 
at the beginning of the night but wb.ioh increase ~ust 
before waking due to a o1rca4ian rbyt~ Other horaonea 
show an increased secretion at night, auoh as thyrotropin, 
aldosterone, naopressin, parathyroid horaone, growtil 
horiaone, and prolactin. In the cases of growth bor.aone 
and prolactin, this nocturnal increase ia aleep dependent, 
and if the subjeot" ataya awake then the increased aeoretioa 
ia delayed until sleep onset. The· increased secretion of 
growth hormone is aaaooiated .with slow waYe sleep, and the 
magnitude of the increase can be increased by daytime 
exercise or by fasting.. The nocturnal secretion of pro-
lactin ia not influenced by exercise, but Vekemans and 
Robyn -(1975b) found tbat the amplitude of the nocturnal 
prolactin peak could be reduced and its duration prolonged 
in young woman by the administration of oestrogen. They 
also reported that daytime prolactin levels are low in 
postmenopausal women, but oan be increased by oestrogen 
administration (Robyn and Vekemans, 1976) but they did not 
in this study investigate nocturnal hormone levels. 
J8. 
Roseneweis e't al (1973) reported that the nocturnal inoreaae 
in prolactin secretion ahowed the same pattern in poat-
m.enopauaal women aa is foud in young aen and woaen. 
In the reproductive horaonea, the Clearest relation to 
sleep has been found arOWld the age of puberty. BOJ&r et 
al (1972) obaen-ed an increase in the level of plaa• IH 
at ~ght in boJ• and sirla .aro\llld the as• of puber'Q', and 
in a later atudJ (Bo7ar et al, 1974) deaonatrated tbat tbia 
increase in ~ is sleep dependent aDd ia accompanied in 
pubertal boya b7 an increase in the secretion of teatoster-
one,and in a tur'ther paper (Boyar et al, 197~) _the7 obaerYed 
that the illoreaae in lB in pubertal girls was acco~ied 
by a fall in oeatradiol levels in the first third of the 
night. !his relationship between LH aDd sleep baa &lao 
been reported in aoae oases of anorexia nervoaa, but other 
than this, there is no clear eTidenoe Of a relationship 
between LH and sleep in adults. Bo7ar et al (1972) and 
Alford et al (1973) could find no evidence of a diurnal 
rhythm in LH levels nor of any change in relation to sleep 
in adult men, but Rubin et al (1972) claimed that 1H level• 
were higher in R111 than in non-a• period a. Results of 
studies of the relationship between LH and sleep in adult 
women too have been conflioting, sinoe mapen et al (1973) 
reported a decrease in LH levels in tbe first three hours 
of sleep in women in the follicular phase of the menstrual 
cycle, but not in the periovulatory phase, and A1ford et 
al (1973) could find no evidence of a relationship between 
gonadotrophins, oestrogena, and sleep, though it should be 
noted that Alford studied only two women on day six of 
the menstrual cycle. 
Billiard and Paaaouan~ (1974) studied aleep pattern• 
and urina17 LH aDd pregnanediol lnela in three no~l 
women in ftrioua pbaaea of the una~rual OJ'Ole, bu~ ~he7 
found no o~ngee in the sleep pattern in relation to the 
pbasea of the menstrual 070le, and no oorrela~ion between 
sleep aD4 hormone levela. Bartmana (19.66) baa also 1nTeat1• 
sated ~he relationship between sleep and ~h. menstrual 
Be reo~r4ecl the aleep of ~our normal women and three 
psychiatric in-patien~a, two of whom were 4epreeaed, and 
. ' ' 
one sociopathic, on one night per weak for three months. He 
foUDCl t~t a• aleep inoreaaed in the premenstrual pbaee of 
the menatrual OJOle, an4 augceated tba~ this obange might 
be · due to increased progesterone levels, but the valldi v 
ot this result ia ·doubttul because of the heterogeneoua 
nature of the population atudiecl, in which three of the 
normal women suffered from pr .. enatrwal tension, and the 
fourth was taking 'the oral contraceptive pUl, while the 
other subJe~ta were takiq aaphetaaines and barbituratea, 
which m83 interfere with sleep. Inadclition, the hormone 
changes of the menstrual cycle are ooaplu, and there is 
no evidence to show which it •DT is associated with changes 
in sleep~ 
The relationship between sleep and sex horaones baa 
also been studied bJ observing the changes in sleep during 
pregnanoJ, but the hormone changes ~t pregnano1 are com-
plex and these studies tell ua little of the effects of 
changes in the levels of the individual hormones. ~pe~ 
and f&.o~ (1968) found that sleep duration increased in 
......... 
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~he tire~ triaester ot pregnancy, an~ although this ma, 
be due to horaonal changes, it cQuld also be due ~o weight 
&&1~, which ia also asaooi&ted with longer sleep duration. 
Xa"-C&D. et al (1968) studied the sleep changes of late 
preananc7 and the puerperium b7 coapariag the sleep ot aft'a 
pregnant women with that of ace-matched controls. !hq 
noted a aborter sleep duration, with more frequent arouaala 
and leea a low wave aleep 1n late pregnanq • followed b7 a 
rebound increase in slow wave sleep in the puerperiwa. 
Similar results were reported b7 Billiard and Paaaouant 
(1974). K&racan considered that the changes in sleep in 
prep.an07 could be due to hol"JJlone cbaases, an4 he carried 
out a further inveatigation on the effect of oeatrosen and 
prosesterone treataent on a 2o-7ear old oophoreotoaized 
woman. She was given 10 daJs treatment with placebo, 
followed b7 10 d&Js on oestrogen, then a further 10 da7 
placebo period, then 10 daya on progesterone, and her sleep 
was recorded on the last three nights of each period. He 
reportecS onlJ preliminary results, which showed a slight. 
increase in RD4 sleep on oestrogen, but this stud7 is of 
limited value since onlJ one subject took part, it was not 
a blind study~ and the subject's sleep patterns '1:1J1t3 have 
changed with time as ahe adapted to the sleep laborator,r. 
Heuser (1968) investigated the relationship between 
progesterone and sleep by giving five v~lunteera 200 ag 
progesterone intramuscularly two hours before bedtime then 
recording their sleep electropbysiologioally. He reports 
that the sleep latency was decreased .bY this treatment and 
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the total sleep tillle 1Jlcrease4, bu~ these results must be 
interpreted with caution, sac• He\lser gives no 1ntor•t1oa 
on hia atudt deailn and doea not even a_, whether hie 
Tolunteers are male or tamale, or give their agea. 
Japi W.lier et al (1974) investigated the reJ.ationship 
between aonado~l'Ophina and sleep in snen 70ung women with 
seoondar,y amenorrhOea froa yar~oua oauaea, inolud1q one 
oaae ot p~~e menopause. The1 tOQild no relationship 
·between PSB, IB, · and ale•p •taB•• but they- did find an 
inverse relationship between sleep duration and mean .son-
adotropbin leYels. Their oestrogen and progesterone 
levels were not inYeatisated nor did the ·&Qthora · atQdt the 
effects ot horaone -.reataent on these patients. O.ther 
than tb.ia, -.here ba~ bean no studies ot the rela~1onah1p 
between horaonea ao4 sleep at the menopause. 
It ia clear that studiea ot the relationship between 
sleep and reproductive horaonea are at an earlJ stage, and 
while the time of pu.bert;.y baa been intensiveJ¥ studied, few 
workers have studied adult subjects and their reaulta have 
been conflicting. 
Little can be learned about ~he relationship between 
sleep and hormones troa studies ot sleep in the mens~raal 
OfCle and during pregnancy- because the hormone ohBDgea in 
both situa~ions are ooaplex, and even it changes in sleep 
pattern are found, it ia difficult to relate them to hormone 
changes. Most workers have studied the effect of sleep on 
hormone secretion, but a few have reported the effect of 
hormones on sleep, and although Heuser (1968) and 
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laracan e~ al (1968) reported that aleep duratio~ could be 
1aorease4 by the administration of progesterone aDd 
oestrocen, the s~d7 daaicJl waa inadequate in both oasea, . 
. so ~h••• reaults should be interpretecl with oaatioa. 
PSYCHOIDGICAL SlMPh(I(S 
Although emotional symptoms such as depreaaioa, 
au1•"7• and .irrit.bility are common at the tiae of the 
menopause, it doea not seem to be an aetiologioal factor ill 
severe psychiatric illness requiring hospitalisation. 
Smith (1971) attempted to assess ita significance ill 
relation to the onset. of mental illness requiring hoapital-
iaation by comparing a patient population of 880 woaen with 
2414 woman in the general population, and since the propor-
tion of women ·reaohing the menopause· in . the preYioaa 7ear 
was the same in the two groups, he concluded that the aano-
pause is not a causative factor of ~ental illness r.quirins 
hospitalisation. This waa a~so the conclusion of Winokur 
(1973) in his study of 71 women admitted to hospital · 
because of affective illness just before or ~fter the ••no-
pause, and· he oalcula ted tba t the risk of developiq an 
affective illness was no greater at this than at other agea. 
The ~enopause does not cause involutional melancholia, 
which oan occur in both sexes, and bas no direct t .. poral 
relationship to the menopause. Nikul.a-Baumann (197·1) 
showed that there was no relationship between the boraone 
changes of the menopause and involutional melancholia, 
since the hormone levels of ca8es and normal controls were 
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14ent1cal. The classical !ora of 1nvolut;1oD&l. ael&noholia, 
with e~toas ot reatleseneaa, agitation, 4epreaa1oa, 
auie'Q, apprehenaion, bl'poohondriaais with bizarre soutio 
delusions, feelings of unreali~, and paranoid ideas, is 
now rare, and it seems doubtful whether it ia a discrete 
ayudroaa or merely a variant of depreaaive psychosis auoh 
ae occurs at all ages, but coloured by the life events of 
aiddle age. ~it et al (1957) failed to find the olaaaioal 
syaptoma ot involutional melancholia in 54 women adaitted 
to a ps7chiatric hospital for the first time between the 
agea of 40 and 55, an4 Boaenthal (1968) .uggested that 
earlJ and effective trea~ent of depression a&J prevent the 
dn-elopment of the tull•blown s711droae. 
Milder forme ot payohologioal illness are co .. on in 
the periaenopaueal period, aa baa been shown by the epiduai-
ological surveys reviewed in previoua sections, but their 
cause is uncertain. Greenhill (1946) claimed that 
psychological syaptoms at the time of t;he menopause are 
psychogenic, due to fear of the loaa of fe~ilit.J and the 
end of an active sex life, or due to an unhappy marriage, 
and also ocour in spinsters and ohildleaa neurotics who 
feel that they have missed something. Stern and Pradoa 
(1946) also consider depression at the time of the menopause 
to be reactive, and they claim that women do not suffer 
from psychoneurosis at the menopause ULless they have a 
good cause for depression or a history of mental illneaa. 
Ballinger (1975) investigated the relationship of 
psychiatric morbidity to the menopause by means of the 
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Goldberg General Healtn Queatiomaaire, a aelt aaaiaiaterecJ 
qv.eatiouaire developed to detect CN.n"en-. eaotioD&l dia-
turb&Aoe in oomwnnit7 sarYeys. She carried out a pos~l 
survey of all women aged 4o-55 on the lists of six Dundee 
general practitioners, and 539 (71~) of the 760 woaea 
approached responded. She identified 155 of these woaen 
as "ps7obiatrio cases", and found an 1noreaa4a in P•7oh1atr1o 
morbidi~ before the aenopauae, lasting for one year af~er 
the last menstrual period. !bose women identified aa 
oases bad ailing or demanding parents, probleu wi-th the child-
ren, and children haTing. left home more frequentlJ thaD 
non-oases, but it was not poaaible to tell froa thia atudy 
whether the .. otional problema caused the faiq probleu, 
or vice-versa. Ballinger went on to interYiew 114 of the 
155 "payohia trio oaaelt' (Ballinger, l976a) and foua4 'tbat 
18 were taise positives, with no evidence of payobiatrio 
illneae. In the rema1Dder, the moat ooJmnon complaint• 
were of anxiety and depreeeion, and the oomaoneat 41agnoaia 
was personality disorder with neurosis (69 oases) followed 
by affective psychosis (27 cases), while phobias and 
obsessional states were leaa common. 
These results should be interpreted with caution, since 
the age group Ballinger studied was very limited. Bagnell 
(1969), in a study of the l-year incidence of mental 
morbidity in the population of Southern Sweden, found tnat 
the incidence of mental illness was hi ghest in women in 
the reproductive years, with a maximum at the age of 45, 
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FIG. Ja The average annual incidence of onset of mental 
illness in women. (Hagnell, 1969) 
l 
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and i~ is possible that it Ballinger had included younger 
women, she would have found that psychiatric morbidi~y 
increased a~ an even earlier age, or that depreasion or 
neurotic s7mptoms occurring at an earlier age recur a~ the 
time ot the menopause. 
HallstrOm (1973) inve.stigated the relationship between 
psyChological and social factors, mental health, and the 
aenopause in middle-aged woaen in Gothenborg. He inter-
viewed a &~ratified sample ot women aged 38-54 by means ot 
a semi-etruotured psychiatric interview, and examined 800 
ot the 899 women selected. He found no significant differ-
enoe in the tnoS4enoe ot aental illness between the T&rioua 
oliaoterio ph&••• but those women who deTeloped a aen~al 
illneaa in ~he ol1maoterio were .ore likelJ to have a tami~ 
hietor,r or a preY1oua hiator,r of mental illness, and bad 
aigDifioantly more psychological atresa factors than other 
woaen. . !hey had raore episodes of marital disruption, 
whether due to separation, ~ivoroe, or the death ot the 
husband, bad more problems with the children, and more 
unhappiness at work. He did find that women in the peri-
menopausal phase, which he defined as having lese than 
twelve months amenorrhoea, complained of a deteriora~ion in 
mental health more often than those in other oltmaoterio 
phases in this study. •• Hallstrom also observed a decrease 
in the sex drive and sexual activity 1~ middle aged women 
in the climacteric, which was most marked in the lower 
social class groups and in women with a mental illness. 
' ... , --... · 
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Depression is approximatelJ twice aa common in women 
than in men during the reprocJucti ve perio4, and Pollitt 
(1917) and Weiaeman and Kleman (1977), who reviewed the 
evidence tor this difference, concluded that it was moat 
likely to be due to endocrinological factors. SJmPtoaa 
of tension, depresaion, &Dd irritability are known to occur 
in women at times of changing hormone levels, such aa the 
pr .. eaatrua1 pbaae of the menstrual cycle, the puerperiua, 
and when t &king the oral contraceptive pill. It 1a widely 
believe4 that cbangea of mood at these times are due to 
cbangea in either the levels of oestrogen and proaeaterone, 
or in the ratio ot oestrogen to progesterone, but the 
evidence for this ia conflicting and conclusive proof 1a 
lacking. The most popular view ia that depression at the 
time of the menopause is due to fallin& oestrogen 1evela, 
but again reports ot this are anecdotal (Kall~aon, 195lt 
Wilson and Wilson
1
196J) ·and proof is . lacking. Utian (1972&) 
atteapted to define the a,aptoll8 of the menopause in a 
atudy of the symptoms developed after oophorectoaJ b7 50 
South African women, compared with nine normal control• &D4 
36 women who had had a hJstereoto~ with oonserY&tion of 
the ovaries. The patients were interviewed immediate~ 
aix months and two years after the operation. He concluded 
that the onl,y symptoms directly related to the oophoreoto113 
were ~ot flushes and atrophic vaginitis, and that depression 
was likely to be of psychological origin, and was not 
improved by oestrogen treatment. However, these findings 
cannot be generalised to women undergoing a na~al 
menopause since ~he subjects · bad had an abrupt obaqe in 
oeatroaen levels due to oophoreotODq't and since the poa.-
menopauaal ovary 1a not in.rt they ~ bave bad other 
hormonal differenoea. Aylward (1973) reported that both 
oestroaen and tree plasma t1'7Ptopban l.vela were low in 
perimenopauaal women and auggested tnat these two taotora 
were related to depression in thia age group. Coppen et 
al (19'72). bad prertoual.7 report~ that t~ee plasma trJptopbaa 
leTela were low in middle aaed female depreasives, and in 
a later repor1 (Coppen et aJ., 1973) claimed that free JlaiiM 
tryptophan levels rose aa the depressed mood iaproTed• 
BoweTer, ·other worker• baTe failed ·to oo~trm a rel&tioa-
ahip between free pla8ll& tmtophan and depreaaioa . (Niskanen 
et al l916t Peet et &lt 19'76t Rilq and Shaw, 1976) though 
it should be noted tbat thq studied patients of all agee, 
and the studies of ft1skanen et al (1976) and Riley and Shaw 
(1976) included male as well as female patients. 
Klaiber et al (1976) bave observed that depression in 
women may be related to the effect of their oeatroaens on . . 
the enzyme monO&mine oxidase (KAO). They found that pla ... 
MAO aotivit.y is inveraelf related to plasma oestrogen 
levels in women, and since MAO is an important en~me in the 
metabolism of several of the neurotransmitters, and inhib-
itors of this en~e are known to act as antidepressants, 
they went on to test the value of oestrogens in the treat-
ment of depression. !hey carried out a controlled trial 
of the effect of treatment with conjugated equine oestrogen• 
on 30 women with severe intractable endogenous depression 
which had failed to respond to other forma of trea~ent. 
After three months, the 16 oestrogen treated paiienta h&4 
a signifie&nt decrease in their plaama JU.O activity, aD4 
their aoore on the Hamilton depression rating aoale bad 
fallen from 29.3 to 18.4, while the 14 placebo treated 
patients showed no chaage in their MAO activity and a fall 
of only 1.7 in their Hamilton depreaaion rating scale score. 
However, iO~ of their patients were premenopausal, aDd the 
pos.tmenopauaal patients b.&4 in fact responded less well . 
than the younger_ women. Also, the population atadiecl is 
highl.Jr aeleoted, and these results oa~mot be generalised to 




~e symptom aoat colllllonll attributed ~ the maopauae 
ia the bot flush, arut' as baa been allown by the epidULi~ · 
locioal surveys reviewed in a ~revioua chapter, hot flushes 
start before menstruation stops in many oases, affect up 
to 93~ of women in the years tmmediatelJ after the menopauee, 
and may even continue tor u}) to 20 years. 
Hot flushes begin with a sensation of wara•h over the 
upper chest, spreading to the neck, face aDd arms, and if 
severe tlley may be accompanied oy g14d1nesa, headache, and 
a feeling of a wave of heat followed by pro~se perspiration 
and a sensation of chilliness. They may ocour several 
t~es a dS¥, and a similar phenomenon, night aweata, may 
occur in bad. Hot flushes can be precipitated by heat, 
alcohol, or emotion. 
l :... . • . 
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Hot tlushea are not merel.J a aub~ecti'Ye experience, aa 
redclelli.q of the skin m~q be seen by observers. Collett 
(1949) obsened a deeper reapiration .• t.-;peratve illorea••· 
and increase in basal metabolic rate during· hot tluahea. 
Molnar (1975) reported that hot fluahea were preceded b7 
taobyoardia and fluctuation in the baseline ot the ICG, 
an4 this waa oont1rae4 b7 Sturcsee et al (1978).. Sturdee 
also observed an aou.te rise in the skiD tem.pe~ture, peri-
pheral vasodilatation, and a 4eoreaaed akin reaiataace 
during the hot flush, and concluded that 'the hot tluah 1• 
aaaociated with a sudden and transient increase in ~thetio 
• tone. 
It ia widel7 belined tha:t hot thtshea are due to 
falling oeatrogen ·l.vela at the menopause. Mulle7 &D4 
Mitchell (1976&) reTiewe4 the eT14ace tor this, aDd stated 
that there was no ooncluaive proof ot a relationship betweea 
hot ~shea and oestrogen leTels, but U'tian (~976) 41sacree4 
with this 'Yiew and stated that the r•sponse ot hot .tlushea 
to oestrogen therapy proved that .oestrogen detioi~nc7 
causes them. Mulley and Mitchell (1976b) replied that hot 
flushes also respond to other treatments, including placebo, 
and since the superior1 ty of oestrogen over placebo has 1et . 
to be established, it would be premature to say that_ 
response to oestrogen treatment proves a hor.monal aetiologr 
for hot flushes. Albright (1936) and Shute (1939) ooul4 
find no correlation between urinary oestrogen and the 
severely of hot flushes. Campbell (l97i&)studied the 
relationship between hot flushes and the changes in hormone 
!i--
l~ela 1n seven poatmenopaua&l women with hot fluahea &D4 
OOJtP.re4 th• with tour age-u:tohed controls .who d14 not 
experience hot fluahea. He oould fiD4 no difference in 
oestrone or oestradiol leTels between his oaaea an4 
controls, and although he obserYed tbat flushing patient• 
ha4 sharp aurcea of oeatre4iol and low baseline leTele, h~ 
conclwled that the correlation between hot tluahea and low 
or falling plaama oestrogen or androstenedione levela. waa 
not oloee enough to prove a causal l_"elationship. Button 
at al (1978) also co~red the hormone levels of woaen with 
hot flushes with those of women with~t vasomotor s~toaa, 
and oonclu.de4 that flwshea ~ere not related to either aw.te 
oh&Dges or mean levels of plaa.a oeatrogeaa. Bot all 
atwti•• of the rela tionahip between honaone ·levels and 
vaa0110tor ayaptoaa bave been negat1Te1· shoe Chakraw.rti 
et al (1979) have reoentl¥ reported that premenopausal 
women with vasomotor 81DPtoa8 incl~ing hot flush•• ha4 
lower plasma oestra4iol and higher goDadotrophin leTela 
than women of a similar age without vaeoaotor aymptou.· 
The theor,- that hot flushes are related to hip 
.gonadotrophin levels has little support now. lluhman 
{1930) found no .correlation between hot flushes and goD&-
dotrophin leTela, and reoentJ..y Kul.ley et al (197·7) reported 
two oases of hot .flushee occurring after bypopbyseoto.,. 
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TREATMlmT Ol MlliOPAUSAL SYMPTOMS 
Surprisingly few patients consult their doctors 
because of menopausal complaints. Bewton and Odoa (1964) 
in their study of 80 American post-menopausal women, found 
that only 23% consulted their doctor because of their 
symptoms. The International Health loundation surTey 
( 1970) found a consultation rate of 41$, and Thoapeon et 
al (197 3) found a similar rate in Dundee, where 38% of the 
post-menopausal women studied bad consulted their doctor 
before their la.st period, and 33% bad consulted hia after 
the time of their last period. llllcKin~ and Jefferys 
(1974) found that the consultation rate among women with 
hot flushes was only 22,:; in their London study, corapared 
to 45% in the study of fnompson et al (1973). 
This low consultation rate fiAT be due to the ailcl 
nat1,1re of the S.YIIptoms, and the IHF survey found that 88% 
of the women who did not consult their doctor said they 
would do so if their symptoms became troublesome, and only 
9% said ·that 'nature must take its course'. llallinlay and 
Jefferjs too found that women were more likely to consult 
their doctor if they experienced acute physical discomfort 
and embarrassment from their symptoms. 
The difference in consulting rates may also reflect 
the attitudes of the doctors, since not all agree that 
menopausal symptoms require treatment, and those who do 
recommend treatment are divided in their opinions of the 
most appropriate treatment. 
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Some favour psychotherapy as being the best form of 
treatment, bu~ others recommend drug treatments such as 
tranquillisers, ant1depressan~s, or hormone therapJ. MaD7 
of the papers recommending these treatments are purelf 
anecdotal, and give no evidence or data to support the 
argument, but a large number of olinical trials have also 
been carried out. It is still not possible to draw &D.¥ 
firm conclusions about the trea~ent o~ the menopause, 
since these clinical trials have not produced comparab.le 
or consistent data. They differ in the treatments and 
doses used, and in the symptoms studied,and many have used 
only crude global ratings including all SJ11LPtoma, and in 
some oases side effects too, ae a measure of change. !he 
Blatt (or X:uppermann) Menopausal Index was deTised b7 
Kuppermann et al (1953) in an attempt to increase the com-
parability of results, and it is a rating scale which 
includes a number of symptoms which are common a~ the time 
of the menopause, giving extra weighting to the more common 
symptoms such as hot flushes (see Fig. 4). It has been 
used in many studies, but its value is in question because 
several of the symptoms included, such a• headaches and 
palpitations, are not now considered to be associated with 
the menopaus •· 
A further problem in evaluating clinical trials is the 
heterogeneous population studied, including women who are 
still menstruating, women up to 30 years post-menopausal, 
and women who have undergone hysterectomy and oophorectomy. 
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Symptoms Weighting severi'Q' Soore Faotor 
1. Vasomotor 4 
2. Paraesthesia& 2 
). Insomnia 2 
•• Nenousnasa 2 
5· Depression l 
6. Vertigo· l 
7. Fati&Ue l 
8. Bone and 1 Joint Pain 
g. Headaohes 1 
10. Palpitations 1 
11. :Pol'llioation 1 
FIG. 4a Menopausal Index Ratin& Scale (Kupperman et &1,1953) 
The a .verity of eaoh symptom is ra teeS on a 4-point 
scale and multiplied by the appropriate weighUq 
faotor, and the sum of these scores gives the 
menopausal index score. 
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A marked and prolonged placebo effect on menopausal symptoms 
baa been reported by Pratt and Thomas (1937), Donovan 
(1951) and Coope et al (1975), but many studies haTe lacked 
a control group, or been inadequatelJ controlled. 
(a) Pazchotherapx 
Controlled tr~als of psychotherapy are almost impossible 
to devise, though this ~reatment has repeatedly been 
reported to be effective in relieving menopausal symptoms 
(Saunders, 19321 McDowell and Paterson, 1940; Hoskins, 1944; 
Greenhill, 1946J Fessler, 1950; Williams, 1971). 
Pearl and Plots (1964) see the aim of treatment aa 
facilitating adjust.ent to a natural change, and consider 
that this can best be done by supporting, reassuring, aDd 
educating the patient, correcting her fantasies, and urgiD.g 
her to use her new freedom from family concerns to extend 
her aotiTities, reactivate dormant interests, and pursue 
unfulfilled ambitions. McCandless (1964) and Steiner 
(1973) advocate the use of marital therapy as well aa 
individual psychotherapy, since the changes of middle life 
ean bring difficulties to both partners in a marriage. Donovan 
(1951) , who relieved most of his patients' symptoms by 
histor.y taking alone, states that the most important factor 
in relieving menopausal symptoms is a good doctor-patient 
relationship, and Jeffcoate (1960) claims that explanation, 
advice, and reassurance will alleviate or prevent meno-
pausal symptoms in 95% of menopausal women, and t bat only 
those who are over-anxious require medication. 
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Most of those who advocate psychother.ap;y do so on the 
basis of clinical impression rather than scientific study, 
and so their papers are mainly anecdotal. Donovan is the 
only one to giYe data, and he was not giving psychotherapy, 
but merely taking a case histor,y. 
(b) Tranau1111sers aJ14 J.ntidepresep.ts 
These are frequently prescribed, but seldoa atudied, 
in the treatment ot menopausal symptoms. Jetfcoate (1960) 
recommends their use tor women with symptoms ot irritability 
and emotional upset who have not responded to psychotherapy, 
and claims that they will also reduce vasomotor inatabilit7• 
Pearl and Plots (1964) endorse this recommendation and 
tu.rther state that the soaewhat noxious aixture ot pheno-
barbitone, belladonna, and ergotamine tartrate, should be 
giYen on a temporar,r basis to the severely distressed 
patient. No data to support the recommendations is given 
in either of these papers. 
Three studies on the use ot antidepressants haTe been 
carried out, by lorman {1968), Kerr {1970) and Wbeatl_, 
(1977). lorman reported a double-blind study comparing 
an antidepressant (amitriptyline) with a tranquilliser-
antidepressant combination (aaitriptyline-perpbenazine) on 
26 women. He concluded that the combination was more 
effective, since 16 patients improved on this compared with 
seven on amitriptyline alone, but the value or· this con-
clusion is doubtful since improvement was measured by a 
crude global scale including relief from all symptoms and 
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the presence of side eftec~s, and no data is given on the 
composition of the two treatment groups or the dose of 
dru&s used. Since no control group was included in this 
study, it is not possible to tell whether these two treat-
ments were more effective than placebo in relieving symptoms. 
Kerr (1970) reported a double-blind a~d7 of amitrip~7lin~ 
against placebo in 50 woaen with 'emotional cb&nge'. fhe 
characteristics of the groupe again are not 1:eported, aa.d 
emotional and phJsioal symptoms were rated together on a 
global scale from 0-4· Kerr concluded tba~ aaitript7l1ne 
improves .. otional symptoms in the menopause, since 76% of 
the treatment group improved, compared with onlJ 25~ of the 
placebo group, but the value of this conclusion is doubtful, 
because of the contused aature of the treatment regiiD.e. 
He gaTe varying doses of aaitriptyline, according to the 
response, but the mean dose was very low (55 mg/day), &Dd 
the results were further confused by the administration of 
oestrogen therap7, again in two different doses, to both 
treatment and control groups. 
Wheatley (1977) compared the effect of amitript,yline 
(25-50 mg. T.I.D.) with or without the addition of 3 mg/day 
piperazine oestrone sulphate on 58 depressed menopausal 
women. He found that all improved, and that the addition 
of oestrogen did not produce any significant additional 
improvement as measured by the Hamilton rating scale, global 
rating, or a self-rating scale. 
These studies, then, have failed to demonstrate that 
antidepressants are significantly more effective than 
placebo in treating depression in the menopause because of 
their inadequate controls. 
(c) Hormone Therapx 
A variety of hormones, including oestrogens, androgens, 
and progesterone, have been used either singly or in co~ 
bination in the treatment of the menopausal syndrome. The 
moat wideJ.¥ used horaone treataent is oestrogen, which JUT 
be g1Ten orallJ, by 1n3ect1on, or as a depot in the form 
of a subcutaneous pellet. Oeatrogena may be olaaaitiecl aa 
natural (oestrone, oestradiol, oestriol), oon3ugate4 (equine 
oestrogena) and synthetio (ethinJl oestradiol, stilboestrol) 
and it haa been claimed that the natural oeatroe;ena are 
safer than the synthetic, though this baa not been oonalua-
ively proven. Progesterone is usuall¥ given oyolical.l7 
in oombiD&tion with oestrogen to produce a withdrawal bleed, 
intended to minimise the risk of endometrial hypertropbT 
or carcinoma,and testosterone, which may in large doses 
have a virilizing effect, is sometimes given to menopausal 
women to increase libido and produce a sense of well-betng. 
Oestrogen treatment is frequently called boraone 
replacement therapy, but this term ia misleading, eince 1t 
implies that the hormones are returned to premenopausal 
levels. It is known to reduce gonadotrophin levels, but 
both La.rsaon-Cohn et al (1977) . and Lind et al (1978) bave 
found that gonadotrophin levels of women on oestrogen 
treatment remained higher than those of premenopausal womea.. 
Many workers have showed that oestrogen treatment causes 
·, 
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an increase in both oestrone and oestradiol levels (Cooper 
et al, 19'741 Daw, 19751 Aylward, 1976; Hutton et al, 19771 
Larsson-OohD. et al, 19771 Lind et al, 1978). Moat of these 
workers bave studied the effect of piperasine oestrone 
sulphate, oestradiol valerate, or equine oestrogena, and 
with these treatments it aeeJU that there ia a veey high 
level of oestrone at the start of treatment (Jaoobs et al, 
19771 Anderson et al, 1978) while oestradiol levels iaoreaee 
onl.y gradual}¥, and the levels of both oestrogen• stabUiaecl 
at the end of a months treatment. !he actual oestrogen 
levels depend on the dose and the type of oestrogen used, 
but it ia surprising to find that piperazine oeatrone 
sulphate and oestradiol T&lerate have the same effect on 
plasma oestrone and oestradiol lrrels, as was reported b7 
Hutton et al (1977), Jacobs et al _ (1977). and Anderson et al 
~978). These authors concluded that oestradiol ~st be 
converted into oestrone either in the gut or in the liver, 
and it seems that treatment with these two oestrogen prep-
arations ~st have the same effect. However, not all · 
oestrogen preparations have the same effect on plasma 
oestrogen levels, and Larason-Cohn et al (1977) found tbat 
oestradiol valerianate and ethinyl oestradiol had different 
effects on both gonadotrophin and oestrone levels in post-
menopausal women. AlthoU&h m&D3 of these workers have 
found that oestrogen treatment can restore plasma oestrogen 
levels to those found in the menstrual cycle, none have 
found that the cyclic pattern of change in the levels was 
restored, or that the premenopausal oestroneaoestradiol 
ratio waa res~ored. BPtore ~he menopauae, ~hia ra~io ia 
lese than one, but in pos~enopauaal women the levels ot 
oestrone exceed those ot oestradiol, and oestrogen treat-
ment baa been foUnd to leaTe this ratio uncbalage4 (Liad 
et al, 1978) or even to increase it (Jacoba et al, 19771 
Larsson-Cohn et al, 1977). 
MaDJ authors baTe giTen advice on the use ot oestrogen 
trea~ent, but given no evi4enoe to support their views 
(Novak, 19401 Connon, 19731 lCerr and Vau,8ban1 1975). 
Wilson and Wilson (1963) bave claimed that the menopause 
is a 4etioienoy disease, to be trea~ed with oestrogen troa 
the onset of 1rre~lar periods till death, and they believe 
that this treatment will prolong youthtulness and good 
health, but few would agree with the utr•e view. It is 
generall7 agreed that oestrogen treatment relieves 
atrophic vaginitis, and Lindsay et al (1976) and Horsman 
et al (1977) have reported that oestrogen treatment can 
stop and perhaps even reverse osteoporosis in postmenopausal 
women, but its value in the treatment of other menopausal 
&JDlPtoaa bas yet to be conclusive}¥ proven. Since there 
is no agreement on which symptoms are related to the 
menopause, studies 1n which the symptoms have been rated 
on scales whioh include several symptoms have given little 
information on the value of hormone therapy. The symptom 
which bas most commonly been studied is the hot flush, 
since this is the symptom most commonly attributed to the 
menopaus£, but even here the value of oestrogen therapy is 
controversial. Cross-over studies carried out by 
Gl , 
Greenblatt et al (1950), Kupperman et al (1953), Utian 
(1972a), Coope et al (1975) and Campbell (197bb)have all 
shown that oestrogen is sicnifioantly more effective than 
placebo in relieving hot flushes. However, Kulle7 and 
Mitchell (1976) oonoluded that the va~e of oestrogen 
treatment 1n the treatment of hot flushes bas not been 
conclusively proven, since other workers found no difference 
between· oestrogen and placebo, and several of the studies 
which did report a difference had design flaws saoh as 
lack of double-blindness, or inadequate controls.· 
Other workers have been ao convinced of the value of 
oestrogen treatment tbat the7 have not included a control 
group in their studies e.g. Reioh et al (1952), Wallach and 
Henneman (1959), Wilson et al .(l963), Tremont (1966), 
Perrell •nd Bennett (1970), Sohle7er-Saundera (1971), 
Villa4olid et al (1973) and Rhoadea (1974)• These have 
all concluded that oestrogen relieves menopausal symptoaa, 
but because of the lack of a control group, the7 have tailed 
to prove that it is aore effective than placebo. 
The studies of Lozman et al (1971), Aylward et al 
(1974) and Wheatley (1977) bave also been inadequatel7 
controlled, since the7 gave their patients a placebo 
followed b7 two oestrogen treatments in a erose-over design, 
but .did not include placebo in the cross-over part of the 
study. 
Other workers have included a placebo period in their 
cross-over stadies (Greenblatt et al, 1950; Coope et al 1 
1975; Campbell, 197fb) and these have all found that 
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oestrogen is more effective than placebo 1n relieving 
menopausal syaptoaa. !he study of Caapbell is of partic-
ular interest since he investigated a number of physical 
and psyohologioal ·aamPtoms 1ndiv1duall7• He aotuall7 
carried out two studies, one on patients with mild ayaptoma 
and one on patients with severe symptoms. !he stud7 of 
the ·patients with aild aymptOJU lasted for one 7ear, 4ur1q 
which the patieata took conJugated equine oestrogen• tor 
three out of tour weeks tor six aonths, and placebo tor six 
aontha, but the stad7 of the patients with severe aymptoaa 
lasted tor only tour months, two on active treat.ent and 
two on placebo. The patients in both studies were asaeaaecl 
ever, two months using the Goldberg general health question-
naire (OHQ), Beck depresaion aelt-rating ·scale, and the 
_,aenok peraonali v inventor,y (EPI), as well aa selt-ratecl 
graphic rating scales for a wide varie~ ot symptoaa. The 
GHQ, Beolt soale, and :§li all showed a Jl&rked placebo 
etteot and failed to differentiate between the oestrogen 
and placebo treatments, but the graphic rating scales 
showed oestrogen to be aore ettective than placebo in 
relieving hot flushes, vaginal dryness, aDd poor maor,y 1n 
the patients with mild &JilPtoma, and hot tlushes, ina011111a, 
vaginal dr,yness, irritability, and headaches in the group 
with severe symptoms. Ooope et al (1975) found no signifi-
cant difference between the oestrogen treated patients and 
placebo treated patients in the first part of the stud7, 
but after the cross-over oestrogen was s1gnifioantl1 more 
effective than placebo. 
The results of these erose-over studies should be 
interpreted with caution, since the patients may have bad 
persistently elevated oestrogen levels after the oroas-
over from oestrogen to placebo treatment. Daw (1975) toun4 
that after three months treatment with piperazine oestrone 
sulphate the oestradiol levels in plasma remained above 
the pretreataent levela for three months, and since both 
Coope et al (1975) and CU.pbell (l97fib,)allowed onl.T a · one 
week ·withdrawal period before the cross-over, the patients 
may not have re~ed to the baseline condition. 
Other studies have compare4 the effect of oestrogen 
and placebo on menopausal woa.n. The earliest of theae 
was the atw!J of Pratt and Thoua (1937), 1n which the 
effeqt of theelin (an oeatroaen preparation given by i.~ 
in3eotion) was compared with the effect of a placebo oil 
in3eotion, and phenobarbitone tablets with placebo tablets. 
The majori1y. of the patients improved regardless of the 
nature of the treatment, and they found the various treat-
ments to be equally effective_ 1n relieving both. physical 
and .psychological symptoms. It should be noted that 50~ 
ot the patients dropped out from this study, and although 
the authors claimed that this was uauall3 because they felt 
well, they give no data to support this. Jlrvinen et al 
(1971) carried out a similar study comparing oestriol 
succinate with placeb.o, and they also failed to show that 
the oestrogen was more effectiye than the placebo treatment. 
Martin et al (1971) compared a sequential oestrQgen-
progestagen combination with placebo, and concluded that 
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oestrogen waa significantly more effective than placebo 
in relieving hot flushes, but their study was unl1kal7 to 
have been 4 ouble-blind 1 aince the pa tiants bad withdrawal. 
bleeding at the end of evar,v month. on aot1ve treataent. 
Cooper et al (197 4) compared the effect of placebo 
and piperasine oestrone sulphate on oophoreotoaized women. 
In their s~dy"1 the control group showed no impro?eaent, 
while the oestrone group bad relief of symptou in nine .out 
of tan cases, though there was no clear cut level of 
oestrogen at which symptoma were abolished. In a further 
investigation, Daw (1975) studied both nine oophorectomized 
women and eight woman with a pbJaiological menopause, all 
ot whom ware gi?en oestrogen treatment for three montha. 
In &eneral, patients with laaa than 40 pg/ml plaa.a 
oestradiol ba4 symptoms, and those with higher levels ha4 
not, though .the cut-off was not in fact as clear as thia. 
Following cessation ot treatment, plasma oestra4iol levala 
remain elevated for twelve weeks before . showing a steady 
fall, and symptoms re~r.red when oestradiol levels fell 
below 40 pg/ml. This study was uncontrolled 1 and, as 
with the previous study, no information is given on the 
nature of the symptoms, nor how they ware rated. 
Many attempts have been made to treat mental illness 
in postmenopausal women with oestrogens, but these have 
met with little success. severingbaus (193)) found that 
oestrogen injections combined with psychotherapy improved 
psychological symptoms in 32 postmenopausal women, and 
Hawkinson (1938) reported excellent results in relieving 
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depression in 1000 postmenopausal women and turther clataed 
to have cured 12 out of 14 women with depreaaive illness b7 
ten weeks o! oestrogen therapy, but other· studies have 
produced oonf11oting results. Bowman and Bender (1932) 
found that onl3 two out ot their seven oases of 1nvolut1oD&l 
melancholia improved, and Shube et al. (1937) found no 
improvement in ten casea. The onlf controlled studJ was 
that of Werner et al (1936), but this trial was not blind, 
and the control group were also given oestrogen treataent 
after six months. They reported a final imprOYeaent rate 
ot 29 out of 40 oases, but m&J11 of these 'IIJJq have i.ltprove4 
apontaneous1J, and th1a atudy waa ina4equatel7 controlled. 
Oestrogen therapy neYer beoaae w1cleq accepted as a treat-
aent tor 4epreaa1ve illness, &Dd ·with the advent of etteot-
1Ye antidepressants ita use was abaD4onned. However, ita 
use in milder cases of depression oont1auea, although the 
results of therapeutic trials have been conflicting. 
The effect ot oestrogen treat-Rent on psychological 
s1Jilptoma baa been studied by- m&IJT worltera, but their reaulta 
have been contlictiDg. Utian (1972b) carried out a single-
blind orosa-over study of the effect ot equine oeatrogens 
on oophoreotoaised women in which their emotional a~te 
·was rated using a 6-potnt global rating scale, in which the 
patient's account, and where possible her husband's account, 
ot how she was coping at home, at work, and soo1allJ were 
assessed. He observed that oestrogen hadamental tonic 
effect, but when George et al (1973) attempted to replicate 
this work using the Beck self rating scale of depression to 
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measur• mood, they found that oestrogen was no more 
et:fective than placebo in improving mood. They concluded 
that the mental tonic effect was dose-dependant, since they 
ha~ used a smaller dose of oestrogen than that used by 
Utian (1972b), but Hawkins and Polakow .(1974) pointe<) ou-. 
that George et al. (1973) ~ onl.¥ studied 13 patients, an4 
that this is too small a gr~p to show atatistioall.y 
significant results. 
qlwarcl (1973) alao found that oestrogen treatment 
improved 4epreaaion in bia double-blind controlled atud7 ot 
the effect ot piperazine oestrone sulphate on the mood ot 
oophorectomized women. At the start of bia study, all 
patients bad low tree plasma tZ7Ptophan l.vele, and 
oestrogen treataent was associated with an increase in the 
tree plasma tr,rptopban levels and relief of depression, 
while the placebo group bad persistently low free plasma 
tryptophan levels and remained depressed. In a later 
paper (.ll'lwar4, 1976) he repo~ted that a double-blind 
controlled study bad showed that piperazine oestrone 
sulphate was significantly more effective than placebo in 
relieving depression in 65 postmenopausal patients, but 
since he had treated all. patients with placebo before the 
start of the study and el.1m.1nated all placebo responders, 
this resul.t is scarcely surprising. It is arguable whether 
or not it is justifiable to exclude placebo responders 
from a study, and a further problem in e~luating these 
two studies is the lack of information about · the actual 
scores of the patients on the Haailton depression ratin& 
scale. 
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The effect of oestradiol valerate on depression in 
postmenopausal women was studied by Fedor-lreybergh (1977). 
He ·carried out a double-blind controlled study on 21 patients 
in which they were assessed, given a supply of tablets 
which they were told would help them, and reviewed at the 
end ot three aontha. The placebo group (n•lO) had showed 
an increase in their mean score on the Hamilton depression 
rating scale. but the oea'trocen treated group (n•ll) showed 
a aignitiQ&Ilt fall in their aoorea. N8Qr0t1c1 .. aa 
aeaaurecl 'b7 the ~aenck peraon&ll v 11lvento17 also tell in 
the oestrogen treated patienta, and increased in the 
placebo group, and on a aeneral health queatiou.aire the 
.patients on actiYe treatment also reported an 11nprOTeunt 
in auiet7, sleep, and meaoq • 
!he atudiea of the effect of oestrogen treatment on 
psychological •1lllptoma at the time ot the menopause baTe 
not all anown .oestrogen to be more effective than placebo. 
Utian (1972a) and llauraao et al (1976) both coaparecl the 
effect ot oestrogen aDd placebo on women after oophorecto., 
in an attempt to determine the relationship between the 
symptoms developed and the change in oestrogen levela. 
Utian observed that depression, irri~bility, and insomnia 
were a1gnificantl.J relieved by placebo and concluded that 
these symptoms must be psychogenic 1n origin, since 
oestrogen was no more effective ~han placebo in relieving 
tnaa. Bauramo also found that oestrogen was no more 
effective than placebo in relieving depression and anxiety 
after oophorectomy, but he found that the oestrogen 
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treated group bad a lower incidence o! complaints of 
insomrd.a. Pra~t and !ho•s (1937), as alreadJ aent1one4, 
failed to show the superiori~- of oestrogen over placebo 
in relieving psJchological symptoms in postmenopausal 
women, and in cro••-over studies both George et al (1973) 
and Oaapbell (1976.)f01Uld that oestrogen was not sipit1-
oantl.7 ure effeotiTe than placebo 1n relieTing depre•aioa 
in poatmenopaual woaen. Strickler et al (19'77) also 
carried out a croaa-oTer a'tud7 of the effect of equine 
oestrogen• on psJOholosioal aymptoma in poataenopauaal 
women, and found that 16 of their 20 patients reaponded 
equall.J to oestrogen and placebo, and onlJ' two reaponde4 
to oeatroc~ and not to placebo treatment, so the1 too 
tailed to show that oestrogen ia the aozre effect1Te 
treatment. 
It is olear froa this reTiew of the literature that 
little is 7et known about the menopause aD4 the aymptoma 
associated with it, and that oestrogen treatment can onlJ 
be evaluated b7 investigating ita effect on individual 
symptoms rather than * group of complaints which mtq be 
unrelated to the menopause. There are likely to be differ-
enoes between women who have undergone a surgical meno-
. pause, perimenopausal women, and women who are 20 or 30 years 
postmenopausal, so in order to s~d7 a homogeneous popula-
tion, the age range included in any stuc11 should be 11llited. 
In view of this, I have investigated the effect of treat-
ment with piperazine oestrone sulphate on sleep, mood, 
anxiet7, and hot flushes in perimenopausal women. 
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SUBJECTS JUTERIALS AND ME'BIODS 
Patients in this study were either referred by their 
general practitioners o~ in a small number of cases,had 
volunteered after hearing about the stud¥ froa their_ 
friends. All patients taking part in the studJ did ao 
with the knowledge and oonaent of their general practitioner. 
!he pati•nta were women aged 45-55, with amenorrhoea for 
at ieaat three months, and aJaptoas of insomnia, depression, 
anxiety, and hot flushes, who ba4 no contra-indication to 
oestrogen therapy such aa a history of throJibo-eabolio 
disorders, aalignancy, or ~aundice. Before comaenciDg the 
study, all patients were 1nteniewe4 so that the study 
could be explained to them all£! a full history taken, and 
thef were shown the sleep labora'*Ol7• ADTone takiDB 
bJPnotics, tranquillisers, or ho~one therap7 was required 
to undergo a 6-week withdrawal period before starting the 
trial. All subjects received £4 per night · for travelling 
expenses. 
The trial was double-blind and controlled, and lasted 
14 weeks for each patient. In the first six weeks all 
patients received a placebo, but in the remainins eight 
weeks half of the patients (desigaated the oestrone group) 
· received piperazine oestrone sulphate ("Harmogen••) in a 
dose of 1.5 mg twice daily, while the remaining patients 
(the placebo group) remained on placebo throughout the 
atudJ as a control. Oestrogen and placebo tablets were 
identical in appearance and were labelled with a code so 
that the patients and staff were unaware of their content. 
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All patients were warned that the pills they received 
aight be blanks. 
Throughout the studJ, patients attended the sleep 
labo~tor,r in pairs on one night per week for electro-
physiological recording of sleep. In each pair, one 
patient was in the oestrone group and one in the placebo 
group. Patients reported to the sleep laborator,r at 9 P••• 
and, after preparing for bed, had silver disc electrodes 
attached to the frontal bosses and the outer canthi for e7e 
m.ovemen t monitoring. Rl.ectrod es were placed in the mid-
line, P-.o-P distribution of the international 10/20 sJatUl 
of electrode pl&caent to give an Em record, and submenU! 
electrode• were used to record muscle tone (aee Pis. 5). 
The patients retired to single bedrooms, and the light• 
were awitohed out at 22.30 and reoordi~ waa oarrie4 out 
froa 22.30 to 07.15. 
ne first two nights in the sleep laborato17 were for 
adaption purposes only, because of the first night effect 
(Agnew et al, 1966) which decreases a• and slow wave 
sleep, and increases the number of shifts to wakefulness. 
The next four nights, when all patients were receiving 
placebo, were in the baseline period, the next four in the 
first treatment month, and the remaining tour in the second 
treatment month. UlttmatelJ the sleep records were 
scored blind according to standard international criteria 
(Rechtsohaften and Kales, 1968) into wakefulness and sleep 
stages 1, 2, 3, 4 and R!M. Wakefulness is characterised 
by low voltage fast activity ando( rhythm in the REG, high 
Earth 
EEG 
FIG. 5a The position of electrodes for electrophysiological 
recording of sleep. 
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muscle tone, frequent movements, and blinking of the ·qes 
(see Fii• o). As the subject passes from wakefulness to 
sleep there is a gradual slowing of the EEG activity. 
The low voltage fast aotivitT of wakefulness is replaced 
by mixed frequency waves predominantq in the 2-7 Hz bancl 
in stage l a~eep. In· ataie 1 there are leas than 50% ·J.,. 
waves in the Em, no sleep apindlea or K OQl~Wlexea, and 
slow rollin~ movement• of the eyes (see Fie• 7) • . After a 
while, e¥e m.ov~nta cease and bursts of l2-l4 Hz ainu• 
soidal · wa~ea, known aa sleep spindles, aDd iaolate4 bipb&aio 
hi&h voltage wavea oalle4 X compl~ea appear in the EEG. 
~is indicates that the aub~eot. haa passed into stage 2. , 
The obaracteriatio featQrea of this stage are shown in 
Fi&• 8. When hi&h voltage delta wavea of o. 5 -2.5 Bs 
appear and oc~pf more than 20~ of the BEG reoordinct the 
subject is ·in stage 3 sleep (aee lis· 9), and when delta 
waves ocoupf aore than 50% in stai~ 4 sleep (see Pig. lO). 
Sleep stages 3 and 4 are known •s slow wave sleep because 
of their typical Em pattern, and these stages occur mainlJ 
in the first few hours of sleep. 
known as Bon-REM sleep. 
Sleep stages 1-4 are 
R~ sleep reours at intervals during the night. In 
this stage of sleep the EEG changes to a low voltage mixed 
frequency pattern, and may show~ reythm and waves of 2-3 Hs 
with a notched appearance known as saw tooth waves (see 
Fig. 11). The EMG shows low muscle tone with occasional 
muscle twitches, and the characteristic eye mov~ents 
appear (see Fig. ll). REM sleep recurs at intervals of 








Sleep record during wakefulness. 
A • Eye blink in the IDG 
B • ()( rhythm in the E:3G 






FIG. 7& S1eep record showing stage 1 s1eep (drowsiness) 
A • Rol1ing eye mov~ents 






FIG. 8a Sleep record during stage 2 sleep. 
A ~ Sleep spindle• 







FIG. 9a Sleep record during stage 3 sleep. 






FIG. lOa Sleep record during stage 4 sleep. 








FIG. U& Sleep record during 1UM sleep. 
A • Rapid eye movement in mG 
B • Low voltage Em 
C • Saw tooth waves in EEG 
D • Low muscle tone 
79· 
usual.ly' between :tour and six Rlll period• per night. As 
the night progresses, the REM periods beooae longer so 
there is a higher proportion ot REM sleep in the later 
hours o:t sleep. 
When recording was complete, the sleep records were 
soore<l visually in 2o- second epochs, and a computer 
programme was used to calculate the total sleep duration, 
. . 
sleep onset latency, sleep stage data, stage changes, and 
REM latency tor each night. Sleep stage changes and the 
amount ot each sleep stage in the first six houra ot sleep 
were also calculated. The changes between the baseline 
period and the first treatment month and baseline and 
second treatment month were examined and the magnitude ot 
t 
the change in the two groups co~ared using a Students t 
teat. A I-tailed teat was used for intervening wakeful-
ness and number of arousals, which we ba4 predicted would 
decrease on oestrogen treatment, and a 2-tailed test was 
used in all other oases. Intra-group ohangea in the differ-
ent periods of the expe~iaent were compared using a t test· 
tor paired observations. 
Patients rated their sleep quality, mood, and anxiety 
levels daily throughout the study using 10 om line visual 
analogue scales. The left hand end of the sleep quality 
scale was labelled "best ever" and the right hand end 
"worst ever". Patients were told that the centre of the 
line approximated to a normal night sleep, and that each 
morning they should make a mark to indicate how well they 
had slept co~ared to a normal night's sleep. 
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The remaining scales of mood and anxiety were completed 
in the evening to show how the patient bad felt during 
tbat dq. The mood scale was marltecl "most depressed evel"' 
at one end and "aoat oheertul ever• at the other end (see 
Fig. 12), and the anxiety scale ran from "terribl.Y agitated•• 
to •• imperturbable tranquilli tyt' • 
Visual analog\le scales were soorecl b7 measuring the 
distance from the left hand end of the line to the mark in 
millime tree. The mean weeklJ score for each sUbject and 
for each group were calculated, and also the mean scores 
for the baseline period, first treatment month, and second 
treatment month. The difference of the weekl.7 uan trom 
the baseline mean was plotted graphioallJ for each week of 
the study in each group and the patterns compared. The 
mean scores in the three periods of the stud7, and the 
ohanges in score of the two groups, were coapared using t 
tests as described for the sleep studies. 
Observer rating acalea of depression (Haailton, 19o0) 
and anxiet7 (Hamilton, 1959) were completed at the beginning 
and end of the baseline period, the end of the first treat-
ment month, and the end of the second trea~ent month. 
El:amples of each rating scale are given in appendix 1. The 
mean soore on eaoh scale was calculated for each group at 
each assessment point, and these were plotted graphicallJ 
to show the changes in each group throughout the study. 
The significance of the changes in each group was evaluated 
using a t test for paired observations, and the magnitude 
of the changes in the oestrone and placebo groups COJ~Wared 
using a Student's t test. 
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MOOD 
NAME DATE . .. . ...... .. ......... . 
Please indicate, by a mark on the line, how you felt in your spirits 
today. If you have felt more lively and cheery than usual you should 
make your mark to the right of the centre, if more listless and gloomy 
than usual, your mark should be to the left. An average day should 
mean a mark in the centre. 
Most depressed 
ever 




Eaoh patient was aSked to note the number of hot 
flushes experienced in the previous 24 hou:ra at the end of 
each dq. Total weekly hot flush counts were oalcula ted 
tor each patient and group means for each week and eaoh 
period of the study determined. The mean weekly hot flush 
count tor the oestrone and placebo groups were plotted 
graphicallJ, and the significance of the changes between 
the three periods of the study and between the two groQps 
was determined using t tests as preTiouslJ deacribecJ. 
The patients were also asked to ooJI1)lete a visual 
analogue scale of hot flush severit.y at the end of each day. 
~his scale was a 10 oa line with "no fluhea" at the left 
hand end and "very bad, couldn't be worse" at the ri&ht 
hand end. The scale was scored by measuring the distance 
from the lett hand end of the line to the •rk made b7 the 
patient in millimetrea, and the results analysed as tor 
the other visual analogue soales, desoribed above. 
lUDROENDOCRINE S1UDIES 
Twelve volunteers attended the sleep laborator,r on 
two extra nights, one in the baseline period and one at 
the end of the first treatment month, for blood studies. 
On these occasions, a catheter was inserted into a forearm 
vein and filled with hepar1nised saline (10,000 units 
heparin in 500 ml 0.9% saline), and electrodes were then 
attached in the usual W&J for electropbysiological 
recording of sleep. When the patient retired to bed, the 
catheter was connected to a catheter extension tilled with 
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h.epariniaed saline . which passed thro~h the beclrooa wall 
into the next rooa, so tba t blood samples could be taken 
without disturbing the patient. Sleep was recorded as 
usual, and blood aaaples were taken at 20 ainute intervals 
thrOU&hout the night. When taking a blood sample, the 
catheter and catheter extension were first cleared ~7 with-
drawing a volume of fluid ~ust greater than that required 
to till tha (this voluae was m.easurecl while assembliq 
the s7sta), then a 10 ml blood sample wae taken and the 
catheter and catheter extension were cleared of blood b7 
in~eoting sufficient heparinised saline to fill th .. , and 
the system was sealed until the time of the next blood 
sample. The sleep record was marked at the start and end 
of each blood sample, to facilitate the correlation of 
blood levels with sleep stages. The blood aaaple waa 
centrifuged immed 1a tel7 1 and the plasma was separated and 
stored at -20°0 until asaa7ed. 
Each aa.ple was assayed for oestrone, oestradiol, 
prolactin, and free and total plasma tryptophan. Oestriol 
levels in menopausal women are known to be low, and since 
a larger blood sample would bave been required tor oestriol 
asa~s it was decided that oestriol ass~s would not be 
justified. The oestrogens were extracted from plaama with 
dietbyl ether and separated by LH-20 column chromatography. 
Oestrone and oestradiol concentrations were then measured 
by radioimmunoassay (Kirkham and Hunter, 1971; Abraham, 
1974) using standard antisera prepared in sheep against 
oestradiol-!~ succ~l albumin (New England Nuclear). 
The antisera had 50% oroee-reaotivit7 with oestrone, but 
since the oeetrogene were separated before aea&J, each 
could be aeaaured against the aue antiserum, uaing 
appropriate standards. !he coefficient of variation of 
this method, based on the use of frosen pooled serua 
aaaa1ed 32 times, waa 14%. Prolactin was measured b7 
rad ioiam.unoaaMy as d eaoribed b7 KoBe ill¥ and Hagen ( 197 4). 
Total plasma tryptophan was measured b7 the method of 
Wapnir and Stevenao~ (1969). Plaama was centrifuged in 
Ce~triflo membrane cones for 30 min• at 1000 g and a 
t•perature of 4°C, and tree plasma tr.yptopban wa.a measured 
in the ultrafiltrate ae described b7 Denokla and Dewe,7 
(1967) and Wapnir and Stevenson (1969)• 
In each case the concentrations of oestrone, oeatradiol, 
and free and total plasaa tr,Jptopban in the two nights were 
compared using a t-test for paired observ.ations. Mean 
concentrations were calculated for each night, and the 
differences between the mean levels on the two nights 
determined for each patient. The magnitude of change 
between the nights in the leTels of each hormone, and of 
free and total plasma tr,rptopban during the night were 
pl.ott.ed for each night, then compared with hiatogr&IIS of 
sleep .stages to show any relationship between changes in 
plasma levels and sleep stages. The .mean leTels of the 
hormones and. of tree and total tr.yptophan during each sleep 
stage were de~ermined, to see whether any sleep stage was 
associated with either higher or lower leyels, and to seek 
evidence of a diurnal variation the night was divided into 
as. 
three periods, using 2 a.a. and 5 a.m. aa ~t-oft points, 
and the mean levels in the three periods of the night 
coapared by analfais of variance. 
!be relationship between obaDgea in horaone level• 
and free and total plasma tryptophan were investigated by 
cal~lating the correlation coefficient, r, for the l.vela 




A total of 61 patients were interYiewt4, 36 after 
referral b7 their GP and 25 at their own request. lot all 
of these were suitable, as soae did not bave s~mptoms of 
insomnia, depresaion, anxiet7 and hot tlQshea, soae were 
not willing to give up their previous medication, some bad 
not yet reached the menopause, and some bad oontraindications 
to oestrogen treatment. However, 42 were both suitable 
and willing to take part in the stud7, though 16 of these 
ha4 to undergo a six week withdrawal period from their 
former treatment (four were on oestrogen, four on tran-
quillisers, six on bJpnotios, one on bellergal, a combina-
tion of atropine, ergotamine, &Dd phenobarbitone, aDd one 
was receiving an appetite suppressant. From BEG appearances 
I nepected that one patient in the placebo group ba4 
continued regularly to take bensodiazepinea during the 
study, but as her results were unremarkable I bave not 
exoluc! ed her. 
Although 42 patients started the stud71 five failed to 
return after the first night anc! two dropped out in the first 
week because of severe side effects (th~ had continued to 
take hJpnotics until the start of the study, and were con-
aequentlt suffering withdrawal effects). One patient 
developed a urinary tract infection in the eighth week of 
the study, after starting oestrogen treatment, and became 
ver,y depressed and tearful, and was therefore withdrawn. 
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A total of 34 patients completed the study, 17 in the 
oestrone group and 17 in the placebo group. The mean age 
of the patients in the oestrone gr~p was 49·7 1 5•7t 
while the placebo group patients bad a ll.eaD age of 48.5 % 
o. g, ·and the two groupe were silailar in the duration of 
amenorrhoea experienced· .by their patients (see Table )). 
TABLE la Duration of Amenorrhoea (years) of Patients in 
the Oestrone and Placebo Groups. 
Duration of Amenorrhoea ·Number ot Patients 
(years) Oestrone Group Placebo Group 
0.25 - 1.0 8 7 
1.0 - ).0 5 7 
).0 - 5.0 1 1 
More than 5.0 l 2 
SLEEP 
1. SQbjeotiye Sleep Qu&litl 
,. 
Both groups showed an improvement in subjective sleep 
quality- as measured by- visual analogue scales throqhout 
the study (see Pig. 13), but there was no significant 
difference between the two groups at a!J1' stage, nor was the 
mean aoore in either treatment period significantly higher · 
than that in the baseline period in either group. 
2. Electropbysiological Recording of Sleep 
(a) Sleep Latency 
Table 4 shows the group mean sleep latency and the 

















SELF-RATED SLEEP QUAUTY 
OESTRONE GROUP 
.... 4 PLACEBO • ._ OESTRONE SULPHATE 
WEEKS 
FIG. lla Visual analogue soale ot sleep quality re~ta 
expressed as the weekly mean difference in 
millimetres from the baseline mean score in the 
two groupe. 
the study for the oestrone and placebo groups. From this 
it can be seen that the sleep onset latency varied widely 
between patients in each group, with aoae patients falling 
·asleep veq quick~ and others taking as long as one or two 
hours ~o fall asleep. The range of sleep .latencies was 
consiste~tly wider in the placebo group than in the 
oestrone iroup throughout the study• but despite this 
there was little di.fterence in the group mean Taluea. 
Both - group~ showed a small decrease in the mean sleep 
latency during the study. The oestrone group showed a 
mean decrease of 1. J a1n. in the first treatment month, and 
3·2 min. in the second treatment month. while the placebo 
group showed mean decreases of 0.2 min. and 7.5 min. It 
is likely that the decrease in sleep latency experienced 
by both groups was due to .increasing .taailiari ty with the 
sleep laborator,y, and since there was little difference in 
the changes experienced by the two groups, it ~·ems that 
oestrogen treatment did not change the length of time 





Sleep Latency (min) in the Oestrone and Placebo-
Groups in the Baseline Period, Pirat Treatment 
Month, and Second Treatment Month. 
· Baseline lst Treatment 2nd Treatment Month Month 
Grou2 
32.1 )0.6 28.9 
7.1 - 67.2 2.2 - 76.1 4·5- 60.3 
.PlaO!bO G£OU;2 
Mean 38·5 )8.3 31.0 
Bange 10.4- 126.5 8.2 - 108.5 o.5- 86.1 
90. 
(b) SleeP D\lration 
The sleep duration also varied widel7 in eaoh group, 
and in the baseline period the mean values of individual 
patients r&D8ed from less than six hours to almost eight 
hours. However, the baseline means were vert similar, and 
there was no significant difference between the two groups 
in the baseline period. 
During the study, the sleep ~uration of both groupe 
increased (see ~ble 5). In the oestrone group, sleep 
duration increased sign1fioantl1 from the baseline mean of 
423.2 ! 8.2 min to 442.2 ! 7•7 min in the first treatment 
month (t • 3·305, P< o.Ol) and 446.5 i 1.2 min in the 
second treatmen't mon'th (t • 2·939, p( O.Ol). The increase 
in the sleep duration of the placebo group from the base-
line level ot 418.2 t 1.2 min to 424·3 i 8.2 min in the 
first treatment month was short of sipifioance, but the 
increase from the baseline to the second treatment month 
level of 429.4 ! 1.2 min was significant (t • 2.735, 
p < 0.02). Although the oestrone group showed a greater 
mean increase than the placebo group in both treatment 
months, there was no significant difference between the 











Slee~ Duration (min) in the Oestrone and Plaoebo 
Groups 1n the Baaeline Perio4, Pirst Trea taent 
Month, and Seaond Treatment Month. 
:Baseline ls t Treatment 2nd Treatment 
Konth Month 
Grou~ 
42).2 442.2 446.5 
)).9 )1.6 29·6 · 
377.1-476.8 370.2-487 .l . 365.6-478.7 
Groue 
418.2 424·3 429·4 
29.5 33·9 29.8 
342.8-457 ··7 349.o-472.0 372.8-470.2 
(o) 
(1.) Ia the Whole Night. !his is a measure of the broken-
ness of sleep, a~d may be defined as the amount of tiae 
spent awake between p.eriods of sleep. In the baseline 
period, the patients in the oestrone group had a wider 
range of mean amounts of intervening wakefUlness than those 
. . 
in the placebo group, but again the difference between the 
means for the two groupe in the baseline period is not 
significant. In both groups the intervening wakefulness 
decreased throughout the study (see Table 6). In the ·· 
oestrone group, the intervening wakefulness in the whole 
night was significantly lower in the first treatment month 
(t a 2.888; p( 0.02) and in the second treatment month 
(t • 2.689; p(0.02) than in the baseline period, but in 
the placebo group these dif ferences were not significant 
92., 
· (t • 1.048; t • .0.931). The oestrone group showed a 
decrease in intervening waketulnesa of 14.4 ! 5.1 ain 
between the baseline periOd and the first treataent month, 
and the placebo group a decrease of 4•r! 4.5 min, but the 
difference between the two groups is nhort of significance 
(t • 1.454). The oestrone group showed a decrease in 
intervening waketulnesa of 15.8 ! 5.9 min between the base-
line period and the second treatment month, which is aigni-
ficantlJ greater than the decrease shown by the placebo 
. + 
group of 2.1 - 2.2 min (t • 2.176, p.{ 0.025). 
TABLE 6: Intervening Wakefulness (min) in the Whole Night 
in the Oestrone and ~lacebo Groups in the 
Baseline Period, First Treatment Month, and 
Second Treatment Konth. 
Baseline lst Treatment 2nd Treataent Month Month 
Q!St£one Grou:2 
Mean 35·9 21.? 20.1 
S.D. 27·8 13·5 15.0 
Range o.o-100.2 0.6-45·7 3·5-44.6 
P~cebo Grou2 
Mean 31.5 26.8 29.4 
S.D. 18.7 14.6 16.5 
Range 4·4-71.8 3.6-57·9 5-4-68.5 
· fi) Intervening Wakefulness in 'the First Six Hours of Sle!R 
To compensate for differences in sleep duration 
between different subjects and nights, the results may be 
considered in terms of the first six hours of sleep. 
Table 7 shows the mean amounts of intervening wakefulness 
93. 
in the first six hours of sleep in the oestrone and 
placebo groups in the three periods ot the stud7, and the 
results in this table have been obtained by oaloulating 
the mean amolUlt ot intervenill8 wakefulness in each hour 
of sleep, ~ben taking the ·sum of· the means tor the first 
six hours. In soae cases the sleep duration was leas 
than six hovs, au where tor exaaple the sixth hour ot 
sleep was complete on three nights, but .on ·the other nisht 
there bad been onlT 30 min 1n this hour, then the mean 
. . 
intervening waketulneaa tor the sixth hour would be 
obtained through division b7 3·5 .instea~ ot 4• This 
extrapolation was nscessar,y on 22 of the 408 nights recorded. 
Theae nights were evenll distributed in the three period• 
ot the stu41t and 9 occurred in patients in the oestrone 
group and 13 in the placebo group. 
Pig. 14 shows the ~lative intervening wake~lneaa 
in the first six hours ot sleep in tb3 'two groups in the 
~aseline period, first treatment month, and second treat-
ment month, and from this it can be seen that episodes of 
wakefulness recurred throughout the night ia both groups. 
In the placebo group there was little change in the amount 
of intervening wakefulness between the three periods, but 
in the oestrone group the amount of intervening wakefulness 
decreased throughout the night w~en the patients received 
oestrogen treatment. The mean values and range of results 
are given in Table 7, and it can be seen from this that the 
mean amount of . intervening wakefulness was nigher and . the 
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PIG. 141 Mean oamulative intervening wakefulness {min) in 
the first s ix hours of sleep in the oestrone and 
placebo groups during t he baseline period, first 
treatment month, and s econd treatment month. 
95· 
oestrogen than in the placebo group in the baseline 
period, but although the difference between the groups was 
large, it was not statisticalJ.¥ significant (t = 1•140). 
The mean intervening wakefulness in the first six hours of 
sleep in the oestr~ne group was significantly lower in the 
first treatment m.onth (t • 2.624, p (0.02) and the second 
treatment month (t • 2.460, P( 0.02) than in the baseline 
period, but in the placebo group these differences were not 






Intervening Wakefulness (min) in the lirst Six 
Hours of Sleep in the Oestrone Group and Placebo 
Group in the Baseline Period• Pirst Treataent 
Month, and Second Treatment Month. 
Baseline lat Treataent 2nd Trea 'blat Jloath Month 
Grou; 
34.6. 17.3 1o.o 
)2.6 12.9 13.9 
0 -122.8 0 -41·2 0.9-44.5 
Place)!g Groui 
Mean 24·0 21·4 2).0 
S • .D. 19.6 14·3 18.1 
Bange l.o-69.7 2.<>-40.4 1·9-56.9 
When we compare the changes in intervening wakefulness 
in the first six hours of sleep between the periods of the 
study, the oestrone group showed a decrease of 17.3 ! 6.6 min, 
and the placebo group a decrease of 2.6 ! 4.6 min between 
the baseline period and the first treatment month. The 
difference between the two groups was significant 
96 .. ·-:. 
(t • 1.816, P< 0.05)• Comparing the baseline period and 
the second treatment month, the oestrone g~oup showed a 
. + 
decrease of 18.0 ~ 7.3 min, and the placebo group a 
decrease of 1,0 ~ 2,4 min, and the difference between the 
two groups was again significant (t • 2.205, p( 0.025). 
. It is Wll1kel3 that the d ifferance between the groupe 
is due to the extrapolations where patients slept for leae 
than aix hours, s!Qoe the proportion of nights in ·which 
this extrapolation waa needed is amallt and it can be seen 
from lig • . 14 thB.t the results would have been the same if 
we had considered only_th• first four hours of sleep; 
which did not include &QT ·extrapolated results. 
lfpmbe£ of A£ousala lo lgtf\!lntt! 
In tht !holt Nicb.S. !ht brokenness of sleep ~ 
also be aeasurtd in terms of the number of episod-e! of 
Waketulneaa during the night. fable 8 shows the group 
mean, etandard deviation, and the range of results of the 
number of arousals in the pat"ients of the two groupe in 
the three periods of the atud7. In the baseline period, 
the patients in the oestrone group bad a higher mean 
number of wakeninga than those of the placebo group, but 
again the difference was not significant. 
The number of arousals to wakefUlness increased 
slightl7 above baseline levels in the first treatment 
month in both groups. In the oestrone group the mean 
increase was 0.1 ! 0•4• and in the placebo group wae 
0.3 ! o.~, but this increase was not significant in either 
97· 
case (oestrone group, t = 0.129; placebo group, t • 0.799) 
nor was the difference between the groups significant 
(t = 0.470). 
In the second treatment month both groups had !ewer 
arousals than in the baseline period, the difference being 
significant in the case of the oestrone group (t • 2.212, 
p (0.025) but not in the placebo group (t • 0.276). 
The oestrone group had a decrease in arousals of o.g 
t 0.4 in this period compared with an increa930f 0.1 t 0.4 
in the placebo group, and the difference between the two 










NWiber o! .lrowsala to Wakeful.D.eaa in the Oeatroae 
and Placebo Groupe in the Baeelirle Periocl, Pirat 
Trea'blent llonth, and Seoond !freauent Koath. 
Baseline · lat Treatment 2nd Treatment Month Month 
GroUJi! 
5·9 6.0 5·0 
4·3 4·7 3·5 
0 -14.5 0.3-14·3 0.8-12.5 
GroUJi! 
5·3 5·6 5·4 
2.5 3.0 ).1 
1.8-11.8 2.3-11.8 2.0-11.8 
98. 
(i~) Arousals to Wgetul.ntss in lht First Six Hours Slt!R 
It is possible that most of the awakenings take plaoe 
either at the beginning of the night or in the last hour · 
ot sletp 1 as morning approaches, and to investigate tbia 
the number of arousals to wakefUlness per hour in the first 
six houra of sleep have bten oaloulated. Pig. 15 shows 
J 
the cumulative arousals to wakefUlness in the first six 
hours of sleep in th• two groups in the three pbasea of 
. the stud71 and it can be seen from this that wakeninss 
recur throughout the night, and art not restricted to 
either the beginning or the en4 of the sleep period. In 
the placebo group there is little. difference in tht 
frequency of arousals in the three periods of the stu47• 
but the oestrone group show a decrease in the number of 
arousals to wake~lneaa in the second treatrunt aonth. 
Table 9 shows the mean number of arousals to walte-
fulntas in the first six hours of aleap in the two groups 
in tht baseline period, first treatment month, and second 
treatment month. Both groups showed·a alight increase in 
wakeninga in the first six hours sleep in the first treat-
ment month, but this increase was not significant in 
either group, nor was there any significant difference 
between the two groups. In the second treatment month, 
the oestrone group showed a significant decrease below the 
baseline level {t • 2.336, p( 0.025) while the placebo 
group showed a slight .inorease {t • 0.59, N.s.). The 
decrease in the number of awakenings between the bastline 
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FIG. 15: ~ulative mean number of awakenings in the first 
six hours of sleep in the oestrone and placebo 
groups in the baseline period, first treatment 
month, and second treatment month. 
lOO. 
was 1.05 ! 0.45, and this is significant when compared 
with the increase of 0.18 ! 0.31 in the placebo group 
( t a 2, 2 60 ~ p ( 0 • 02 5) • 
WLI 9a ftwaber of Arousals to 'faketulnesa in the lirst 
Six Hours of Sleep in the Oestrone and Placebo 
Groups in the Baseline Period, First Treataent 
Month, and Second Treatment Month. 
Baseline 1st Treatment 2nd freatment Month Konih 
Qlst£01! G£2§ 
Kean 4 .• 8 . 4·9 3·7 
S.D. 3·8 3·9 2.8 
Range 0 •13.0 0 •12.0 o.J-8.8 
Plao!b2 Gr2!!E 
Xean 3·9 4·1 4.1 
S.D. . 2•5 2.5 2·9 
BaD&• o.~10.o 1.5 -9•0 1eJ-9e5 
(e) Staat l Slt'P 
The mean amounts of atage 1 sleep in the whole night 
and in the first six hours ot sleep in the oestrone and 
placebo groups in the three periods of the study are shoWil 
in Table 10. Neither group showed any significant ob&Dge 
in the amount of stage 1 sleep, nor were there any signifi-
cant differences between the two groups either in terms of 
the amount of this stage, or in the changes between the 
baseline and treatment periods, in either the whole night 
or in the first six hours of sleep. Since the amount of 
stage l sleep also fell slightly in the treatment periods, 
101. 
the decrease in the amount o! intervening wakefulness in 
the oestrone group in the active treatment periods cannot 
have been due to an increase in drowsiness. 
T.ftBLi lOa Amount of Stage l Slee~ {min) 1n the Whole Ni&h" 
and First Six Hours ot Sleep in the Oestrone and 
Placebo ·,Grou~s in the :Baseline Perioc;l, First 
!reatment Month, and Second !rea tment Month. 
Baseline lst Treatment 2nd Treatment Month Month 
O!S:!i£2&! Gro!l2 
!otal + 34.0-2.3 + 34·3-3.1 31.2!2.8 
In the let 
28.6!2.6 27.~!.2.7 + Six Hours 24.g.;.2.6 
Sleep 
Plaoeb2 Groul!· 
!o"al + 40.~).1 + 36.7-3.3 + 37.~3.3 
In the lst 
33.):!:2.6 + )0.6!2.6 Six Hours 27.g.:.2.1 
Sleep 
The number of shifts to stage l sleep are shown 1n 
Table 11, and from this it can be seen that the number ot 
arousals to stage l was greater in the oestrone gro~p in 
the first treatment month than in the baseline period, but 
fell again to baseline level in the second trea~ent month. 
Tae placebo gro~p had a fall in the number of shifts to 
stage 1 in the first treatment month, but the levels in the 
second treatment month were the same as those of the base-
line period. The number of shifts to stage 1 in the whole 
night was increased in the oestrone group by 3.5! 1.7, 
and decreased in the placebo group by 2.2 ! 1.5 in the 
first treatment month, and the difference between the two 
-
grolllls is significant (t • 2.441, p(0.025)• However, 1a 
' the second treataent month, ~hese changes are reversed, 
so that the oestrone group have 0.5! 1.7 and the placebo 
group 0.1! 1.5 fewer shifts to stage 1 than in the base-
line per1o4, and the cS.iff~rence between the two groups ia 
not significant (t • 0.200). 
When cons1d ered in teras of the first a·ix hours ot 
sleep, the difference between the two groupe ia much leaa 
(see T~ble ll). In the first treatment month, the oeatroae 
group showa an inoreaae of 1. T ! 1. 7 and the placebo group 
a 4eorease of 2.3 ! l•5 sbitts to s~~ge. 1 in the first six 
hours aleep, but this 41fterence ia short of significance. 
(t • 1.788). In the seoon4 treatment month, the means 
were aimilar to baseline levela 1n both. groups, with the 
oestrone group showing a decrease of 1.4 i 1.8 and the 
placebo group a decrease ot 0.3 ! 1.2 shifts, and there waa 
again no significant difference between the two groups 
(t • 0.497). 
Since the increase in the number of shifts to stage 1 
sleep shown in the first treatment month by the oestrone 
group is considerably greater in the whole night than in 
the first six hours of sleep,·it may be due to an increase 
in the number of arousals in the later part of the night, 
associated with an increase in sleep duration. However, 
this does not entirely account for the increase, and when 
the results are analysed in terms of hours of sleep, an 
increase in the number of shifts to stage 1 oan be seen in 
the third and fourth hours of sleep. 
103. 
TABL'S 11: · Number of Shifts to Staga 1 Sleep in the Whole 
Bight and liret Six Hours of Sleep in the 
Oestrone and Placebo Groups in the Baseline 
.Period, lirat Trea'taent Month, and Second 
Treatment Month. 
Baseline lat Trea-tment 2nd Treatment Month llonth 
218l~'2!&1 Group 
~otal 31.1!2·2 + 35·2-3·3 + 31·2-2.4 
In 1st six · + + + 
Hours Sleep 27.1•2·5 28.8~3·3 25·7-2·3 
.Placebg Grou;e 
Total + 35·2-2.4 + 33·0.:.2.5 + 35·1-2.2 
In 1st Six + 27.~2.0 + Hours Sleep 30·2-1·9 29.~2.0 
(t) Stage 2 Sleep 
Both groups showed an increase in stage 2 sleep 
throll&hout the study (see Table 12). In the case ot the 
oestrone group the total amount of stage 2 sleep increased 
significantly from the baseline level of 215.4 ! 6.7 min 
to 230.0 ! 6.9 min in the first treatment month (t • 2.821, 
P< 0.02) and to 232·1! 6.7 min in the second treatment 
month (t • 2.704• p< 0.02). The changes in the placebo 
group between the three periods ot the study were not 
s ignificant. Although the oestrone group showed a greater 
mean increase in the amount of stage 2 sleep than the 
placebo group, the difference between the two groups was 
not significant. 
The changos in the amount of s t age 2 sleep are related 
to changes i n sle~p duration, as when the results are con-
sidered in terms of the first six hours of sleep, there 
104. 
are no significant differences between the three phases 
of the ex~er~ent in either group {see Table 12). 
WLB 12a Amount of S"age 2 Sleep (min) in the Whole Bight 
and First Six Hours of Sleep in the Oestrone 
and Placebo Groups in the Three Periods ot the 
Study 
Baseline let Treatment 2nd !reataent Month Month 
Qt•t£2ne Grcnll! 
fotal 
.· + 230.o!o.g + 215·~·7 232.1~.7 
In lst Six 182.715.5 188.2!7.1 188.0:5·5 Hours Sleep 
Pl!oebo Grou2 
total + 209·4-7.4 210.8!8.1 217.617.7 
In lat Six + 179·2!6.) • • Hours Sleep 179.~5·5 180.7-5.0 
fhe aean number of ahifta to stage 2 sleep in the whole 
night increased in the first treataent month in the oestrone 
group and decreased in the placebo group, but was sill1lar 
to the baseline level in both groups in the second treat-
ment month (see Table 13). When the changes between the 
baseline period and the first treatment month were compared, 
the oestrone group showed an increase of 3.9 ! 2.1 in the 
number of shifts to stage 2 and the placebo group a 
decrease of 2.4 :!: 1 •. 6, and the difference between the 
groups was significant (t • 2.436, P< 0.025). Between the 
baseline\ and the second treatment month, the number o~ 
+ shifts increased by o.a - 2.0 in the oestrone group and 
I + 
showed no mean change (0.0 - 1.7) i n the placebo group, and 
there was no significant difference between the two groups 
lO;. 
{t • 0 • .30). There was no significant difference between 
the mean number of shifts in the three periods of the 
study in either gro~. · 
When considered 1n terms of the first six hours of 
sleep, there were no significant changes either between 
the groups or between the three periods of the stud7. The 
inorease in the number of shifts to stage 2 sleep in the 
oestrone group is much smaller when considered in the first 
six hours of sleep than the whole night, which suggests 
that muoh of the increase is due to the patients having 
more stage 2 in a longer ni&ht's sleep on oestrone. 
WL)lla lumber of Shifts to ·Sta&e 2 Sleep in the Whole 
Hight and First Six Hours of Sleep in the 
Oestrone and Plaoe"Do Groups 1n the !hree Perio4a 
of the Study~ · 
Baseline lat Treatment 2nd ~-eat Month lloath 
21•t£2BI 21"0\li 
I 
!otal + 40.2-2.1 + 44·1-3.1 + 41.~·5 
In lst Six + )6.g!).l + llours Sleep 34·~2·2 )4.~2·4 
Pla2eb2 GroUJ! 
Total. + 44.7-7·2 + 42.)-2.4 + 44.7-2.6 
In let Six )8.7!1.8 )6.6!1.8 )8.6!2.4 Hours Sleep 
106. 
(a) Slow Wave Sleep 
There was considerable variation in the amount of slow 
wave sleep in the sub~eo~s o! the two groups. In the 
oestrone group, the mean amount of slow wave sleep ranged 
from 13.6 min to 103.6 min, and 1n the plac·ebo &roup from 
38.5 min to 119.7 min, but despite this• tne baseline meaDe 
ot the two groups were very similar (see Table 14). Since 
slow wave sleep occurs predominantly in ·the first part of 
the night, the amount of slow wave sleep in the first six 
hours of sleep is almost identical to that in the whole 
night. 
There were no significant changes in either the total 
amount of slow wave sleep, Qr in slow wave sleep in the 
!ir~t six hours of sleep throughout the study, nor were 
there &fl1' significant differences between the changes 
experienced by the two groups. there were no changes in 
the number of shifts to sta&es l + 4 in the whole night or 
in the first six hours o! sleep in either the oestrone or 
placebo groups. 
TABLE l4a Amount ot Slow Wave Sleep (min) in the Whole Kight 
and the First Six Hours ot Sleep in the Oestrone 
and Placebo Groups in the Three Periods ot the Study. 
Baseline lst Treatment . 2nd Treatmellt Month Month ' 
0!Bt£S!D! GrOU.l! 
Total + 60.4-6.9 58.9!7.6 + 57-7-6.0 
In lst Six 58.8!6.3 + + Hours Sleep 55·9-7.1 56.1-5.7 
Plac!b o Grou~ 
Total + 65·4-5.0 + 70.5-=-6.1 68.3!5.6 
In lst Six 6).7!4.4 68 • .¢5.8 66.8i5.3 Hours Sleep 
I· 
i 
(h) R114 Sleep 
As can be seen from Table 15, the oestrone group bad 
a higher mean amount of REM sleep in ~he baseline period 
than the placebo group, but this diffe~enoe was not si&ni-
ficant (t a 1.51)• · Both groups showed an increase 1n RBI 
.·· sleep thro\16hout th~· study, ~ut this increase wa• not 
signifioallt_in either treat.alent month in the placebo group, 
or in the oestrone group in the first treatment month. 
However, in the oestrone group the increase from the base-
line le~el of lll·5 min to 126·9 min in the second treat-
ment month was significant (t • 2.577, p(0.02). 
In both treatment periods the oestrone sroup showed 
a sreater increase in REM sleep than the placebo group. 
I-n the first treatmen-, month, the oestrone group showed an 
increase of 5.6 t l·l min above baseline levela, aQd the 
placebo gro\lp an increase of 3.4 ! 2. 9 min, but the 
difference between the two groups was not significant 
{t • Oe530). The ·differenoe was signifioant when compar1ng 
the baaeline and the second treatment month, when the 
oestrone group showed an increase ot 13.3 t 4.7 min and the 
placebo group an increase of 2.3 ! 2.0 min (t • 2.184, pc0.05). 
When considered in terms of the first six hours sleep, 
there was little change in the amount of REM sleep in 
either group {see Table 15), suggesting that the changes 
durin& the whole night are related to changes in sleep 
duration. 
There were no significant changes in the number of 
shifts to REM sleep in either group in the ·whole night or 
108 c-
in 'the first six hours sleep, and no significant difference 
between the changes in the two groups. 
WLR 15& Amoun~ ot Rill Sleep (ain) 1n ~he Whole Right ad 
First Six Hours o! Sleep in the Oestrone and 
Placebo Groupe in the Three Periods ot ~he S'W47• 
Baseline la~ Treaaen~ 2nd fr•"-•at Month Month 
01Sl£Qng G£0® 
Total + l.l3. ~5·7 + 119.1-5·5 + 126· ~5.5 
ln la~ Six 89.313.6 88.713.9 + Hours Sleep 91.3-3·3 
P.ao1b2 G£S!Ii 
Total + 10).4-3·5 106.84.1 + 105.7-3.1 
In let Six 82.g!2.7 84.0t3. l 81.~1.8 Hours Sleep 
(1) Rill Onaet Latency 
There was little change in REM onset latency in either 
group, as can be seen trom ~able 16, and ~here waa no 









R3d Onset latency (min) in the Oestrone and Placebo 
Groups in the Baseline Period, First Trea~aent 
Month, and Second Treatment Month. 
Baseline lst Treatment 2nd Treatmen~ Month Month 
GrOU];! 
88.3 80.4 81.1 
+ 54.g.;l40·4 + 52.~147·3 59.6%137.0 
Grou];! 
87.7 86.4 86.3 
+ 64.~116.2 60.6!129.8 54.11153.8 
... , _ 
Both groups showed an improvement in mood aa measured 
b7 both the Hamilton depression rating scale (see lie• 16) 
and the visual analogue scale of depression (see lig. 17), 
but neither scale showed a significant difference between 
the oestrone and placeb 0 sroupa. 
At the start of the study the Hamilton .depreaaion 
~core of the oestrone sroup waa 16.3 ! 1.9, and of the 
pla~ebo &roup was 18.2 ! 2.0, indica tins depresaion of · 
onl¥ m.o4erate severity in both groups. As can be seen 
!rom lie• 16, the Hamilton depreaaion score fell markedlJ 
. + in the baseline period in both groups, to a mean of 7.9 • 
1. 2 1n th~ oee~ne ~up and 10.1 t 1. 5 111 the pl&cebo 
.grOQp. · !heae a cor•• indicate onl7 mild depresaion, aa4 
are so low tbat they leaYe little soope for improvement- in 
the a.ctive tr.atment period. !be Haailton depression 
aoo:re of the oes-t~n~ .&rOUP fell to 7.3 t 1. 3 at the end 
of the first treatment month, and 5·9 t 1.8 at the end of 
the second treatment month, while the placebo group scores 
fell to 6.2 t 1.3 and 4.5 t 0.7 respectively. 
In both groups the difference between the Hamilton 
depression scores at the beginning and end of tbe baseline 
period is significant (oestrone group t • 4.465, p < 0.001; 
p~cebo group t • 6.125, p< 0.001). The placebo group 
also showed a significant decrease in the score from the 
end of the baseline period to the end of the first treatment 
month (t • 2.810,. p( 0.02) and to the end of the second 
treatment month (t • 3.301, P< 0.01) but in the oestrone 
110. 
group these changes were not significant ( t • o. 997 an4 
't. 1.552). There was however no significant difference 
between the groups when the cbaJl&es in score of the two 
groups are compared. 
The visual. 'analo~e scale of de_pression showed little 
difference between· the baseline period and the two treat-
. . 
men~ months in either &rOQP• ~he mean score of 'the · 
oestrone group was 47.1! 1.9 in the baseline period, 
47.9 t 2.3 in the first trea·tment month, and 49•1! 3.0 1a 
the a.econd trea tlaen't month; while the scores of the plaoebo 
group were 47.6 ! 2.2, 50·5 ! 1.9, aud 52.4 t 3.4 respect-
ive]¥. There was no ai&ni!icant difference between the 
three periods ot the s-tud¥ .in. either group, D.Or between 
the changes in acore of the groupe. . 
. . 
Pi&• 17 shows 'the weekl¥ mean scores o·r the two groupa 
expressed as 41!ference from the baseline: mean. ~is ahowa 
a gradual improvement in mood in both groups, s1Dlilar 'to 
the changes shown by the Haailton depreaaion rating scale~ 
There was a significant negative correlation between the 
. . 
Haailton depression rating scale score and the v.isual. 
analogue scale score at the start of the study, and at 
weeks 10 and 14 (r ·-0.53, -o.45, and -o.49; p< o.Ol), 
but not at week 6 (r •-0.10; N.s.). There was also a 
significant negative correlation between the change in 
scores on. the two scales between the end of the baseline 
period ana the end of the first treatment month (r .-0.34, 
p( 0.05) and between the end of the first treatment month 
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FIG. loa Mean Hamilton depression rating scale soores of 
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FIG. 17: Visual analogue scale of mood reaul ts expressed 
as t he weekly mean difference in mill~etres from 
the baseline mean score in the oestrone and 
placebo groups. 
, 
cbaa.ges between the start and end of the baseline per1o4 
were considered, the correlation was short of s1gnif1oanoe 
(r • .:.0. Jl) • ~e c~~elationa are negative beoauae improve-
ment is ahown on the Hamilton 3ting soale bz a fall in 
the score and on the visual analogu.e soale by an increase 
in· the score. 
wim 
•• 
Both oestrone and placebo groups showed a steac11 
decrease in their aJ;aXieV levels throU&hout the s~43. 
This parallels the improvemen-t in depression, as can be 
seen b3 comparing Figs. l6 .and 18, which show the results 
of the Hamilton depression and anxiety soalea, and liss.l7 
aD4 ·19, which ahow the visual aD&l.osue eca1e reaulta. 
. . 
In both groups, the Haai1ton anxiet1 aoale showed a 
marked improvement in the aoore 1n the baseline period • 
with a turther improvement in the two treatment months • .. 
. + 
The score of the oestrone group fell from 17.2 - 1.8 at the 
start of the study to 9.7 ! 1.3 at the end of the baseline 
period, 7.7 t 1.2 at -the end of the first treatment month, 
and 5·6 t 1.4 at the end of the second treatment month. 
Over ~he same period, the score of the placebo group fell 
from 20.1 ! 2.1 to 11.4 t 1 • .3, to 6.5 ! 1.1, and to 
+ 5·4 - 0.7 at the end of tha study. 
In both groups the difference between the score at 
the start of the study and the end of the baseline period 
i.-3 significant (oestrone group t • 5·455, p ( 0.001; placebo 
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FIG. 181 Mean Hamil ton anxiety rating s cale scores of 
t he oes trone and plaoebo groups. 
the baseline period 'to the end ot· the first treatment 
group is significant for the placebo group (t • 4. 363, 
p < 0.001) but not for the oestrone croup (t • 1. 748) but 
the decrease from the end of the baseline period to the 
end ot the study is significant in both groups (oestrone 
group, t • 3.442, p( 0.011 placebo group, t • 4.348, 
p < 0.001). Although the placebo group showed a greater 
change in score than the oestrone group, the difference 
between the groups was not significant. 
Visual analQ&Ue aoale scores showed a similar pattel'D 
of improv•ent, as can be seen froa lig. 19, but tailed to 
show aigoificant differences between the three phases ot 
the study or between the changes in score of the two groups. 
The baseline mean score of the oestrone group was 47.1 ! 
1.7, increasing to 47.9 ! 1.1 in the first trea~ent aonth 
and 48.7 ! 2.2 in the second treatment month. The score 
of the placebo group was 47.4 ! 1.9 in the baseline period, 
49.8 ! 1.9 in the first treatment month, and 51.5! 3.0 
in the second treatment month. On this rating scale a 
high score indicates calm, a low score anxiety. 
There was no significant correlation between the 
Hamil ton anxiety rating scale score md the visual analogue 
scale of anxiety score, nor between the changes in score 
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SULPHATE 
FIG. 19s Visual analo0~e s cale of anxiety results 
expressed as the weekly mean differ ence in 
millimetres from the baseline mean score in 
the oestrone and placebo groups. 
HO?! FIDSHBS 
The number of hot flushes experienced by the patient• 
vP.ried widel¥• Two patients in the oestrone group and 
one in the placebo group experienced no hot flushee at all 
during the study, and one in each group coaplained that 
her hot flushes were ao frequent that she could not keep 
cowtt of them. The maximwa recorded in one day was 12, 
but aoat of the patients bad only one or two hot fluahea, 
and since the daily mean waa so low, the result• are 
expressed as the weekly total. In the oestrone group the 
weekly total of hot nushea ranged froa 0 to 67, and in 
the placebo group from 0 to 72. 
The number of hot flushes experienced by each group 
fell during the :J'tud7t aa can be seen from lie• 20. The 
placebo group had a higher mean hot fiush count than the 
oestrone group throughout the study, but there was little 
difference in the rate of fall in the hot flush count in 
the two groups. In the baseline period, the mean weekly 
hot flush count of the oestrone group was 11.8 ! 3.4 and 
this fell to 6.7 ! 1.7 in the first treatment month, and 
6.5 ! 2.0 in the second treatment month. Although the 
hot flush count fell, it was not significantlf lower in 
the active treatment period than in the baseline, and it 
oan be seen from Pig. 20 that the greatest fall in the 
number of hot flushes occurred in the baseline period, and 
there was little further change after the start of 
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FIG. 201 Mean weekly hot flush count of the oestrone 
and placebo groups. 
-·· + 
weekl1 hot flush count in the baseline period was 15·4 -
4•4 and although 'this ia higher than the baaeline mean of 
the oestrone group the d itterenoe between the group a waa 
not aignitioant (t • 0.67). The weekl7 hot flush oount 
ot the placebo group tell to 13.2! 3.4 in the first 
treatment month and 10.8 t 3·5 in the seco~ trea~ent 
month,- but these levels are not signitic&rltlT lower tban 
the baseline aeaa. 
The oestrone group showed a alightlT greater tall in 
the hot flush count tban the placebo group, but the differ-
ence between the groups was not significant. Between the 
baseline period and the first treatment month, the oestrone 
group showed a mean deoreaae of 5.1 ! 3.1 hot tlushea per 
week, ancS the placebo group a mean 4 ecreaae of 2. 2 ! 1. 8 
hot flushes (t. 0.83, x.s.), aDd between the baseline aD4 
second treatment month the hot !lush count of the oestrone 
group tell b7 5·3 ! ).J, oompare4 with a tall ot 4.6 ! 2.6 
in the placebo group (t • 0.171, N.s.). 
The patients also rated the severity of their hot 
flushes on a visual analogue scale, an4 only one patient 
in the placebo group tailed to complete this rating. The 
results are shown in Fig. 21, which shows the difference 
o:t the mean weekly score from the baseline mean :tor each 
week ot the study in each group. lrom this it can be 
seen that the hot nush severity fell during the study in 
both groups. 
The mean baseline score of the oestrone group was 







HOT FLUSH SEVERITY- DIFFERENCE FROM BASELINE MEAN 
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FIG. 2la Hot flush severity r~ting expressed as the 
weekly mean di!fer enoe in millimetres from the 
baseline ~ean i n t he oestr one and placebo groups. 
121. 
placebo group, 26.0 ! 5.1, the difference between the two 
groups waa not significant ( t • 1. 06). The me&rl aoore 
+ of the oestrone group waa 12.1 - ).0 in the firat trea'tment 
month, and 12.1 ! l• J 1n the aeoond treatment month, and 
both of· these are significantly lower thaD the baseline 
mean (first month, t • 2. 32, p < o. 02 5J second month, 
t • 1.79, P< 0.05)• However, inspection of liB• 21 ahowe 
that the fall in aoore ooCNrre4 mainl.T 1n the baseline 
period, and there was little change in the score after 
the start ot active trea~ent. 
In the placebo group, the mean aoore 1n the first 
treatment ~nth, 19.8 ! 4.3, waa not significantly lower 
than the baseline mean (t • 1.71) but in the second treat-
ment month there was a further fall 1n the score to 18.4 ! 
5.2, and this is aignifioantlJ lower than the baseline mean 
(t • 2.00, P< 0.05). 
!rile magnitude of the obange in a oore was similar in 
the two groups, and there was no significant difference 
between th... Between the baseline period and the first 
treatment month the score of the oestrone group fell by 
7.o! 2.8, and the plaoebo group b7 6.2! 3.6 (t • 0.390, 
N.s.), and between the baseline and second trea~ent month 
the score of the oestrone group fell by 1.0 ! ).8, 
compared with 7.6! ).8 in the placebo group (t • O.l20,N.s.). 
The hot flush severity scale shows a similar pattern 
of change to tbat shown by the hot flush count, as can. be 
seen by comparing Figs. 20 and 21. There was a signifi-
cant positive correlation between the dailJ hot flush count 
122· 
and the severity rating tor that da7 ,.in all caaea. 
O'bviousJ.T, where the patient bad no hot flushes the 
severity was also rated as o, eo in oases with no hot 
tlushea the correlation was absolute, but in the other 
caaea the correlation coettioient r ranged trom 0.54 to 
0.95 (p < 0.001 in all caaea). 
!here was no sisDitioant correlation betweea the ae&D 
hot tluah OO\ll1t or hot tlush aeveri v aoore and the uaa 
total intervening waketulneaa or sleep duration in the 
three periods ot the siu4y, nor was there &DY oorrela tion 
between the obangee in the hot tlush count or hot tluah 
severity score and changes in either intervening waketul-
neaa or sleep duration. 
l!WRO:mfDOCRIN3 S1UDIES 
Blood studies were carried out on. twelve patients, six 
in the placebo group and six in the oestrone group. For 
these investigations, the patients attended the sleep 
laborator.y on two extra nights, one in the baseline period 
in week tour and one at the end of the first treatment 
month. Blood study nights were carried out either three 
or tour nights before the next routine recording night, 
·to avoid influencing the results of the sleep study. On!¥ 
tour ot the patients in the oestrone group completed the 
second blood night, since it proved impossible to cannulate 
a vein on that night in one patient, and a second patient 
dropped out halt way through the study because of a urinary 
tract infection. Table l7 · ahows the age of patients 
123. 
undergoing blood studies, and the duration of amenorrhoea 
before the start of the study. 
XA.BLE l7a Age and Duration of Amenorrhoea in Patients 
in Neuoroendoorine Stud7. 
Duration ot 
Case No. .lge Amenorrhoea 
(years) 
P~c1b2 GrJ2]12 
1 48 O.J 
2 51 2.0 
J 5J 7.0 
4 52 5·0 
5 45 O.) 
6 49 2.0 
Ql&t£2!!! G£2!m 
7 51 1.5 
8 56 a.o 
9 44 0.5 
10 50 O.J 
ll 49 4.0 
12 56 a.o 
Sleep Resul-ts 
As was predicted, patients did not sleep so well on 
blood study nights as on normal recording nights, because 
of the stress of having an intravenous cannula i~serted 
and of sleeping with it taped in place. Table 18 shows 
the mean values of sleep latency, sleep duration, and 
amount of the sleep stages for each blood night, and also 
for the last night recorded before each blood night, and 
. J..i4.·.~ - . 
it will be seen from this table that sleep duration waa 
shorter on the blood nights than the preceding night, and 
the amount of intervening wakefulness and stage l sleep 
was greater. The difference in sleep duration was not 
significant, but there was signitioantl7 more stage l sleep 
in the first blood night than the preceding night (t • 2.160, 
p ( 0.025) and in the second blood night there was aignifi-
cantly more inter'f'ening waketulneaa (t • 1.828, p < 0.05) 
and less stage 2 sleep (t • 1.948, P< 0.05) than in the 
preceding night. 
unchanged. 
Slow wave sleep and REM aleep were 
TABLE 18a Sleep Onset I.e.tenc7, Duration, aad the AmoUD.t 
ot each Sleep Stage (min) on the two Bloo4 
Bights and the Preceding Bight. 
Sleep Stage Blood Preoe41D8 Blood Preceding Night 1 Right Right 2 Kight 
Sleep latency 30.0 26.6 22.0 30.5 
Sleep Duration 420.9 427.9 410.5 439.9 
Inter'f'ening 
Waltefulneaa 35·7 2).8 35.1 15.7 
Total Stage l 5).2 39.6 42.0 35.6 
Total Stage 2 216.3 236.8 192·7 220.2 
Slow Wave Sleep 51.4 51.8 71·5 62.2 
Total Rlll Sleep 99·9 99·4 104.3 115.3 
OIStJlOG!R LEVJLS 
Oeslront 
In all oases, both oestrone and oestradiol levels 
showed episodic Yariation throughout the night. The 
levels varied widelY and rapidlJ, and this variation 
persisted even when the patient was on oestrogen treataent, 
as oan be seen from Fig. 22, which shows the oestrone 
levels during nights l and 2 in case 10, ·a patient who 
received oestrogen treatment in the second part of the study. 
There was considerable varia-tion in the uan oestrone 
levels between patients, as can be seen froa fable 19, but 
in moat oases the mean level was within the range expected 
in the early menstrual o.rcle. In aoae patients in the 
placebo group there was a eurprisingly large difference 
between the mean oestrone levels on the first and second 
blood nights, e.g. Oase l showed an increase of 293.6 paol/1 
(7.9 ng/dl) and C&se 5 a decrease of 170.1 pmol/1 (4.6 ng/dl), 
but when the levels of the two nights were compared in 
each case, using a t-test for paired observations, this 
ohange was significant only in Case 5 (t • 2.830, p (0.01). 
The patients in the oestrone group showed an increase 
in their mean oestrone levels on the second blood night, 
as would be expected attar tour weeks treatment with 
piperazine oestrone sulphate, but the magnitude of the change 
varied considerably between patients. Case 9 showed only 
a small increase, of 81.5 pmol/1 (2.2 ng/dl), but the 
remaining three patients showed a marked increase, of 
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Nocturnal plasma oestrone l evels (pmol/1) in 
Case 10 on placebo (Night 1) and after one month 
of treatment with piperazine oestrone sulphate 
3 mg/day {Night 2). 
in Case 8, and of 428.0 pm.ol/1 (11.6 ng/dl) in Case 10. 
When the oestrone levels on the two nights were compared 
using a t-test for paired observations, the change was short 
of a1gn1fioant in Case 9 (t • 1.212), but the oestrone 
concentrations were significantly higher on the second blood 
night in Case 7 (t • 2.875, P< 0.02), Case 8 (t • 4.886 1 
P< 0.001), and Case 10 (t • .).801, P< 0.001). 
Mean Nocturnal Plaaaa Oestrone Concentration t 
Standard Error of the Kean (paol/1). 
Oaae 1fwlb er Bight 1 Bight 2 
f;Laclb g G£2ii 
1 29.3.2 :t 151.0 586.8 :t 60.1 
2 + 155.1 - 36·5 148.4 :t .31.6 
.3 + 155·5 - 68.5 66.9! 16.5 
4 + 209.2 - 16.8 1.75·7 :t 18.7 
5 + 494.9 - 24.3 324.8 ! 56.8 
6 147.6 :!: 32.0 128.2 :!: 15.2 
Mean 242.6 238.4 
Oestron1 G£2!!:2 
7 + 252.4 - 54·7 7.35.8 :!: 150.2 
8 108.7 :!: 2.3.6 298.0 :!: 30.7 
9 278.4 :!: 37.1 + 359.9 - 58.2 
10 + 290.0 - .33·.3 718.0 :!: 110.0 
11 + 161.3 - 39.6 -
12 + 221.7 - 42·9 -
Mean 218. 8 527.9 
The mean levels of the two groups were similar on the 
first blood night, that of the oestrone group being 218.8pmol/l 
(5. 9 ng/dl) and that of the placebo group 242.6 pmol/1 
128. 
(6.6 ng/dl). Although there was considerable variation 
in individual cases, the mean level of the placebo group 
showed little change between the two blood nights, with a 
mean decrease of only 4.2 pmol/1 (0.1 ng/41). The 
oestrone group showed a mean increase of 295•5 pmol/1 
(8.0 ng/dl), and when the changes in the two groups were 
compared using the Mann-Whitney U test the difference 
between them was significant (0 • 3, P< 0.033). 
There was no signitioant correlation between the mean 
oestrone level and the duration ot amenorrhoea (r
8 
• 0.45, 
K.s.), though _the mean oestrone levels were higher in 
patients with amenorrhoea for less than one 1ear. 
There was no evidence of a diurnal rhythm in oestrone 
levels during the night. lluotuations in the oestrone 
level were irregular, and when the night is divided into 
three periods, there was no significant difference between 
the mean levels of each period. 
The changes in hormone level bore no relationship to 
changes in sleep stages, and there was no correlation 
between mean oestrone levels and sleep latenc1• sleep 
duration, or the amount of any sl.eep stage. 
Oestradiol 
The oestradiol levels also fluctuated rapidly during 
the night both when on placebo and when on oestrogen treat-
ment, as can be seen from Fig. 23, showing the oestradiol 
levels of Case 10 on the two blood nights. 1'he mean levels 
for the two nights are shown in Table 20, and from this it 
600 
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FIG. 23a Nocturnal plasma oestradiol concentrations 
(pmol/ 1) i n Case 10 on placebo (Night 1) and 
after one ~onth of treat~ent with pi pera zine 
oes trone sulphate 3 mg/day (Night 2 ). 
1.30. 
can be seen that some ot the patients bad oestradiol levels 
similar to those ot the early menstrual cycle, while others 
bad ver.y low levels. There was a significant correlation 
between the mean oestradiol level and duration of amenorrhoea 
(r
8
• 0.55, P<0.05), but it oan be seen from F1g. 24 that 
the level was highest in patients with amenorrhoea tor lees 
than one year, and there was little difference in the 
hormone levels in relation to the duration of amenorrhoea 
after this. 
tABLE 20a Mean Noo~al Plasma Oestra41ol Concentration ! 
Standard Brror of the Mean (paol/1). 
Oaae Number Kipt 1 Nicht 2 
~·ao!l!2 G£9J!i 
1 + 171.7 - 43·7 251.8 ! 49·9 
2 + 46·4 - 14.1 + .37·5 - 10.9 
3 46.8 ! 17·4 + 42.3 - 10.2 
4 + 54.3 - 5·2 uo.8 .t 19.2 
5 158.6 ! 20 •. 6 + 61.4 - 15.7 
6 78.8 :!: 22.8 100.3 ! 58.7 
Mean 92.8 100.7 
018~£0De G£23!1! 
7 26.9 ! 12.8 181.5 :!: 2.3.2 
8 47.7 ! 17.0 + 149·3- 41.1 
9 + 174.0 - 27.2 + 74·7 - 1.3·5 
10 + 2 .31. 5 - 27. 7 226.3:!: 29.0 
11 63.4 ! 16.6 + -
12 + 93·5 - 36.2 -
Kean 106.2 158.0 
RELATIONSHIP BETWEEN MEAN OESTRADIOL LEVEL AND MENSTRUAL AGE 
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FIG. 24a The relationship between the duration of 
amenorrhoea and the mean plasma oestra~iol 





CoiiP&ring the ugni tude of change in the two groupe 
between the first and second blood nights, the oestrone 
group had a mean increase of 37.9 pmol/1 (1.0 ng,/dl) and 
the placebo group a mean increase of ·7·9 pmo~l (0.2 ng/dl) 
but because ot the wide variation in individual results the 
difference between the groups was not siBDifioant (t • 0.548). 
Som.e of the patients in the placebo group showed a 
marked cbange in their mean oestradiol leTela between the 
two nights. 
(2.2 ng/dl), 
(1. 5 ng/dl)' 
(2.6 ns/dl). 
Case 1 showed a mean increase of 80.1 P•ol/1 
and Case 4 an increase of 56·5 pmol/1 
while case 5 ahowed a 4 eorease of 97.2 paol/1 
When the oestradiol levels on the two nights 
were co~ared using a t-teet tor paired observationa, the 
difference was significant in Oase 4 (t • 3.118, p< 0.005) 
and Case 5 (t • 3·716, P< 0.001), but the change shown b7 
case l was short of significance (t • 0.680). 
The pa.tienis in the oestrone group did not show a 
consistent pattern of change in their plasma oestradiol 
concentrations between the first and second nights of the 
study. The mean oestradiol level of Case 7 increased b7 
1 54 .6 :pmol/l (4.2 ng/dl), and Case 8 had a smaller increase 
of 101. 6 pmol/1 (2.8 ng/dl), but Case 9 showed a decrease 
ot 99.3 pao~l (2.7 ng/dl) and Case 10 a decrease of 
5.2 pmol/1 (0.1 ng/dl). When the plasma oestradiol con-
centrations of the two nights were compared, they were 
found to be significantly higher on the second night in 
Case 7 (t • 5.279, P< 0.001) and in Case 8 (t • 2.656, 
:.;;.. ! . ·~ 
133· 
p < 0.02), and significantly lower in case 9 ( t • 3.1.2 5, 
p < o.oo.5), but the difference was not significant in 
Case 10 (t • 0.135). When the magnitude of change in the 
two groups was compared, the difference between tb.e groups 
was not significant. 
There was no evidence of a diurnal rhythm in oestradiol 
levels; and the changes were irregular and bore no relation-
ship to changes in sleep stages. There was no correl-
ation between mean oestradiol level and either sleep 
latency, duration, or the amount of any sleep stage, nor 
was there any difference in the mean oestradiol levels in 
each sleep stage. 
There was a significant positive correlation between 
the mean oestrone and mean oestradiol levels in the twelve 
patients on night l (r • 0.59, p 0.05) and tb.e six patients 
on placebo on night 2 (r • 0.84, p 0.05) 1 but in the 
oestrone group in the second blood · night the correlation 
was short of significance, possibly because of the small 
number of patients. However, when the changes in the 
two hor.ones throUghout the night in each patient are 
considered, there was no consistent relationship between 
the oestrone and oestradiol lavale. 
Oestrone a Oestradiol Ratio 
It can be seen from Table 21 that the oestrone 1 
oestradiol ratio varied widely, but in all cases was greater 
than 1. The lowest value was that of Case 101 who bad a 
ratio of 1.3&1, and the highest was that of Case 7 1 who had 
a ratio of 9·3•1 after 18 months amenorrhoea. 
groups there was considerable variation between the two 
blood nights, and oestrogen treatment bad no consistent 
effect on the ratio, increasing it in two cases and 
decreasing it in two. 
There was no significant correlation between the 
oes trone& oestradiol ratio and the duration of amenorrhoea. 
TABLE 21& Mean Oestrone a Oestradiol Ratio 
Case Number Night 1 light 2 
P~aceb2 G£2BR 
1 1.7&1 2~211 
2 l·l•l 3·911 
3 )a3&1 1.6a1 
4 ).Sal l.ial 
5 ).lal 5·311 
6 1·911 l.)al 
Qsstrone Grou2 
7 9·311 4a0al 
8 2.)&1 2.0&1 
9 1.611 4.8al 




The mean nocturnal plasma prolactin concentration 
varied widely between patients and also between nights, aa 
can be seen from Table 22. On the first night, when all 
patients were on placebo, it varied from 124.1 miU/1 
(6.2 ng/ml) to 990.8 miU/1 (49.5 ng/ml), with the mean 
135. 
value of the pl.a.cebo group, 269.2 aiU/1 (13. 5 ng/ml.) being 
auch lower than that of the oestrone group, 4l 0 ·6 miU/1 
(20 . 5 ng/al), though the difference between the two groupe waa 
not significant (t • 1.42, N.s.). Although the group mean 
nocturnal plasma prolactin level ot the placebo group on the 
second night was similar to that of the fir·st night, the 
individual patients showed considerable variation,with Case 2 
showing a decrease of 163.8 miU/1 and Case 4 an increase ot 
176.6 miU/1. Oestrogen treatment had no consistent etteot 
on the aean noo~l plasma prolactin levels ot the oeatrone 
group, and only one patient,case 7, showed a large 1ncreaae 
of 294.4 mlU/1, while one showed a smaller increase, oae a 
decrease and another no obange. There. wae no e1gn1t1caa.t 
difference in the magnitude of ehange between the two nights 
in the oestrone and placebo group. 
TABLE 22t Kean Nocturnal Plasma Prolactin Concentration ! 
Standard Rrror ot the llean (miU/1). 
case Nwaber Right 1 iight 2 
Placebo Grgu;e 
1 206.6 :!: 26.1 ' + 222.0 - 12.0 
2 436.6 t 26.1 27,.8 ;!; 36.1 
3 240.8 t 36.1 + 291.0 - 64. 1 
4 + 221.0 - 20.0 397.6! )2.1 
5 208.4 t 34.1 + 144.0 - 14.0 
6. 301.4 t 66.1 435.0 t 110.2 
Mean 269.2 293·8 
O!strone Grou;e 
7 990.8 ;!; 102.2 1285·2 :!: 98.2 
8 + 574.4 - 70.1 + 435·0 - 72.1 
9 + 274.4 - 20.0 + 27).4 - 30.1 
10 + 370.4 - 58. 1 553.6 ! 46.1 
11 + 28.1 124. 4 - -
12 129.2 :!: 32.1 -
Mean 410.6 636.8 
1)6. 
Hoo~l prolactin secretion is known to show a 
sleep dependent increase, so the results have been analysed 
in relation to sleep onset. · The levels of all patients 
were lower before sleep onset than during sleep on both 
nights, but varied from 0 to )00.0 mi0/1 (o-15 ng/ml). 
In the placebo group, the mean plasma prolactin concentra-
tion before sleep onset of 1)8.0 i 52.0 mi0/1 (o.g ± 2.6 ng/ml) 
on the first night was higher than that on the second blood 
night, 46.0 ± 46.0 miU/l (2.) t 2.3 ng/ml). In the 
oestrone group, one patient, Case 7 1 tell asleep before the 
first blood s-.ple could be taken on both nights, but the 
mean plasma prolactin level before sleep onset of the 
remaining patients was 84.0 t 60.0 ml0/1 (4.2 ± ).0 ng/ml) 
on the first night and 134.0 ! 1)4.0 ml0/1 (6.7 ! 6.7 ng/ml) 
on the second night. 
The plasma prolactin concentration increased within 
6Q-90 minutes of sleep onset in all oases except case 9 on 
the first night, when it took 160 minutes, and Cade 5 on 
the second night, when it took 140 minutes. This increase 
in secretion lasted tor 6-8 hours, but the pattern of the 
increase, and the peak levels, showed considerable 
individual variation. Case 7 bad a rapid rise with a 
series of ver,y high peaks on both nights, as can be seen 
from Fig. '5• and bad much higher levels than the other 
patients. Other patients, e.g. cases 3 and 10, had a 
single high peak, and others a series of lower peaks. The 
peak prolactin values ranged from 284.0 to 1620.0 miU/1 










































23.00 24 . 00 01.00 02 . 00 03 . 00 04.00 05 . 00 06.00 
Noo~l plasma prolaotin concentrations 
(m.lU/1) in Case 7 on placebo (Night 1) aDd 
after one month of treatment with piperazine 
oestrone s~pbate 3 mg/day (Night 2). 
1)8. 
from Table 23, and the mean peak prolactin of the oestrone 
group was· a1gn1ficantly higher than that of the placebo 
group on this night (t • 3.130, p ( 0.02). In both groupe, 
some patients bad higher peak values and some lower on the 
second blood night and oestrogen treatment had no con-
sistent effect on the magnitude of the peak values, with 
two patients showing an increase and two a decrease in 
their peak prolactin leTela. 
TABLE 23a Peak Nocturnal PlaSDI& Prols.ctin Conoentration(miU/1) 
Case Number Night l Kight 2 
P~oebo Grou2 
1 284.0 312.0 
2 ooo.o 5l0.0 
3 580.0 970.0 
4 )92.0 580.0 
5 294.0 480.0 
6 790JJ o2o.o 
!lean 500.0 578.6 
01atron1 Gro!m 
7 1620.0 1960.0 
8 1110.0 730.0 
9 4)0.0 470.0 
10 984.0 940.0 
11 554.0 -
12 406.0 -
!lean 850.6 1025.0 
The resul ta of the two groups have also been analysed 
as hourly mean levels after sleep onset on each night, as 
shown in Figs. 26 and 27. In the placebo group there was 
139 • 
.. 
a clear increase in plasma prolactin concentrations after 
sleep onset and there was little difference in the pattern 
of secretion or levels of prolactin on the two nights. 
From comparina the two figures,· it can be aeen that the 
oestrone group had higher mean levels than the placebo 
group on both nilhts. The nocturnal increase in prolaotin 
secretion ocaurred more rapidly when the patients were on 
oestrogen treatment but there ~s little difference in the 
peak levels on the two nights. However, if the resulta 
of i~ividv.al patients are considered, instead of the sroup 
aean, it oan be seen that -the response varied oona1derablT 
between patienta. The two patients who showed the 
greatest 1noreaae in their plasma oestrogen concentration• 
showed the aoat aarked change in their prolactin aeoretioaa. 
Case 7 showed an earlier increase in her prolactin aeoretion 
when on oestrogen treatment, with a series of higher peaka 
(see lig. 2.5), and case 10 showe4 an earlier and aore pro-
longed increase, with a aeries of lower peaks instead of a 
single high peak (see lig. 28). caa es 8 and 9, who b.a4 
smaller increases in their plasma oestrone levels, ahowe4 
no clear change in either the pattern of secretion or the 
concentrations of prolactin on oestrogen treatment. 
There was no relationship between changes in p_rolaotin 
and changes in concentration in oestrone or oestradiol 
during the night, nor was the correlation between mean or 
peak prolactin levels and mean oestrogen levels significant. 
The correlation coefficieutr bttween peak nocturnal prolactin 
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FIG. 27a Hourly mean prolactin concentrations (miD/1) 






0 /X 1\ I \ I 
I \ I 
I \ I 
I '" I I 0, I 
I ' I 
















: 0.--o NtQaT 2 
I ',/(()~ROGEN) 
I ' 
~-o-~ o ... 'O 
\ 
K......._ X 
X / 'x NIGHT 1 
........._ '-x........_x/x'( (PLACEBO) 
0~---r------r-------r------r------~-----.----,-------.-----~---
23.00 24.00 01.00 02.00 03.00 04.00 05.00 06.00 D'l.oo 
TIME 
liG. 28t Nocturnal pl asma prolactin concentrations 
(mi0/1) i n Case 10 on placebo (Night 1) and 
at ter one mont h of t reat ment with pi perazine 
oestrone sulphate 3 mg/day (Night 2) 
·,. 
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aecond nigh~ in the oestrone group, and between mean 
prolactin concentration and mean oestrone concentration waa 
o.88, but beoause of the small numbers this was not 
statistically significant. The correlations between mean 
and peak prolactin concentrations and total plaama oeatroaen 
concentration were lower (r • 0.85, r • 0.83) and &&&in 
these correlations were not significant. There was no 
evidence of a relationship between either mean or peak 
prolactin coaoentrations and age or duration of amenorrhoea. 
On the first blood ni&ht, there was a s1cn1f1cant 
positive correlation between the mean plasma prolactin 
ooncen tra tion and the aaount ot slow •ve sleep when all 
twelve patients were considered (r • 0.66, p( 0.05), but 
this was not found on the ·aeooD4 night 1n either croup. 
Other than this, there waa no oorralat1on be~een either 
mean or peak plasma prolactin oonoeatration and the &IIOunt 
ot any sleep stage, sleep onset latency, or sleep duratioa. 
The changes in prolactin levels during the night bore no 
relationship to changes in sleep stage, and the mean con-
centration of prolactin was no different during Rm4 sleep 
or slow wave sleep from that in the other aleep stagea. 
trlp$opb.ap 
Because of a laborator,y accident, only samples from 
the first blood night in Cases 4 and 5 and the second blood 
night in Case l were analysed. The patients were receiving 
placebo on these nights, so no information is available 
on the effect of oestrogen treatment on plasma tryptophan 
levels. 
1.44. 
The mean total plasma tryptophan concentrations were 
72.6 t 2.2 pmo~l (14.8 ! 0.5 p&/ml) in Case 1, 67.1! l.~o~l 
(13·7 :!: 0.2 )18/DLJ.) in Case 4, and 65.7 ! 1.9 pmol/1 · 
(13·4! 0.4ps/al) in case 5· fbe mean tree plasma 
tryptophan concentrations were g.o ! 0.7 fAOl/1 (1.8 ! 
0.1 pg/ml) in Case 1, 4.4.! 0.2 pmol/1 (o.g ! o.o f8/ml) 
in Oase 4t and 7.0! 0·4 pmo1/l (1.4 ~ o.lpg/ml) in 
Case 5· The results were also. considered aa ~ free pla ... 
trnrtopban, and the mean values for the three patients were 
12.2 ± o.~, ·6.6 ! 0.2~, and J.D.6 1 0.5,t respectivel.¥• 
Both free and total plasu tryptophan levels tluotute4 
d\ll"ing the night in all tbree oasea (see lia•• 29 and 30). 
In .Oases 1 and 4 there waa a aisnifioant positive correla-
tion between tree and total plasma tr,yptophaa concentrations 
f 
(Oaae 1, r • 0.65; Case 4 r • 0.54, P• o.ol in both caaea), · 
but in Oase 5 the correlation was no·t sipifioant (r • 0.)1, 
B.S.). The total plasma tr.yptophan levels were lowest in 
the earl.¥ ·hours of the morning, as can be seen _from 
inspection of !'ig. 30 ,and to seek evidence of a diurnal 
variation, the results were analysed by dividing _tbe n1sht 
into three periods (Pl• P2, and P3) using 2 a.m. and 
5 a.m. as out ott points, as described by Chen et al (1974). 
Table 24 shows ·the mean total plasma tryptophan concentra-
tions in the three periods, and it oan be seen that in all 
three patients the levels were lowest in P2. The differ-
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FIG. 29& Nocturna l free plasma try.>tophan concentr ations 
~ol/1) in Case 1 on Night 2 (on placebo) and 
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PIG. JOa Nocturnal total plasma trypt ophan concentrations 
~unol/l) in Case l on Night 2 (on placebo) and 







Total Plasma TrJptophan Concentrations ! 
SW.ndard Error of 'the Jlean (pm.ol/1) iu Three 
Periods of the Night. 
Sleep Periods 
P1 P2 Pl 
(Up io l.. 59•·••) (2a.m. to 4e59a.a.) (After 5 a.a.) 
1 + 75·7 - 2.5 + o1.7 - ).0 80.2 t 1.6 -
4 66.8 1 1.7 64.8 t 1.9 + 71.0 - o.1 
5 71.4 :t 2.8 + 60.9 - 3·5 + 63.7 - 1.7 
Although there. was no obvious pattern of ohange in the 
levels of free plasma 'tr,yptophan during the. n;ght, these 
results too were analysed by comparing the mean values of 
three periods of the night, as deaoribed for total plasma 
tryptophan. These results are shown in Table 25, and i't 
oan be seen from this that although the free plasma 
tryptophan levels were lowest in P2 in cases 1 and 5, the7 
were highes~ at this time in Case 4, and there wae no con-
sistent pattern in the three patients, and the difference 
between the three periods ot the night was not significant 




Mean Free Plasma Tryptophan Concentrations 1 
Standard Error of the Mean (pmol/1) in Three 
Periods of the Night. 
Sleep Periods 
Pl P2 
(Up to 1. 59a.m.) (2a.m. to 4·5_9a. m._l 
P3 
(.After 5 a.m.' 
1 + 1·1 - 1.1 + 7.4- 0.9 11.9 :!: 0.6 
4 + 4·4 - 0.3 + · 4.5- 0.2 + 4.4 - 0.1 
5 7.8 :!: 0.9 + 5·9 - 0.4 + 7.4 - 0.7 
. us. 
There;waa a high correlation between changes in tree 
plasma tryptophan and plasma oeetrogens; as oan be seen 
from Table 26. fhe correlation b etw•en the tree plasma 
tryptophan and total plasma oestrogen concentration 
(oestrone + oestradiol) was highlJ' signitioa.nt in all tbree 
. ~ . . 
oases (Case 1, r • o. 91, p < 0.0011 case 4t r • 0.87, 
.P< O.OOlJ Case 5, r • 0.49, p < 0~0~>'.~.. When the relatioa-
ship with plasma oestrone alone is considered, the correl-
ation 1 s lower but still s1gn1!1cant in all tbree oasea 
{Case 1 1 r • 0.64, p ( 0.011 Case 4, r • 0.8J, p < O.OOlJ 
case 5, r • 0.46, p .f 0.05), but the correlation between 
tree plasma tryptophan concentration and plasma oea~ra4iol 
concentration ia s1gnif1c~t onlJ in Oase 1 (r • 0.62, 
p < 0.01). !he relationship between total plaama oestroaea 
concentration and ~ tree plasma tryptophan is even oloser, 
and it oan be seen from inspection of Figs. 31, 32 an4 33. 
that they change almost in parallel during the ni&ht 1n 
each case. ~he correlation coefficient ·r between the 
total plasma oestrogen concentration and % free plasma 
tryptophan was o.gg in Case 1, 1.00 in Case 4 1 and 0.81 1a 
Case 5 (p ( 0.001 1n all oases). !he correlation between 
plasma oestrone concentrations and % tree plasma tryptopb&a 
ia also significant, though lower than the correlation 
between % tree trn>tophan and total oestrogen levels, ai'J4 
the correlation with plasma oestradiol is again lower, but 
significant in Cases l and 5, but not Case 4 {see Table 26~. 
There was no significant correlation between total pl&aaa 
tryptophan concentration and the concentration of either 
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FIG. 31: Total plasma oestrogen concentrations (pmol/1) 
and % free pl~sma tryptophan in Case 1 during 

















FIG. 32: 7otal plasme oes tro~en concentrat i ons {pmol/1) 
and 1· free plasma tr-,tp t ollhan in Case 4 duri ng 
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nml { froc :; lr.~s:n t rJ) t0.:,1h::tn in Case 5 duri ng 
~~i.;ht 1 ( o~• .,;l~:t ccbo) . 
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TABL~ 261 The Relationship Between Free Plasma Tryptopmt.n 
Concentration and Plasma Oestrogen and 
Prolactin Concentrations. 
Correlation Coefficient r 
case 1 case 4 caae 5 
r p r p r p 
Plasma oestrone 0.64 <O.Ol o.Sl cO.OOl 0.46 c0.05 
Plasma oestradiol 0.62 cO.Ol 0.34 N.s. 0.37 N.s. 
Total plasma 0.91 cO.OOl 0.87 <0.001 0.49 co.Ol oeatrogena 
Plasma prolactin -o.41 .(().05 -o.07 N.s. -o.50 <0.01 
TAJLE 27a The Relationship Between ~ Free Plasma !r,yp~opban 
and 2lasma Oestrogen and Prolactin Conoentra~ione. 
Correlation Coefficient r 
Case 1 case 4 Case 5 
r p r p r p 
.Pla8DI& oestrone 0.78 cO.OOl 0.96 <0.001 0.71 <0.001 
Plasma oestradiol 0.57 <0.01 0.35 N.s. 0.68 (0.001 
Total Plasma Oe 99 (0.001 1.00 <0.001 0.81 (().001 oestrogen 
.t>rolactin -o.s1 <0.01 o.os N.S. -o.40 <0.05 
In cases 1 and 5 there was a significant inverse 
correlation between plasma prolao~in concentration and both 
concentration and % free plasma tryptophan, but in Case 4 
the relationship was not aigni~ioant, and none of the 
patients showed a correlation between plasma prolactin and 
total plasma tryptophan concentrations . 
153. 
Jere was no direc-t tempo~l relationshi» between 
changes in either tree or total plasma tryptophan 
concentration and any sleep stage and the number of 
patients atudied ia 1nsutf1o1ent to demonstrate .an, 
sicn1f1oant relationship between sleep dura-tion, sleep 
la~enc7, or 'the &moWlt of 8Df sleep s'tage aDd the. mean . . 






In Iq study, visual analogue scales of sleep quality 
have tailed to show that oestrogen is significantly more 
effective than placebo in improving the sleep quality of 
menopausal women. This agreea with the results of 
Utian (1972a). He found that oestrogen was no more 
effective than placebo in relieving insomnia in 
oophorectomized women, but he used a global scale of 
severity of insomnia rated o-3, and this may not bave been 
sufficiently sensitive to show a change. Qampbell· · 
(1976b) oarried out two double-blind cross-over studies, 
one lasting tor four months in patients with severe meno-
pausal symptoms, and one lasting a year in patients· with 
mild symptoms. Using a visual analogue scale of 
insomnia, he found that oestrogen was significantly more 
effective than placebo in relieving insomnia in patients 
with severe symptoms, but not in those with mild symptoms. 
My patients may resemble the patients with " mild" symptoms 
in his study rather than those with "severe•• symptoms, 
but as he gives no further details of their symptoms it 
is not possible to be certain of this. There were 
differences between my study design and that of Campbell 
(1976b) in that his was a cross-over study and mine a 
comparison between groups, and also differences in the 
administration of our rating scales , as my patients 
completed thei.r scales every day, and his completed them 
only once in two months. We used different visual 
155. 
analogue scales, since his measured insomnia and minr --·-
sleep quality, and, in rating their sleep quality, 
patients take into account not only their sleep duration 
and frequency of wakings, but also whether they had bad 
dreams, felt they bad slept deeply, or felt unrefreshe4 
in the morning. 
Visual analogUe soales of sleep quality gave differ-
ent results from the eleotrophysiological recording of 
sleep in ~ study. This JJJ11Y in part be due to their 
measuring different things, since the visual analogue 
scales of eleep measure how satisfied the patients are 
with their sleep, and the sleep record shows preciselJ 
how long the patient spent awake and asleep during the 
night. Visual analogue scales are less aenaitive tban 
the objective, eleotropbysidbgical measures of sleep, and 
it is possible that a larger number of patients would be 
needed to demonstrate a difference between the -o groupe 
by the visual analogue method. 
3lectropbysiological recording of sleep -showed a 
wide variation between patients in sleep latency, sleep 
duration, and the number and duration of episodes of 
intervening wakefUlness. There was no consistent pattern 
of sleep disturbance, and although all of the patients 
complained of insomnia , some appeared to sleep well and 
had a sJeep dura tion of eight hours, whi le others bad only 
a few minutes of intervening wake~lness. This finding 
is not aurprising, since numerous studies have failed to 
156. 
demonstrate any consistent abnormality in the sleep- pa""tterns 
ot insomnia patients. There are wide individual differ-
ences in sleep duration and pattern, and in a recent 
review of research· on insomnia Beutler at al (1978) 
remarked that not all who complain ot 1nsoJII11a have an 
abnormal sleep pattern, nor do all people with an abnormal 
sleep pattern complain of insomnia. 
Oestrogen treatment decreased the number and duration 
ot episodes ot ~etulnesa that interrupt sle~p in peri-
menopausal women in my study. There was little change 
in intervening waltetulnesa in the placebo group throughout 
the stud7, but in the oestrone group it was decreased in 
the first month ot active treatment, and in the second 
treatment month there was a further decrease in the am~t 
ot intervening wakefulness and also a decrease in the 
number of episodes ot wakefulness. Analysi~ of the 
distribution of wakefulness during the night showed that 
oestrogen treatment d eoreased the amount of intervening 
wake~lneas throughout the night, not just at the 
beginning or end of the sleep period. In the oestrone 
group, there was no increase in the amount ot stage 1 
sleep in either treatment month, so the decrease in 
intervening wakefulness oannot have been due to an increase 
in the amount ot drowsiness. There was an inorease in 
the total number of shifts to stage 1 sleep in the oestrone 
group in the first treatment month, which was significant 
when compared to the small decrease shown by the placebo 
group. Since the amount of stage 1 sleep was unchanged 
157. 
this means that the patients had more arousals but went 
back to sleep more quiok}¥. When the number of shifts 
to stage l in each hour of sleep are examined, it can be 
seen tba t there are more arousals in the third hour of 
sleep in the first treatment month than in the baseline 
period in the oestrone group, but that -.his accounts tor 
onl7 part of the increase. The oestrone group had a 
longer sleep duration in the first treatment month than 
in the baseline period, and when the sleep duration is 
kept constant, i.e. when the results are considered in 
terms of the first six hours of sleep, the difference 
between the groups is no longer si&n1fic811t, so lllUch of 
this increase in the number of shifts to stage 1 JllWit be 
due to the patients sleeping longer. 
Between the baseline period and the first treatment 
month the oestrone group showed an increase in the number 
ot shifts to stage 2 sleep, which simply means that after 
arousal to stage l the patients sank baCk into a deeper 
sleep. !his increase too was short of significance when 
the results were considered in terms of the first six 
hours of sleep, indicating that the change was related to 
a longer sleep duration. In the second treatment month, 
the number of shifts to sleep stages 1 and 2 returned to 
baseline levels in both groups. 
Sleep onset latency decreased slightly in both groupe 
throughout the study, and the patients also slept longer 
as the study progressed, and this may have been due to 
the improvement in their symptoms or to their growing more 
158. 
used to the sleep labora~ory. There was no evidence 
that oestrogen treatmen~ bad any effect on sleep onset 
latency, and although the increase in sleep duration was 
greater in the oestrone ~han in the placebo group, the 
difference between the two was not signifioan~. In both 
groups, the increase in sleep duration led to an increase 
in the amount of stage 2 sleep, as this is the OOIIIDOneet 
sleep stage and occupies moat of the night between periocla 
ot REM sleep. REM sleep periods become longer and aore 
frequent towards the end of the night, so it is not 
surprising tba t the amount of Rlll sleep also increased 
with the increase in sleep duration, or tbat the inoreaae 
in REM sleep was greatest in the oestrone group. Slow 
wave sleep was not obanged in ei~her group, and there 
were no changes in the amount of arrs sleep stage in the 
first six hours of sleep, or in the distribution of the 
sleep stages during the night, other than the changes ill 
intervening waketulneee. 
In a 4oubl.e blind study patients are randoml..y 
allocated to treatment groups, and it is always possible 
that the groups will not be comparable by chance . In 
rq study the two groups bad similar results during the 
baseline period for all parameters except tor intervening 
wakefUlness. The oestrone group had more broken sleep 
than the placebo group, and although the difference 
between them was not significant, the conclusion that 
oestrogen improves sleep could have been more confidently 
derived had the groups been more closely matched. It 
159· 
is possible that the patients with a very high level of 
intenening waket\llnese adapt on}¥ slowJ.7 to the sleep 
laborator.y, and that the effect of oestrone trea~ent ia 
an artefact due to there beiDg more patients with very 
disturbed sleep in this group. However, inspection o~ 
the results of individual patients shows that the iJaprove-
ment in intervening wakefulness in the oestrone grOQp ia 
not confined to patients with a high level of intervening 
wakefUlness 1 and on~ one patient in the placebo gr~p 
with ver,y disturbed sleep showed an improvement. Twelve 
patients in the oestrone group showed a decrease in inte~ 
vening wake1Ulnesa 1 compared with only' five in the placebo 
group, and the magni'tude of the change was much greater 
in the oestrone group, so the difference between the 
groups is not likely to be .due to an arte~act. In 
absolute terms the decrease in intervening wakefulness 
is relatively small, and was insufficient to cause a 
difference between the two groups on the visual ·analogue 
scales of sleep quality, so it is unlikels that this 
effect will be of great clinical importance, yet it seems 
that it cannot be an artefact, and so oestrone must be 
judged to improve sleep in perimenopausal women. 
Sleep is regulated by the brain, and there are · 
several ways in which oestrogens may influence the 
activity of the brain. Since oestrogen receptors have 
been located in many areas of the brain (Stamp!, 1971; 
Pfaff and Keiner, 1973) the effect of oestrogen on sleep 
may be due to a direct action on the brain. There is 
160. 
also evidence that oestrogens oan influence the metaboliaa 
ot the neurotranaaitters e.g. by changing the level of the 
precursor of serotonin, tr,JPtophan, in plasma, oeatrogens 
could change the metabolism of serotonin in the braiD • 
. Various workers have reported that the rate of production 
or the concentration of serotonin in the brain depends 
at · least partly on the concentration of tree plasma 
tr.yptopban (Fernstrom and Wurtaan, 19711 Knott and CQrson, 
1972; Gesaa and Tagliam.onte, 1974), although there is 
some conflicting evidence in that Fernstrom et al (1976) 
have recentl1 reported that total plasma tr.yptophan is 
the controlling factor. In my study I found a high 
positive correlation between nocturnal plasma oestrogen 
and tree plasma tr.JPtopban levels in perimenopausal women, 
and both Aylward (1973, 1976) and Coppen and Wood (1978) 
have reported that oestrogen treatment leads to an 
increase in free plasma tryptophan concentration in meno-
pausal women, and this suggests that oestrogen influences 
cerebral serotonin metabolism. Jouvet (1969, 1972) 
bas postulated that cerebral serotonin is responsible 
tor the maintenance of sleep, since ·in animal studies 
surgical ablation of the serotoninergic neurons in the 
mesencephalic and pontine raphe systems leads to insomnia, 
and inhibition of serotonin synthesis by p-chlorphenyla-
lanine leads to severe insomnia, which can be reversed 
by giving the serotonin precursor 5 hydroxyphenylalanine. 
Other workers have questioned the validity of these 
results, and Ross and Trulson {1976) pointed out that in 
• 
· operating on the serotoninergio nuclei, fibres of 
passage or non-serotoninergio nuclei 'IIIIA1 bave been 
damaged and this JJJa1 have been the cauae of the sleep 
diatu.rbanoe. The insoJIIlia produced in ardmala b7 
p-chlorpheJJ¥l.alanine bas been shown to be transient, 
last inc o~ a few dqa, even though the &7Jltheaia of 
serotonin remains suppressed (Dement et al. l972J Roaa 
and Trulson, 1976), aDd this obaer.ation led Boas 8D4 
Tru.laon to suggest that the insomnia cauae4 b7 this 4ru& 
'/IB.:f be due to toxic or irritative effects other thaa. 
the depletion of serotonin. !be.r also observed tbat the 
behaviour of animals treated with J-ohlorpheJl1'lalan1ne 
suggested a hyper.respons1v1ty to sensor,r events rather 
than insoania. 
Breuer et al (1978} found that oestrogen influence• 
the metaboliaa of oatecholallines 1n the rat brain. The7 
found that the activity of the ensfDle oatechol-o-metbyl 
transferase { OOJ4T) in the brain was highest in normal 
female rats, but was decreased by ovariecto~. This 
enzyme is concerned with the first step of the breakdown 
of noradrenaline on release from the nerve endings, 
methylation from noradrenaline to noraetanepbrine. These 
workers went on to stud7 the effect of exogenous oestrogens, 
and were surprised to find that the administration of 
oestradiol-l7p to ovariectomized rats caused a turther 
decrease in the production of the methylated metabolites 
of noradrenaline in rat brain. The authors inferred 
that oestradiol bas a direct effect on the methylation of 
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noradrenaline, but that the mode of action could be 
reduction of the availability of the cofactor of OOKT, 
s-adenosylmethionine, or by increasin& the uptake of 
noradrenaline by the cells, or by competition of the 
catechol oestrogena for the en.,me OOKT. !here is some 
evidence to support the second possibility, since Enderab7 
and Wilson (1974) found that in ovariectomized rata the 
ac~um,lation of noradrenaline by brain slices was increased 
by pretreat.ent with oestrogens, but Br~er et al (1978) 
favoured the theor.y ~bat the action ia due to competition 
of the oestrogen metabolites, the oatechol oestrogens, 
tor OOMT, ainoe they had found that in vitro the catechol 
oestrogen& had a higher affini" tor this en.,me than the 
catecholaaines (Br.uer and E~ster, 1974). 
There is evidence that oeatrogens ~ also influence 
the metabolism of the neurotransmitters by an inhibi to17 
effect on the en~e monoamine oxidase (MAO). · This 
en~me is widely distributed throughout the body, and ia 
responsible for the first stage of one route of the 
degradation of tyramine, tr.yptamine, noradrenaline, 
adrenaline, dopamine, and serotonin. Klaiber et al (1971) 
reported that plasma MAO activity is inversely related 
to plasma oestrogen levels during the menstrual cycle, and 
is highest in women with low oestrogen levels, e.g. after 
the menopause and in women with amenorrhoea, and in a 
later paper (Klaiber et al, 1976) they reported that 
oestrogen administ~ation decreased plasma MAO activity. 
There is some evidenoe that this is not merely a peripheral 
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etteo~, as Kobajashi et al (19~6) found that ovariecto_, 
increased KA0 .ao~lYiV in the rat bTPO~balNLUa t an4 
adain1stration ot exogenous oestrogen& caused the aot1v1t7 
to decrease again-. It seems therefore that oestrocena 
have a complex action on brain metabolism, intluenc1nc 
several n~otransmitter systeas aa well as acting 
direotlJ on the brain~ However, the relationship between 
oestrogens and brain metabolism and the neurochemical 
basis of sleep are incompletely understood, so it is not 
yet possible to toraalate a theor.y ot how oestrogen• 
affect the sleep ot menopausal women by their action on 
the brain. 
It is Uftlikely that the greater improv•ent in sleep 
experienced by the oestrone sroup ia due to cbangea 1n 
the number of hot flushes, or in mood or anxie~, sinoe 
the two groups showed similar changes in all of these 
symptoms. One possible cause tor the change in sleep 
pattern on oestrogena which was not investigated in this 
study is change in weight. Crisp and Stonehill (1976) 
found that weight i~crease was associated with longer 
and leas· broken sleep, and weignt loss with shorter and 
more broken sleep, and oeatrogena are anabolic hormones, ao 
they m8¥ have caused a weight increase in the oestrone 
group. Notelovitz (1975) found that one year's treatment 
with oestrogen did not cause weight gain, but he used a 
smaller dose of oestrogen, administered cyolicallJ, so 
our studies are not comparable. Depression too can be 
associated with weight change, either increase or decrease, 
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aD4 as the depreseion improves the appetite re~s to 
normal, so mood chaDgee ~ have oaused weight cb&D&e• 
in either group in m:r stwly. In re~rospeot, it would 
have been advisable to weigh the patients in ~q study. 
The last three patients in each group were weighed at the 
start and end ot the baseline period, aD4 at the end of 
the study, and I found that one patient in the placebo 
group loet 5 lb and another 1 lb during the baseline 
period, but the weights of the other patients were unchanged. 
During the two trea~~nt months, one patient in the 
oestrone group gained 3 l'b and another gained 1 l'b, and 
one pa tien~ in the placebo group gained ll lb, which ahowa 
that patient• in both groups __, have had weight cbangea, 
but the nWibera are so amall that it would be wrong to 
extrapolate these results to the rest of the patients. 
PSYCBOLQGialL SXMP~MS 
None of the patients in mT study bad psJohotio 
symptoms such as delusions or hallucinations, an4 the mean 
scores of the two groups on the Hamilton depression 
scales, 16.) and 18.2, would be considered to indicate 
depression ot only mild or moderate severity by most 
workera. These mean scores are similar to those ot the 
patients studied by Wheatley (1977), but are lower than 
these reJorted by Fedor-Freybergh (1977), whose patients 
had a mean score of 22 on the Hamilton depression aoale. 
The Hamilton Rating Scales showed a significant 
improvement in both depression and anxiety in the two 
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groups 1n rq study.. The visual analogue scales showed 
a aimilar pattern, but no signifiO&Dt obalages. !here 
was a significant correlation between the Hamilton 
depression scale score and the visual analogue scale of 
mood score at the start ot the study and at weeks 10 and 
14 (r •..:0.53, -o .. ,4.5t ..0.491 P< o,ol) bu~ the correlation 
waa not sipitiO&Dt at weelt 6 (r • .-'0.10).. ~eae correl-
atioll8 are inverse beoauee a lessening in the severity of 
the depression was represented by a decrease in the Hamilton 
depression soale score and an increase in the viswal 
analogue scale score. They are lower than the oorrelatiue 
between Hamilton 4epr .. aion rating scale scorea and 
visual analogue scale of 4epression scores reported b7 
Zealley and Aitken (1969), ainoe the7 found the correlation 
coefficient to be 0.79 in depressed in-patients, but the7 
also tound tbat the correlation fell to · -o.o6 on recover,, 
suggesting that the relationship aa, V&r.J with the severity 
of the depression, and that the lower correlation between 
the soalea used in my stud7 may be due to the patients 
being lees depressed. The difference between B.aailton 
depression rating scales and visual analogue saales ~ 
be part due to their measuring different thine;s, aa the 
visual analogue scale measures only mood, but the Hamil ton 
scale is heaYil.y weighted towards the somatic symptoms 
accompanying depression, many of which are common meno-
pausal symptoms even in the absence of depression. 
Althoug~ Hamilton anxiety ratlag scales ard visual 
analogue scales of anxiety showed a sWlar pattern of 
change, there ••~• no significant correlations between 
either the ecoree or changes in score of the two aoalea. 
Again, it is likel.J tba t the two scale a are measurina 
different paraaetere, aince the "fiaual analogue measures 
subjective anxiet71 and the Hamilton anxiet1 rating soale 
is intended for measUring the severity of anxiety neurosis, 
and includes the pb¥sical ooncoai tants of anxiety-. 
Neither Hamilton rating scales nor visual anaiosue 
scales showed any difference between the two groups of 
patients. !hie ia unlikely to be due to ina4equaoy of 
the aoalea, since. other workers have used the Haailton 
depre.aaion rating aoale and have folUld them to be 
sufficiently sensitive to show a difference between 
oestrogen and placebo treated groupe (A7lward, 197 3, 19761 
Fedor-lretbergh, 1917). O&mpbell reported a aignificant 
effect of oestrogen on anxiety in menopausal women, 
measured by visual analogue scales, so it aeaaa tbat this 
rating scale too is autficientlf sensitive to show ohangea. 
However, the numbers in rq study are small, and it would 
have been possible only to show a very large 4ifference 
between the two treatment groups using this number of 
patients. 
My results showed a very marked placebo effect on 
symptoms of anxiety and depression in menopausal women, 
and this effect was so great that at the end of the 
baseline period neither the oestrone group nor the placebo 
group were auious or depressed. fheir. scores on the 
Hamilton ft.tiDB aoales at thia tillle wel'e so low that it 
would be diffiou.lt to show much imprOYement, and it ia 
thus not surprising that I did not find oestrogen to be 
s1p1ficantJ.¥ more effective than placebo in relieviq 
anxiety and depression. !his improvement persisted for 
the duration of the study 1Jl both groups. 
!1aa3 workers have colllllented on the marked aDd pro-
longed placebo effect on menopausal &7JilPtoma (Pratt aDd 
Thomas, 19371 Donovan, 1951J Kupperman et al, 19591 
Utian, l972a & bl Clayden et &l, 19741 Ooope et al, 19751 
C&mpbell, 1976bJ Striokler et &l, 1977). Pratt aD4 
Thoaas (1937) compared oestrQ&ena given either orallJ or 
by 1n.1eotion with placebo tablets, placebo in~ ections, 
and phenobarbitone tablets ill 100 menopausal women, an4 
found that ptvsioal and psychological sJJD.PtODIB 1m.prOYe4 
to a similar degree regardless of which treatment was 
given. Otian (l972a) reported that oestrogen had onl.¥ 
a placebo etfeot on depression occurring after oophoreoto., 
in 85 women, but in a later study (Utian l972b) he re-
ported tbat both oestrogen and placebo had a 'mental 
tonic' effect on 50 .ocphcreotom1zed women. This second 
study was a cross-over trial, and he found that the 
sense of well being diminished after the cross over in 
women who were given p~cebo after oestrogen treatment. 
George et al (1973) failed to replicate this in a double-
blind cross-over study of the effect of conjugated equine 
oestrogens on ll oophorectomized women, and concluded 
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that the mental ton~c effect mu.st be dose related, 
since they .bad used a smaller doae tban Utian. George'• 
study bas been criticised by H•wkins and Polakow (1974) 
on the gro\Ulda tbat the numbers stwiied were too small 
to d •onstrate a statistically significant difference, ao 
this ia another possible cause :tor the difference between 
his reaul ts and those ot Utian (1972b). Rauramo et al 
(1976) also :tailed to show tba t oestrogen was more 
e:t:teotive than placebo in relieving anx.iety or depression 
in oophorectomized women, and Clt.mpbell (1976b) also 
taUed to show that oestrogen waa significantly more 
effective than placebo in relieving depression in hia 
cross-over studies on 64 wo.aen with severe menop~sal 
symptoms and 56 women with milder symptoms. He co.mented 
on the marked placebo effect, which lasted for six aontha 
in many oases and found that both oestrogen and placebo 
produced a significant tmpro.ement in depression, and 
although oestrogen had a greater ettect than placebo, the 
difference between them was not significant. He con-
eluded that oestrogen was more effective than placebo, 
but that the rating scale used, the Beck self rating 
scale, was not sufficiently sensitive to demonstrate this. 
Strickler et al {1977) also found a marked placebo 
effect, with no significant difference between oestrogen 
and placebo treatment• in their cross-over study of the 
effect of conjugated equine oestrogens on climacteric 
symptoms in 20 women. They attributed the marked 
placebo effect to the sympathetic interest or ·a health 
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oare worker, ainoe ~hey ba4 controlled for pbysici&D-
·dependenoe by arranging tor patients to see a different 
dootor at each visit, but the health care worker saw the 
patients at ever.y visit. This agrees with the opinion 
ot Donovan (1951) who relieved syaptO.S 1n the major1 ty 
ot patients by history-taking alone, and 1D the r .. inder 
b7 a plaoeb.o in3eot10l'l. Be stated that the aoat 1Jiportant 
factor in symptomatic relief is a good doctor-patient 
relationship, in which the patients could discuss their 
a,mptoms freely, and it this is so, the placebo etfeot in 
rq atud7 could have been due to the attention received b7 
the patienta,· since they spent an hour a week talking to 
Jll'SeU or rq assistant while the electrodes were bein& 
attached for sleep recording, and bact breakfast with ua 
the next mornins. 
Aylwa~ reported that oeatrO£en was more effective 
than placebo in relieving depression in oophoreotoaised 
wo11en (.lylwa~, 197 3) and in postmenopausal women (Aylward, 
1976). In his first etudy he related depression to low 
free plasma tryptophan l.Vela, and obserTed that oestrogen -
treatment both relieved depresaion and raised the free 
plasma tryptophan levels. He reported a significant 
correlation between changes in tree pl~sma tryptophan 
levels and change in the severity of depression, but since 
no information was given about the actual scores on the 
Hamilton depression rating scale, it is not clear how 
depressed the patients were, nor how greatly they improved. 
In his study of the effect of oestrogen treatment on 
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poataenopausal women, he treated all patients with placebo 
before the start of the study, and entered on]Jr those who 
failed to respond to placebo treatment. The 65 patients 
who did not respond to plaoebo were randomlY allocated to 
either placebo treatment or treatment with piperaziGe 
oestrone sulpbate_, and he found that the score of the 
oestrogen treated patients on the Hamilton depression 
rating scale tell, while the placebo-treated patient• 
became more depressed, and showed an increase in their 
scores, but as his results are expressed only ae ~ change 
it is impoaeible to tell how seTerely depressed the 
patients were, or how significant were the differences 
between the two groupe. 
Fedor-Preybergh (lm) also found that oestrogen wae 
aignitioantl1 better than placebo in relieving depreeaioa. 
In hie study, 21 postmenopausal women with s1Jilptoma of 
depression were given a aupply of tablets, told that thia 
treatment would make them better, and giTen an appointment 
tor three months time. Ten oases in this study were 
given placebo, and 11 given oestrogen. At the end of 
the three months, he found that the patients on placebo 
had deteriorated, and those on oestrogen improved signifi-
cantl.y. In his study there was no placebo effect, and 
this may be due to the limited number of interviews, which 
prevented the development of a supportive relationship 
with any member of staff of the clinic. It seems, then, 
that attention and supportive interviews are very effective 
in relieving depression and anxiety in postmenopausal 
\ , 
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women, and that the placebo effect · can last for as lone 
aa siX montha ( Campbell• l976b) • "'o of the a'tuc51es 
which claiaed that oestrogen trea~ent ia more effective 
than placebo in r•li.ving depression 1n postsenopauaal 
women have either eliminated plaoebo responders froa the 
studJ (Aflwar4, 1976) or reduced oonta~ between patient• 
an4 staff (ledor-lreybergh, 1977), so 1 t ia possible that 
oestrogen bas an antidepressant effect on some patients, 
or that this effect is masked by the placebo effect when 
the patient receives more attention. Overall it would 
suggest that even if oestrogen ia batter than placebo tor 
ayaptom relief, ita contribution 1a probablJ aaall in 
clinical practice compared with tbat of the dootor-patient 
relationship. 
The main purpose of rq study waa to inveatigate the 
effect of oestrogen trea~ent on sleep disturbance, and 
in view of the small numbers s-tudied, it 1a not surprisiq 
that oestrogen was not found to be more effective than 
placebo in relieving psychological symptoms. It did 
show, however, that the improvement in sleep in the 
oestrone group is not likely to have been due to lesseniDB 
ct anxiety or depression, since the groups showed a 
similar ~prOYement in these symptoms as rated by both 
subjective and observer ratings. 
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HOT liJlSHES 
In both the oestrone and the plac.ebo group there waa 
a decrease in the fr.equeno.J and aeverit¥ o~ hot flushes. 
There was a Ver¥ high correlation between the number of 
hot flushes and the severity rating~ which auggeata that 
either the number of hot flushes was the main factor to be 
taken into aooount when the seYerity rating was coaplete4, 
or the number and seYerity of the hot flushes changed ia 
parallel. It should also be borne in mind that the nWib•r 
and ee'Yerit7 of hot flushes were recorded at the sam.e tia• 
each dq, so the second rating ma7 have been influenced 
by the first. 
M7 stud7 failed to show that oestrogen was more 
effective than placebo in relieving hot tlushea, but since 
the number of patients in each gro~p was relativel7 small, 
this result should be interpreted with cautioa. Pratt 
and Thomas (1937) in their stud7 of 100 patients, also 
failed to show tbat oestrogen was more effective than 
placebo, as did Coope et al (1975) in the first three 
months of their cross-over study, before the orosa-over 
period. 
The placebo effect on hot flushes has been known for 
some time, and was d esoribed by Donovan (1951) , .. Kupperman 
et a1 (1959), Clayden et al (1974), Ooope e~ a1 (1975), 
and Campbell (1976b), but as yet we know little about 
'this effect. Greenblatt et al (1950) suggested that 
women who responded to placebo treatment were psycho-
neurotics, and Lauritzen (197)) that they did not bave 
173~ · -· 
true menopausal symptoma, but sinoe the symptoms of 
placebo responders and non-reaponders are the aaae thia 
theoey is doubtf\ll. Campbell (l976b) toun4 that the 
placebo effect o0\11.4 last tour six aontha, and in h1a 
cross-over studies touna that the effect of placebo treat-
ment was •isnitioant in patients with mild •JilPtoae 
(pc 0.05) , and short of si&n1fioanoe in patients with 
severe e,mptoms, but that in both groupe oestrogen waa 
aigrdtioantl3' .more effective than placebo in relieTing 
hot flush••• Marq other orosa-over s-tudies haTe ahOWil 
oestrosen to be more effeot1Te than placebo in the treat-
ment of hot tlushea, e.g. Greenblatt et al (1950), 
Xupperman et al (195l), Jlarl1n et al (1971), lAuritsen 
(197 3), Utiaa (1972a), and Coopt et al (1975), but when 
the ~idenoe for a relationship between oestroaen and hot 
flushes was reviewed by Mulley and Kitchell (1976a), th., 
concluded that there was no evidence that oeatrosen wae 
significant~ more etfectiT• than placebo. Utian (1976) 
and Coopt (1976) disagreed with this view, and S'turde.e 
and Gustafson (1976) pointed out tbat Mull•¥ and Mitchell 
(1976a )bad reviewed only two studies, those of Pratt a!l4 
!hom.as (1937) and Coope et al (1975), M\llley and 
Kitchell (1976b) replied that they had been unable to find 
any other well conducted double-blind croea-over studies, 
and discounted the studies mentioned by Sturdee and 
Gustafson (1976) on the grounds that the study of 
Greenblatt et al (1950) could not have been double-blind 
because vaginal cytology was carried out on the patients 
during treatment; and the studies ot Kupperman et al 
(1959), Martinet al (1971) and Lauritsen (197)) did not 
include a croas•over period with plaoebo. However, 
Pratt and fhomas (1937) make no mention of oroaa-over of 
treatments, and while Coope et al (1975) found that there 
was no difference between placebo and oeatrocen 1D the 
first part of their study, they found oestrogen to be 
significantly more effective after the oross-over. fbia 
controversy over the value of oestrogen treatment can 
only be resolved by research into the cause of hot fluahea 
to enable us to understand the reasons for these con-
flicting reeulta, and a large, long-term s~dy to oompare 
oestrogen and placebo treatment. 
Campbell (l976'b) fo\lDd that insomnia was relie'Yed 
by oestrogen treatment only in women with vasomotor 
symptoms, but there were insufficient patients without 
hot flushes in my study (one in the placebo group and ~o 
in the oestrone group) to teat this hypothesis. There 
was no correlation. in my study 'between the mean bot flush 
count or severity rating and either the amount of inter-
vening wakeflllness or sleep duration in the three period a 
of the study, nor was there a significant correlation 
between the changes in these parameters. Sinoe the 
oestrone and placebo groups showed similar changes in the 
number and severity of hot flushes, the improvement in 
sleep in the oestrone group is not likely to have been due 
to a change in vasomotor symptoms. 
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Campbell (197Gb) also 4escribed a "domino" effect, 
in tba t when one symptom 1mprove4 • U.TJ¥ other comi)lainta 
were relieved at the same time, and by co~ariq patient• 
with ana without vasomotor S1Jil.Ptoms, he concluded that it . 
was the abolition of hot fiushea and vaginal atropbJ- which 
caused the improvement in the other, unrelated aymptoaa. 
In rq stu.dJ too measures of raood • anxietJ, sleep quali t7, 
and hot fluahea showed that these ~proved in para,llel, 
but it was not possible to sh~w whether the iaprcw~ent 1a 
one symptom led to the change 1n the others. Since 
anxiety ia one of the factors known to worsen hot flushea, 
it ia posaible that reduction in the anxiety level re4uoe4 
the physiological arousal and thus lesaene4 the number of 
hot flushes, rather than vice veraa. 
NWROEJ!DOCRINJ STUDIES 
Oeatro&ens 
Jq patients showed rapid, episodic variations in . 
their plasma levels of both oestrone and oestradiol, and 
since the coefficient of variation of the assay was 14% 
1 t is unlikely that this finding was due entirely to 
unreliability of the ass&¥ method. My finding of erratic 
variations in the plasma levels of both oestrone and 
oestradiol in perimenopausal women confirms the results ·ot 
Jacobs et al (1977) and Hutton et al (1978), and like 
them I could find no evidence of a diurnal rhythm in the 
levels of either hormone. Their studies were similar 
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to mine in that they took blood samples f!Yery 20 or 30 
minutes for several hours from their· pat~ents. Campbell 
(l976a) also noted fluctuations in both oestrone and 
oestradiol levels in menopausal woment but he found a 
diurnal variation in plasma oestrone leTels, with the 
lowest levels occurring between 18.00 and 02.00. 
Vermeulen (1976) also reported a diurnal variation· in 
plasma oestrone levels, with the nadir occurring between 
midnight and 04.00, but these authors took blood aaaplea 
onq eveey two hours from a small number of patients, &rld 
the differences in their results may have been due to the 
different frequeno;r of taking blood suplee. 
There waa no clear relationship between the cbangea ' 
in oestrone and oestradiol levels during the night in 
individual patients, but there was a significant positive 
correlation between mean oestrone and oestradiol leTels 
when we consider all twelve patients on the first blood 
night , and also the patients in the placebo group on the 
second blood night. Campbell (l976a) obserTed that two 
of the patients in his study who had high oestrone levels 
also had high oestradiol levels, but other than this he 
found no relationship between plasma levels o! the two 
hormones, and Hutton et 'al (1978) in their extensive study 
found no correlation between mean oestrone and mean 
estradiol levels. 
The mean oes trone levels of the patients in my study 
were low, but were comparable with the lower levels found 
during t he menstrual cycle. The mean oestradiol levels 
in many oases were lower than those expected during the 
menstrual oyole, but 1n the four pe.tient·s who bad 
amenorrhoea of lesa than one years duration the mean 
oestradiol levels were compatible with those of the early 
tolliou.lar phase of the menstrual cycle. ~here was a 
significant inverse relationshi~ between the mean oeatraaiol 
level and the duration of amenorrhoea whQn the levels in 
the patients on the first blood night were considered, 
but the relationship between the mean oestrone levels and 
duration of amenorrhoea was short of significance. The 
I 
levels of both oestrone and oestradioi were highest in 
the patients with amenorrhoea for less than one year. 
Chakravarti et al (1976) also found that oestrogen levels 
changed with tiae after the menopause. Th&¥ fo\U'ld that 
the levels of both oestrone and oestradiol fell progress-
ively after the menopause, but while the oestrone levels 
remained low, ·the oestradiol levels seemed to rise again 
after 20 years. However, Hutton et al (1978) could find 
no relation~hip between either age or duration of 
amenorrhoea and oestrone or oestradiol levels. It is 
difficult to see why ~ results should differ from those 
of Hutton, since we used a similar sampling schedule and 
patients of similar ages, tho~gh the duration of amenorrhoea 
experienced by his patients ranged from 0.4 to 15 years, 
and was therefore wider than the range in my study. 
It oan be seen from Table l that the mean oestrone 
and oestradiol levels of menopausal women reported by 
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various workers vary widelJ. fbe mean plasma oestrone 
and oestradiol of my patients on the f1rs1 blood night, 
when all were receiving placebo, are similar to the mean 
levels reported by Qampbell (1976a) and by Hutton et al 
(1978), but are higher than the values reported by manr 
other workers. The difference between ~ results and 
those of other workers ma, be due to differences in assay 
methods, ~pling schedules, or populations studied. In 
my study and that of Hutton et al (1978), blood samples 
were taken ever, 20 or 30 minutes, while Qampbell (1976a) 
and Vermeulen (1976) took samples ever.y two hours and 
most other workers took only a single sample from eaoh 
patient. In view of the wide and rapid fluctuation 1n 
oestrogen levels in menopausal women, both C&mpbell (l976a) 
and Jacobs et al (1977) have stated that single sample 
studies are inadequate in assessing their oestrogen status, 
and this may be the cause of the differences reported by 
the various authors. They have also s~died different age 
groups, as can be seen from Table l, and this too may have 
contributed to the differences between studies. As pre-
viously stated, Chakravarti et al (1976) found that 
oestrogen levels varied with age after the menopause, and 
although Button et al (1978) did not confirm this finding 
they used a much more lt.ited age range, and this may be 
the cause of their different results. It is not likely 
that the differences in the mean oestrogen levels reported 
by the different authors were due to the inclusion of 
women who had undergone oophorectomy, since Rader et al 
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(1973) found that the oestrogen levels of oophoreotomise4 
women were the same as the leTels of women who had wadez-
gone a physiological menopause. 
The oestroneaoestradiol ratio of the patienta .in., 
study was greater than l in all oases, as would be expeotecl 
in postmenopausal women. It varied oonsid,rablJ betweea 
patients, but there was no significant relationship 
between the ratio and the duration of amenorrhoea exper1eaot4. 
In the study of Chakravarti et al (1976) the oestroDel 
oestradiol ratio was highest in the first ·year after the 
menopause, and after 10 years was actuallJ.. leas than 1. 
None of the patients in my study had more than eight yeara 
amenorrhoea, so our results are not inconsistent. The 
oestroneaoestradiol ratio in _, patients was in most oaaea 
higher than tba t reported by Jacobs et al (1977), who 
found a mean ratio of 1.6al, and Chakravarti et al (1976) 
and Hutton et al (1978), who tou.nd l.7al. Others too 
have found a higher oestroneaoestradiol ratio, rangeing 
from Vermeulen's ratio of 2.4al to Baird and Guevara, 
(1969) who found a ratio of 5.5al. Before the menopauae 
the ratio of oestrone to oestradiol is less than one, an4 
the increase in the ratio after the menopause indicates 
that the fall in oestradiol levels is greater than that 
in oestrone. 
When comparing oestrogen levels on the two nights, it 
is surprising to find so much variation in the mean 
oestrogen levels in the placebo group. One patient 
showed a decrease in both oestrone and oestradiol levels, 
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ano~her an increase in oestrone levels, and a third an 
increase in oest~d~ol levels. !he first patient had 
amenorrhoea tor only six months, and observed aome alight 
bleeding 10 days before the second blood night, and the 
aeoond patient bad amenorrhoea for tour months, so both 
aay still have been uDdergoins the· menopausal transition, 
as described by Sherman et al (1976). These workers 
reported a variable potential for hormone secretion in the 
residual ovarian follicles ot older women, leading to 
erratic fluctuations in oestrogen levels, and irregular 
bleeding, and they observed that there oould .be as long 
as five months between period• in this transitional pbaae. 
This would not account for the increased oestradiol leYela 
ot the third patient, since ehi ~ eight years amenorrkoea. 
Coope (1976) ~ested that the placebo response 
shown by menopausal women might be due to an increase in 
the secretion of endogenous oestrogena, but m, results do 
not support this theory. The placebo group showed littl• 
mean change in the levels of either oestrone or oeatra4iol, 
and when the changes in individual patients are considered, 
two showed a pronounced increase in thei.r oestrogen 
levels, and one a large decrease, but there was no obvious 
difference in the changes in hot flushes, mood, or anxiet.J 
between these three patients. · 
The effect of oestrogen administration on the 
oestrogen levels of postmenopausal women depends on the 
type of oestrogen, the dose, and the duration of treatment. 
Hutton et al (1977) found that giving 1.5 mg of pipera~ine 
. ; ; 
····· 
---~ . 
·"' oestrone aulpbaf• to previo~sly untreated menopausal 
women causes a 4-~ told rise in oest~ne l~vels within 
six· hours to ·a peale of approximatel¥ 36 ng/dl (1407 paol/1), 
and oestra4iol levels to rise 2-3 told to 5 ng/dl (185 ~1/l). 
Jacobs gave 3 mg of this preparation and found that the 
-
. plasma oestrone oonoentration inoreased to over 40 11114~ . 
(1481 pmol/l) while the oestradiol l•vels changed little, 
but he gives no further details of his results. 
Anderson at al (1978) inTestigated the effect of 
giving l~5 mg piperazine oestrone sulphate to women who 
had been on oestrogen treatment for some time, but had 
UDd ergone a 48-hour wi tMrawal period before the atud7, allcl 
she found that the plasma oestrone oonoentl'&tion rose to -- · 
a peak of 900 paol/1 (2~·· 5 ng/dl) again within a1x hours 
but their oestradiol level• .were unohaDged, and reaa1De4 
at 294-367 pmo~l (8.0 - 10.0 ng/dl). 
Although m¥ patients took 1·5 mg piperazine oestrone 
sulphate one hour before the start ot blood eamplinat 
they did not show an increase in either oestrone or 
oestradiol levels to a peak level, but showed in all cas•• 
erratic fluctuations in the levels of both hormones, with 
a series of peaks and troughs. Again, these variations 
are too wide to be due entirely to unreliability of the 
assay method~ Their peak plasma oestrone concentration 
ranged from 511 •. 0 pmol/1 (13.8 ng/dl) to 2085.2 pmol/1 
(56.3 ng/dl), with the average value being 1326.0 pmol/1 
(35.8 ng/dl)~ Although there was considerable variation 
between patients, the average is slightly lower than the 
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peak value reported b¥ Jacobs in his study of the effect 
ot this dose on untreated women, but it ie higher than 
the levels reported b¥ Hutton and Anderson, who used only 
halt . the daily dose received b¥ rq patients. !he peak 
plasma oestradiol concentrations of rq patients r&D.Becl 
from 231.6 paol/1 (6.) ng/41) to 415.0 pmol/1 (ll •. J nc/41), 
with the average value being 338·2 pmol/1 (9.2 11&'141). 
!his average va.lue is higher 1ban the peak oestradiol 
concentration reported b¥ Button, but similar to tbat of 
Anderson. 
!rhe difference in our results ma:y be due to irregular 
absorption from the gut 1n rq patients, caused perhaps 
by taking the tablet at night ~u.at before sleep. Little 
is known of the metabolism of oestrogen in patients on 
long term oestrogen treatment, so it is diffi~lt to 
think of any other cause for the episodic changes 1n 
oestrone and oestradiol levels in the patients who bad 
r~oeived tour weeks oestrogen treatment. The difference 
in peak levels could also be due to our patients having 
different lengths of treatment, since Jacobs at al (1977) 
reported tbat .at ,the start of treatment the patients had 
very high plasma oestrone concentrations, while oestradiol 
levels rose only graduall71 but after three weeks treat-
ment, the ingestion of oestrogen tablets produced little 
change in either oestrone or oestradiol levels. They 
give no data to support this statement, but it can be seen 
from oom,paring the results of Hutton et al (1977) with 
those of Anderson et al (1978) that Anderson's patients, 
who had only undergone 48 hours withdrawal from oestrogen 
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i treatment, showed lower peak levels and bad higher 
oestradiol levels than the patient reported by ~tton, 
who was previousl.7 untreated. Cooper et al (1974) and 
Daw (1975) investigated the effect of treatment with 
piperazine oestrone sulphate 3 mg/day on the plaama 
oestradiol concentration of oophorectomized women, aDd 
found that oestradiol levela rose to a peak in the earlJ 
weeks ot trea~ent, then after a month stabilised at 
approximatel¥ 3-4 times the baseline level. 
Beoa~se of the small numbers of patients studied on 
oestrosen treatment, the results of the changes in their 
oestr~en level should be interpreted with c~tion. !he 
mean oe~trone levels increased in all patients after four 
weeks of oestrogen treatment, aa wo~ld be expected, bu~ 
the magnitude ot this increase varied be~ween patients. 
Two of the patients showed onJ.¥ small increases, but the 
others nad mean levels of 736 pmol/l (19.9 ng/dl) and 
718 pmo~l (19.4 ng/dl), levels which are similar to or 
slightl1 higher than the highest plasma oestrone concen-
trations found during the menstrual cycle by ~ant et al 
(1972) and Judd (1976). Oestrogen t~eatment bad ·no 
consistent effect on the plasma oestradiol concentrations 
of my patients as two patients showed an increase, one a 
decrease, and one little change in their mean plasma 
oestradiol levels. The patient who showed the greatest 
increase in her mean plasma oestrone level showed the 
greatest increase in her oestradiol level, while the 
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patient with the smallest increase in her plasma 
oestrogen concentration showed a dearease in her mean 
plasma oestradiol level. The patients who showed a 
decrease or onlJ a small increase in their plaema 
oestradiol levels may not nave bee~ taking their tablet• 
' . 
resularl.l,· as compliance is :trequentll low in patients 
. . 
who are given a proloqed cour&e of treatment, but the 
patient ~ho showed a decrease in her oestra4iol level•·. 
had been taking antibiotic treatment for a urinaq . tract 
infection for 10 dQ¥s before the second blood night and 
this may have atteoted the absorbtion ·ot the oestroa•A 
' .:...; ~ 
tablet, as bas been reported tor the oral oontraoept.1ve 
pill. 
l4ost of the workers who bave investigated th~: efteot 
;~ .! 
ot a prolonged course ot oestrogen treatment have taken 
only single blood samples from eaoh patient, so the levela 
they have found will depend on the oestrogen used, . the 
dose, and possib·ly the time since ingestion ot the last 
tablet. Aylward {1976) studied the effect of treatment 
with piperazine oestrone sulphate 3 mg/day on postmeno-
pausal women, and found that after one month their plaau 
oestrone concentration had increased by 60Q-lOOO%, and 
oestradiol by 5Q-400%. This is much greater than the 
increase in the mean oestrone level in m, patients, who 
showed increases ranging !rom 30-200%, and in ~ study the 
change in plasma oestradiol levels varied from a decrease 
ot 601~ to an increase of 580,_. Unfortunately·, Aylward 
gives only a % change, and not the absolute concentrations 
e! the hormones~ so it is .not posaibl• to tell whether 
11f3' patients bad siailar=' oestrogen levels to his either 
before or a!te~ . treataent. 
Cooper et al (1974) and Daw (~97-'5) r:eported the 
change in plasma oestradiol concentration in oophorectoa1se4 
women treat4td with piperazine oesvaae sulphate 3 m&'d..,.~ 
Betore treatment. the plasma oestrad.iol levels ot his 
patients were similar· to the mean plasma oestradiol 
levels of W3 patients on placebo, but at the end ot one 
month his patients bad plasma oestradiol concentrations 
of 9-10 n&/dl (lll-588 pmol/l), a conaid erabl.7 greater 
increase than that shown b7 rq patients.. OUr atu.diea 
differed 1n that Cooper and Daw took onlJ sin&le aampl•• 
from. each patient a1; weekl7 intervals• and their paticta 
were oophorectomized women, and this ~ account !or the 
difference in our· results. Cooper· also correlated 
symptomatic relief with a rise in plasma oestradiol con-
centration to above 4 D&/dl (148 pmol/l), bu.t JD¥ stu.dJ 
does not contir.a this finding, since the placebo group 
patients showed as great a subjective improvement 1n 
their symptoms as the oestrone grou.p, while their 
oest radiol levels remained below 148 pmo~l in all except 
one case. 
Lind et al (.1978) studied the changes in plasma 
hormone levels of nine postmenopausal women on CJClic 
oe~trogen treatment (4 on piperazine oestrone sulphate 
1. 5 mg/day, 2 on equine oestrogena 1.·25 mg/day, 3 on 




~le at the ·end of each 20 day course of treatment tor 
six months. He found tba t their mean plaama oestrone 
concentration increased by 64~ to 596 pmol/1 (16 n&/dl), 
an<! their mean oes tradiol by 470% to 357 paol/1 (9.7 ng/41). 
Although he used smaller doses than. were use4 in 1'4¥ stu41t 
the increases in plasma oestrone and .oestradiol in his 
patients were greater than the mean changes in aine. · fbi• 
may be <Sue to the different oestrogens used in his stud7, 
but is more likely to be due to selection of patient•• 
since the oases reported by Lind were ~ected beoauae of 
their high oestrogen levels on treatment to inveat1iate 
the relationship between chaqes in oestrogen aDd 
prolactin levels. · 
Hutton et al (1977), Jaooba et al (1977) aD4 Aaderaoa 
et al (1978) reported that the effect of oestradiol 
valerate 2 mg/day on plasma oestrone· and oestradiol did 
not differ significantly !rom that of piperazine oestrone 
sulphate 1. 5 m&/~ay, so it is sarp.rising tha~ Lars•on-
Cohn et al (1977) found tbat treatment with oestradiol 
' 
valerate 2 mg/day caus~d a greater increase ~n plasma 
oes trone than was found in my patients, who received 
3 mg/aay piperazine oestrone sulphate. The mean plasma 
.oestrone concentration of their patients increas ed by 
587% to 810 pmol/1 (22 ng/dl), which is ~oh greater than 
t he increase shown by ~ patients. Their mean plasma 
oestradiol concentration increas ed by 235% to 191 pmo~l 
(5.2 ng/dl), ·and although this is lower than the mean 
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oestra~iol level. of the ~wo patients in ·uq stUdy whose 
oestradiol .,level 1noreas~d marke4q ~ &fild. is close to the 
averag• ot the mean oestradiol· lev~ls of ~ to~ patienta, 
it should be· noted that Hutton et al, (lm) •nd · Andersoa 
et al (1978) tound this ·dose to be. equivaleQt to 1. 5l1lc 
piperazine sulphate, when my ~tie1,1ta were ,on twice this 
dose· da11.7• . How~er, Hlltton compared the eftecta 9D17 
on patients on the t~st d$1 of treatment, ' and Anderson 
on patients who bad undergone 48 hours ·wi.thdrawal ~oa 
their oestrogen therap7, so it ia not conclusivelY proven 
that long-term treatment with piperazine oestrone sulpba~e 
.. '• 
and oestradiol nlerate baa the same ettect on plasu . .. 
oestrogen concentrations, and the difference in our reeulta 
ma7 ·be due to the different tTPee of oestrogen treataent 
use4. · 
Jacobs et al (197-7) remamed tbat oestrogen treatmeat 
is not phfsiologioal because it does not restore the 
oestrone:oestradiol ratio to t~at of premenopausal women, 
and m3 results support this view. Although the ratio 
increased in two patients and decreased in two in my 
study, it was not lower than one in any patient, and if 
-the mean values are considered in the four patients in 
the oestrone group who completed both blood nights, the 
ratio was unchanged. On the first night, when the 
patients were on placebo, the mean rati~ was 3.6zl, and 
on the second night, after a month's oestrogen treatment, 
the ratio was 3·5:1. Lind et al (1978) also found that 
oestrogen treatment produced little change in the 
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oestroneaoestrad1ol ratio, but JacObs et al (1977) fowa4 
that it increased. Jacobs gives no det~ls of his 
results, but since he found that oestrone levela rose 
before oestradiol levels, it is possible tbat be waa 
referring to women who bad just started oestrogen treat• 
ment. It is interesting to note that the me•n oestronea 
oe~tr~diol ratio of individual patients in the placebo 
group in my study also varied consi~erably between the 
two nights studied • showing an increase in three oases. 
and a fall in three oa.ees, though the group mean was 
little changed, being 2.9al on the first ni£ht and 2.6al 
on the second. 
I could find no relationship between ohangea in 
hormone levels and changes in sleep sta&e, nor was there 
&Qy correlation between mean hormone concentrations and 
sleep duration or the amount of an~ sleep stage or inter-
vening wakefulness. This .agrees with the results of 
Alford at al (1973), who s~died the oestrogen levels 
during sleep of adult women. The only report of a rela tioa-
ship between oestrogen levels and sleep in normal sub~ecta 
is that of Boyar et al (1976), in which they found a fall 
in oestradiol levels during sleep in pubertal girls, but 
since the time of puberty is uni~ue in the changes in 
hormone regulation, it may be inappropriate to compare 
this study with s tudies of adult subJects. 
-. 
frolaotin 
In rq Rtienta, the plasaa prolactin oonoentrationa ·. 
before sleep onset ra~ed from 0 to ~0 miU/l (o-15.0 ag/111) ., 
with the average being ll8 miU/1 (5.9 ng/ml.) on the firat 
blood night~· .I .n the placebo group the mean plasma 
prolactin concentration before sleep onset was lower oil 
the secoDd night than the first, and in the oestrone srcNP 
it was higher, but the numbers s'Wdied were too small for 
this difference to be significant, and the level m&¥ baYe 
been a:t!eoted by factors such aa the stress of having aa 
intravenous catheter inserted, since stress is known to 
cause a rapid increase in prolactin secretion. The 
average plasma prolactin concentration before sleep on 
the first night was lower than the mean prolactin level 
o:t menopausal women reported by Lind et al (1978), whioh 
was 166 miU/1, and also lower than the mean level reportecl 
by Vekemans and Robyn {1975&) :tor women in this age 
range, but these authors took blood samples earl¥ in the 
day, while mine were taken after 10 p.m., so the differ-
ence in our results may be due to a diurnal variation 
during waking hours. · 
Studies of the effect of oestrogen treatment on 
prolactin levels during the daytime bave also bad con-
flicting results. Delvoye et al (1972) found that a 
combination of oestrone and oestradiol reduced plasma 
prolactin levels in postmenopausal women after a three 
week course of treatment, but after a further three weeks 
of oestrogen treatment the levels were the same as those 
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toun4 before starting treatment. Robyn and Vekemans 
(1976) found that administration of ethi~l .oestra41ol 
50 p&/d_, caused a s~gnifioant i~orease in ~he. plasma 
prolaoti~ concentration of postmenopausal women after tea 
days, but Lind et al (1978) found that Q¥Olic treatment 
with a var1ev of oestrogena ca\lSed .. marked increases in 
. ' 
the plasma oestrogen levels of nin• ~ostmenopaaaal w~ea, 
but ha4 no effect. on ·their plAsma prolac:t~ '.' ' th~ dUtez-
ent results m~q be due to the various worlters using differ-
ent oestr()lena or· testins the effeo;t after different 
leugths of treatment, but since they studied onl.¥ dqtia• 
levels it 18 not' surp~aiq it their, resul.ta differ trO. ·.~~-- · 
mine. 
My· patients all showed an inC·rease ~n the secretion 
of prolactin aftel" aleep onset, oont#,rming the r·~Jlort of :. :, 
Rozenoweig et al (1973) that the pattern of secretion ot 
prol@.otin is unchanged aft.er the menopause. The pattern 
of secretion of my patients was aiiaila.r to that observe4 
by Sassin at al (1972) and Parker et al (1974) in their 
studies of younger people~ Like 5assin1 I found that the 
increase in prolactin secretion began in most oases witbin 
60-90 mins. of sleep onset, and took longer than l2omina. 
in on1y two oases in my study. The increased secretion 
lasted for 6-8 hours, until the end of the sleep period, 
and since the secretion of. prolactin is episodic, there 
were a series of peaks in plasma prolactin concentration 
during the night. The magnitude of tbe increase, and · 
tbe peak values observed, varied widely between patients 
( 
in rq study, and although there was some variation in 
the peak and mean values between nights in the same 
subject, the overall pattern was consistent. saaain 
et al (1973) also remarked on the variability between 
subjects, and this m!J¥. in part aocowt for. the ditf.;eaota 
in the peak prolaoti.n levels repo~tea by various auth~a, 
though ·there '111&3 also have been ditferenoes ~ ';the 
sensi tivi v ot the assay method in different lab..r&tor1ea. 
Saaain at al (1972) observed peak values of 50 ac/alt ...... 
and Parker et al (1974) of 35 ng/ml.t while Ko•noweis at · 
al (1973) reported peaks of 200 m. U/ml in pos'tmenopaus&l 
women• In rq swdy; the mean of the peak prolaotiD 
concentrations was aWlar to the peak lwe1a reported 
by sasain and Parker, but the raDB• of individual values 
was very wide. Saeain at a1 (1972) reported that the 
peaks of prolactin grew progressively higher durin& the 
~leap period, but this was not the case in most of the 
patients in rq study, nor in the study of Parker et al 
(1974h· Parker found tbat the peaks of prolactin 
secretion occurred just after REM periods, but other 
wo~ers have not reported this, and it was not found in 
my study. The only relationship found between prolactin 
and sleep in my study was the correlation between mean 
nocturnal plasma prolactin concentration and the amount 
of slow wave sleep,. and this was observed only on the 
first night, and has not been reported by other workers, 
so may be due to chano• .. 
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!here was no significant correlation between mean 
prolactin levels and mean oestrone, oestradiol, or total 
plasma oestrogen concentrations, nor between the changes 
in prol~ctin ana oestrogen concentrations during the 
night, and the mean and peak prolactin levels were un-
related to either age or duration of amenorrhoea. 
Because of the small numbers of patients studied while oa 
oestrogen treatment, and the T&riability of the changes 
in hormone leTels, no firm conclusions can be drawn~· 
~ results about the effect ot oestrogen treatment on 
nocturnal prolactin secretion. Two of the patients, 
Cases 8 and 9, showed little change in either the leTele 
or the pattern ot secretion ot prolactin while on oestroaea 
treatment, but also showed only' small changes in their 
oestrogen levels. The two patients who showed the 
~eatest change in their plasma oestrogen concentrations, 
Cases 7 and 10, also showed changes in prolactin. secretiOib 
Oase 7 had a very high mean and peak prolactin concentra-
tions on the first blood night, when on placebo, and 
differed markedly from the other patients on this night. 
The cause of her high prolactin levels is not known, 
since she was a healthy though slightly overweight woman, 
and had no significant medical history. She was not on 
the oral contraceptive pill, or any other medication, 
and did not report any unusual stress or exercise, so the 
cause of her high prola·ctin levels remains unknown. When 
on oestrogen treatment, she showed an earlier increase 
in her plasma prolactin concentration, and higher mean 
-· 
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and peak values than found on the f'~st night. Case 10 
also showed a Obafl&e ~n prolactin seQl'ation· when on 
·oestrogen treatment, w1-th an earlier increase and a 
series of low peaks rather than a single high one._ ~eae 
results suggest that the nocturnal pattern of secretion 
ot prolactin ma, be altered by a major inore••e in 
oe:Jtroeen levels, but beeause o.t the e.maJ,l: number ot 
patients, and the va.riabilitJ between nights and subjeot•.· 
even on placebo, this ~s not certain and a much l~ger 
study would be necessary.-to test this theo17. 
OnJ.¥ Copinsohi et al (1975) and .V_ekeman~ a~d RobYD ,.,_ 
.(1975b) have studied the e:tfeot of' oestrogen treatment 
. -
on the circadian changes in prolactin secretion, and bo• 
. . 
he.ve studied young 1JODlerh Oopinsohi· found _ that _t~e 
- . ' 
oral contraceptive pill ba4 no ettect on the diurnal 
changes in prolactin secretion, but he took blood sample• 
only every !our hours in 7 subjects. V ekemans and Rob1Jl. 
reported that treatment with·· ethinyl oestradiol in a dose 
of 400 pg/da1 for 10 d93s changed the pattern or prolactin 
secretion in five young woman, in that the increase in 
secretion started in the afternoon instead of after sleep 
onset, and the amplitude of the nocturnal peak was 
decreased •. Since the patients in my study were older, 
and had been trea ted with a different oestrogen !or a 
longer peri_od, it may not be comparable with those of 
Copinsohi or Vekemans and Robyn, and there were also differ-
ences in the sampling schedules of our studies, which 
could cause differences in results. 
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+mtophy 
The mean total plasma tr.yptopban concentrations ot 
rq patients are s imi.la.r to those of other workera. I 
:to\md that there were rapid variations in total tr.yptopball _ 
concentration during the ni&ht in all of l1f3 patien~s, aa 
did Chen et. al (1974) ~ their study -of nocturnal plasM 
tr.yptopban levels in young women. I also found a 
diurnal variation in total tr,yptopban, with the lowest 
levels occurring between 2 a.m. and 5 a.m., which contiraa 
the findings of Fernstrom and Wartman (1974) and Niskanu. · 
et al (1976), but disagrees with the results of Chen et al -
(1974) and Yo\Ulg et al (1969). Chen foun4 that total 
plasma tryptophan concentrations fell throughout :the 
night in JOWl& _women, but it is not clear from his paper 
how often he -took blood samples, and this makes it ditti-
cult to evaluate his results. Young found tba t the total 
plasma tryptophan levels of young men rose between-l a.a. 
and 8 a.~ and showed that the diurnal pattern waa 
related to dietary pattern since it could be abolished b7 
changing the frequency ' of meals, so it is possible -that 
the different nocturnal plasma tryptophan levels are due 
to differences in diet. The effect of the diet on plaaa 
tryptophan levels is complex, and Wurtman et al (1968) 
found that tbe diurnal variation persisted in volunteers 
who ate no protein for two weeks~ while ~~rliss et al 
(1970) found that it could be abolished by fasting. 
This led Fernstrom and Wurtman (1974) to suggest tbat 
the diurnal changes in plasma tryptophan are of 
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nutr1 tiona.l origin, and JDB.1 be due to · the postprandial 
·release ot insulin and other hormones ·whioh modift tissue 
uptake of amino acids. 
The free plasma tryptophan concentrations of the 
patients in =1 study are similar to those reported ~~ 
Aylward ( 197 3, 1976 ) , Chen· e t al ( 197 4) , Niskanen et al 
. .. 
(1976) Peet et al (1976), and Cop pen and Wood (1978), ln1' 
are lower than ~hose reported by Riley and Shalf (1.976)• 
I found that the free plasma tr,yptopban concentration• 
also fluctuated rapidly thJ"oughout the night in =1 pati•nt.a 
as did Chen et e.l (1974), but I ·could find no consistent 
pattern or diurnal variation, while Chen found that the · · 
free plasma tryptophan levels of his sub3ecta . fell dviDC. 
the night.. He also reported a significant inverse 
correlation between mean levels of free an4 oound plaau 
tryptophan but the number of patients in ~ study was 
insufficient to give alll valid results of such a relat1o...,.. 
ship. When the relationship between changesi~ free and 
bound plasma tryptophan levels during the night i s 
considered in individual oases, only one of ~ patients 
showed a significant correlation between tree and boun~ 
plasma tryptophan levels, - while two showed a correlation 
between free and total plasma tryptophan concentrations. 
I could find no relationship between changes in either 
free or total plasma tryptophan levels and changes in 
sleep stages, which confirms the findings of Chen et al 
(1974). He reported a significant inverse relationship 
between mean free plasma tryptophan concentration and the 
........ _  .. 
.· 
:Lg6 • .. 
j r 
I ' 
amount of non-Blil4 sleep, and a positive correlation 
between mean tree plasma tr,fptopban concentration &Dd ~he 
amount of lUM sleep (Chen et al. 1974) but a subsequen"• 
larger s~cly failed to confim the relationship betwe•n 
free plasma tr.yptophan and Rll4 sleep (Chen at al, 197,). 
The number~ ot :patients in zq stu.dy are insuffioiellt 'to 
show any significant relationships betweon mean tree &D4 
total plaama tryptophan ooncentrations al¥1 the amount ot 
ar13 sleep stage. 
I have found a .. ~ignifioant positive oorrelat,ion 
between oestrogen levels and both level and % tree pl&..a 
tryptophan. ll though the o~rrela tion is a1p1fioant tltk*a 
• • • • 0 •• 
oe~trone, total oestrogens, aD4 level or ~ ot tree· ·pla~~ 
tr,yptopban are oonsidered, the·-relationah1.,p is h~est 
between total plasma. oestrosen aDd % free p-la.-. _tx:yptop..._ 
':_ 
Tryptophan oiroulates in plasma bound to albumin (MoHeaui 
and Onoley 1 1958) and since oestrone too oan bind to 
albumin, and oestrogens have been shown to displace 
tryptophan from albumin bindi~ in vitro (Aylward and 
Maddook, 1973) then ti.J.is relationship ·is probabJ.¥ due to 
a direct action ·of oestrogen in displacing tr.yptOpban 
from its binding sites~ A¥lward (1976} bas also reported 
a significant correlation between free })lasma tryptophan 
concentration and both oestrone and oestradiol levels in 
a study of 79 })erimenopau.sal patients.. This holds true 
for the mean levels in m¥ t~ee patients, ~hoU&h it should 
be noted tba t the numbers are too small to be significant_. 
When the changes occurrill8 throughout the night are 
.. 
197. 
considered, then I found a significant correlation · 
between oestrone levels ant! free plasma tryptop~n con-
centrations in all three oases, but between oestradiol . . 
and free plasma tryptophan concentratiom in onlJ' one case. 
Aylward has postulated that this relationship 
between oestrogen levels and free plasma tr.y,ptophan is 
' . 
of aeticlogioal significance 1n depression 1n pertmeao-
pausal 1'!0men. lie reported (.Aylward, 1973, 1976) that 
depressed perimenopausal woman had low tree pl.a"sma. 
tryptophan levels. Coppen et al (1972) first reporte4 
a relationship between free plasma tryptophan ~evela an4 
mood in the middle aged women when they observed low 
free plasma tr,yptopban levels in depressed menopausal 
women compared with controls, and found tbat ·the levels 
returned to normal on recover, trom depression. Other 
workers, however, have found conflicting results. 
Niskanen et al (1976) in a s~~dy ot depressed hospital 
in patients of both ·:sexes, mean age 43t found free pla8111& 
tryptophan levels to be higher in oases than in control• 
when both were receiving a standard diet, while Peat et 
al (1976) in a study of female in-patients and controls 
receiving a standard diet, could find no difference 
between cases and controls. Riley and Shaw (1976) in a 
study of fasting blood levels 1n both sexes also failed 
to find a difference· between depressives and controls. 
The differences in these results may be due to dietary 
factors, since Coppen and Wood (1978) have demonstrated · 
that a high protein diet can abolish the difference· in 
I 
198· 
tre• plasma tryptophan levels between depressives and 
controls~ Another· taotor in the diff~rent results ~7 .. 
be the age group .of ·patients atl.ldied~· Kost authors baTe 
included middle aged women, whose fr.ee plasma tr,yptoph&D 
levels tall in p~liel with their· oestrogen levels 
(Aylward, 1976)i Copj?en and Wood .. (~·978) also obs~r....e4 
a tall in free plasma tr:rpto})UD leYels in p erimeliopausal . . . " 
women in the oont~ol group, though not in the deprese1Te 
group, in their •W47• 
Aylward (1973; 1976) has claimed tb&t oestrogen 
treatment both ~roves depresaion and inoreases fr•• 
. . 
plasma tryptophan .levels 1n d epresee4 .. peri.meopausal 
women, ·while plao•bo· ·,1~eatment has no effect on either 
parameter. Cop pen . and Wood (1978) have also obaened 
that oestrogen treataent inoreasea · t~ee plasma t:JPtopbaa 
, . 
levels in female depressed patients, but they do not, ho~ 
ever, give details of the age group of their patients an~ 
the oases in their study were two bipolar and one unipolar 
depressives all of whom were .reoeiving lithium, but ha4 
mild residual affective symptoms. They did not find arq · 
significant difference in mood .when cases treated with 
placebo and oestrogen were oompared 1 but this is hardly 
surprising in view of the small numbers studied. 
-
:. .. ' 
• • t ~ 
QQNCIIJSION 
I have Shown by ob3ective meaS\lres tl:vlt oestrogen 
treatment decreases the brokenness ot .sleep in perimeno-
pausal· vromen complaining o! insomnia. This improvement 
in sleep was present in the first ~onth of treatment, aD4 
. . 
W&s ·greater in .tl'l.e s ·econd ~on~h, bu-t · ~ther studies. 
would be require~ to ~etemine whether this imprav•eut . 
persists or in~reases with further treatm•t• and .whether 
it is reversed by withdrawal of oestrogen trea~ent. 
I found onJ.¥ placebo effects on mood, anxiety, and 
hot flushes in ~ patients. This m8¥ be· due to the a~ 
·.i . 
number of pati4tnt~, and a larger atudi' might have fP.vtiD · 
. . . . ~ .. .. ' ;.~~ ',· 
different .results.~ The patients in rq study r~~~1·e4 &·/~· · 
great deal of attention," which wa.Ud enballoe the placebo 
effect, and 1 t i~ possible that oestrogen i~'. aore et:teotiYe 
tban placebo in relieving menopau~al symptoms in patients : 
who receive less attention. Further work will be required 
, . 
to determine the duration of the placebo· e:tfeot, and aiaoe 
the work of Aylward (1976) suggests that some depr·esae4 
, women respond to oest'rogen but not to plaoeb.o treatment, 
the difference between placebo responders and non- · ..... 
responders · in terms of symptoms, previous history, and 
hormone levels should be investiga~ed. It . was surprising 
to find that oestrogen was no more effective than placebo 
. . 
in ~elieving hot flushes, because it is widely believed 
that oestrogen treatment abolishes vasomotor symptoms, and 
I was advised at the start of the study that it is not 
possible to carry out a double blind study of the 
... . , . 
:· ·· (•' 
. ~· 
·f' • .. 
. ;: .. ': ·. 
.. ~- ,, . 
t. •. 
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ettectiveneaa ot oestrogen therapy because ot this. I 
was unable to tell either from the reduction in hot 
flushes or the side effects experienced which patients 
were receiVing oestrogen and which placebo. 
Keuroendoorine stadiea showed a nocturnal increase 
in plasm& prola.otin levels such as is found in 1ounger 
. . 
peopl'e, but the leve·ls of oestrone and oestradi~l 
fluctuated widely and rapid~ in all oases, w1 th no . clear 
diurnal rhythm or relation to sleep during the night. 
,. 
Unfortunately onlY four patients were studied atte~ 
oestrogen treatment, and while all showed an increase in 
their noc~l plasma oestrone levels, no oona1stent - . . ~ .. 
change in either oestradiol or prolactin was ·t~und•. ~. 
effects ot oestrogen treataent seam to V&r7 with the dura-
tion ot trea~ent, so it would be usetul to inTeatigate 
the effect of oestrogen treatment on a larger n~er ot 
patients after various lengths of treatment to olarif1 
the effect of oestrogen on plasma hormone levels. 
Tryptophan assay~ were carried out on only thre•. patient• 
and showed a high correlation between plasma oestrogen 
levels and the concentration of free plasma tr.yptophan, 
but the number studied was insufficient to show any 
relationship between their mean levels, or between mood 
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APP~DIX I HAMILTON RATING SCALES 



















Glo~ at~itude, pessimism about 
Peeling ot sadness 
Tenc!eno7 to ••Ill 
Sadness, eto •••••••• 1 
Occasional weeping •• 2 
Frequen~ weeping •••• 3 
k~rae alJI.Ptom.a • • • 4 
Guil.l 
~he tuture 
Sel.t-reproaoh, feels he bas let people down 
Ideas ot suilt 
Present il.lneas is a punishment 
Delusions ot guilt 
Hallucinations of guil~ . 
Suicide 
Peels lite is not worth l.iving 
Wishes he were dead 
Suicidal ideas 
Attempts at suicide 
Insomgia, initial. 
Ditfioul~y in falling asleep 
Insomnia, middlt 
Patient restless and disturbed during the 
night 
Waking during the night 
lssomnia, delayed 
·-·aking in early hour;j of the morning and 
unable to tall asleep again 
Work and Interests 
Feelings of incapacity 
Listlessness, indecision and vacillation 
A. lWrliLTOB BATING SCALE OF DEPRESSION oontd. 








Work ap4 Interests contd. 
Loss ot . interest in hobbies 
Decreased social activities 
Productivi~ decreased 
Unable to work 
·Stopped working because ot present 
illness only •••••••••••••••• 4 
(Absence from work after treatment or 
recover, ma7 rate a lower score.) 
Reta£dat1op 
Slowness of thought, speech, and aotivit7 
Apat~ 
Stupor 
Slight retardation at interview... 1 
Obvious re~ation at interview •• 2 
Interview difficult•• ••••• •••••••• 3 
Complete stupor••••••••••••••••••• 4 
Agipt10B 
Restleaaneaa aaaooiated with anxiety 
Anxietz, psxchio 
Tension and irritability 




Gas trointestinal, wind, indigestion 
Cardiovascular, palpitations, headaches 
!~e s.tJ i.ra tory, genito-urinary, etc. 
Somatic Symptoms, Gastrointestinal 
Loss of appetite 
Heavy feelings in abdomen 
Constipation 
A. lW!ILTOlf RATING SCALE OF DEPRESSION oontd. 














Soptio SYJ!i)toy, General 
Heaviness in limbs, back, or head 
Diftaae baCkache 
Loss of energy and fatieu&bility 
Genital SzaptQ!! 




Preoccupation with health 
Querulous at'ti~de 
Hypochondriacal delusions 
Lost of We1sht 
Insighl 
Lose ot insight ••••••••••• 2 
Partial or aoubti'ul loss •• 1 
No los•••••••••••••••••••• 0 
(Insight must be interpreted in terms of 
patient's understanding and baCkground) 
Diurpal Variation 
Symptoms worse in morning or evening 
Note which it is 
Depersonalization ana Derealization 
Feelings of unreality ~ 
Nihilistic ideas ' Specify 
Paranoid Symptoms 
Suspicious 
Ideas of reference 




Bot with a 
depressive 
quality 
Obsessive thoughts and compulsions, against 
which the patient struggles 
B. HAKILTON RATING SCALE OF ANXIETY 
All items are rated from 0-4 in severity~ 
It.. Symptom No. 
1 Apxiou.s m.ood 
Worries 





Feelings of tension 
Fa tiguab ili ty 
Inability to relax. 
Startle response 
Koved to tears eaail7 
~mbling 




Being left alone 








Difficulty in falling aalee~ 
Broken sleep 
Unsatisfying sle~p and 




Loss ot interest 






(mu.soular and sensory) 




Grinding ot teeth 
Unsteacl7 voice 
Tinnitus 
Blurring of vision 
Hot and cold flushes 





Pain in cheat 
Throbbing of vessels 
Fainting feelings 
Missing beat 
Nightmares 9 Respiratory symptoms 
Night terrozos 















Difficulty in swallowing 
Will4 
Dyspepaia·a 








•working' in abdomen 
BorboeySQd 
Loosen••• of bowels 
Loss of weight 
Constipation 
11 GepitQ=!£iparx sxmptoss 
Frequency of micturition 
Urgency of micturition 
Amenorrhea 
Menorrhagia 
Development of frigidity 
Ejaculatio praecox 
Loaa of erection 
Impotence 
12 Autonoffiic s,tsptoms 
Dry mouth 
Flushing 
- PaU . .Jr 
Tendency to sweat 
Giddiness 
Tension headache 





Behaviour at interview 







Treaor of banda 
Furrowed brow 
Strained taoe 















1 pmol/1 ~ 0.204 H/'lll 
1 pmol/1 ~ 0.0270 ng/100 Ill 
1 pmol/1 ~ 0.0272 ng/100 ml 
1 IU/1 ~ 0.0.50 . ng/ml 
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Reprinted from P ROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE, November 1976, Vol. 69, 
No. 1 1, pp. 829-830 (Section of Psychiatry, pp. 17-18). 
Double-Blind Study on the effect of 
<Estrogen on Sleep, Anxiety and 
Depression in Perimenopausal 
Women: Preliminary Results 
by Joan Thomson MB MRCPsych 
( U11iversity Departme11i o/Psychiatry, 
Morningside Park , Edinburgh, EH 10 5HF) 
I report preliminary results of a double-blind, 
controlled study of the effect of <l!Strogen therapy 
on the symptoms of insomnia, anxiety, depression 
and hot flushes in perimenopausal women. 
Surveys carried out by Ballinger ( 1975), 
Jazman et a/. ( 1969) and Thompson et a/. (1973) 
have shown that these symptoms are very common 
about the time of the menopause. Hot flushes are 
believed to be due to <l!Strogen deficiency, but the 
cause of the other symptoms remains obscure. 
Feinberg et a/. ( 1967) found that older people 
have more broken sleep, which may account for 
the complaint of sleeplessness. Possible causes of 
the psychological symptoms associated with the 
menopause include the social changes of middle 
age. fear of ageing and of loss of att ractiveness. 
and restrogen deficiency. 
McKinlay & McKinlay ( 1973) reviewed studies 
of the effect of <l!strogen therapy on menopausal 
symptoms but could draw no firm conclusions 
because of differences in age groups studied, and 
difficulties in assessment of change. There is no 
agreement on which symptoms can be included in 
the menopausal syndrome. or as to when it 
occurs. A further problem is the pronounced 
placebo effect. which may last for several months 
(Coopeetal. 1975, Donovan 1951). 
Method 
Sixteen women, aged 45- 55, with at least three 
months' amenorrhrea, and symptoms of hot 
!lushes, anxiety, depression and insomnia were 
.udied. The aim is to complete the study on 40. 
Juitable patients who were not receiving any 
medication were referred by local general prac-
titioners. The study lasted for fourteen weeks. 
T>atients were paired, one serving as a control for 
the effects of time, placebo, and attention from 
tl-te researchers. Both patients received a placebo 
for the first six weeks of the study, and one 
recei'ved piperazine <l!Strone sulphate (H armogen) 
in a dose of 3 mg per day for the remaining eight 
weeks, while the control patient remained on 
placebo. All patients were told they might be 
given an inert pill. 
Patients attended the sleep laboratory one 
night per week for electrophysiological recording 
of sleep. The first two nights were for adaptation 
purposes only, the next four for gathering base-
line data and the next four were during the 
transition period , while restrogen intake became 
established ; the remaining four were in the final 
month. The sleep records were scored according 
to international criteria (Rechtschaffen & Kales 
1968). Patients rated their sleep quality, mood and 
anxiety daily using 100 mm visual analogue 
scales, and also noted the number of hot Rushes 
they had each day. Observer rating scales of 
anxiety (Hamilton 1959) and depression (Hamil-
ton 1960) were completed at the beginning and 
end of the baseline placebo period, at the end of 
the transition period, and the end of the final 
month. 
Patients also attended one extra night in the 
baseline period and one in the final month for 
blood studies. On these nights electrophysio-
logical recording of sleep was carried out; in 
addition, blood samples were taken at 20 minute 
intervals through an indwelling cannula (Ogun-
remi et at. 1973). Blood was centrifuged im-
mediately and the plasma stored at - 20"C. Each 
sample was assayed for restrone, ccstradiol, free 
and total plasma tryptophan, and prolactin. 
Results 
Sixteen people so far have completed the trial. 
Seven others dropped out in the first week, and 
two more left because of taking tranquillizers. 
2 Proc. roy. Soc. Med. Volume 69 November 1976 
The placebo group (n =8) had a mean age of 
48.8, and the restrone group (n = 8) had a mean 
age of 50.1. In each group the1 e were 3 women 
with amenorrhrea lasting between three and 
twelvemonths, 3 with 2- 5 years' amenorrhrea, and 2 
who were more than five years post-menopausal. 
Both groups showed a decrease in the numbers 
of hot flushes, but there was no significant 
difference between the two groups. At the present 
preliminary stage, subjective measures of mood, 
anxiety and sleep quality have failed to show a 
significant difference between the two groups, 
and only objective measures of sleep have shown 
a significant difl'erence. No significant difrerence 
between the baseline placebo period <:nd transi-
tional period was found. Comparing. however, 
the baseline period and the final month, there 
was a mean increase in sleep duration of 24.1 ± 
7.7 min in the restrone group. The placebo group 
bad a mean increase in sleep duration of 3.7± 
5.2 min. Using a Student's t test the difference 
between the two groups is significant (t ~"2.2, 
P < 0.04). An 1-tailed test was used , since this 
change had been predicted . 
When comparing the brokenness of sleep in 
the baseline period and the final month, inter-
vening wakefulness (the amount of time spent 
awake between first going to sleep and the time 
when a total of 6 hours' sleep had been accumu- · 
lated) was decreased by 9.6± 4.4 min in the 
restrone group. The placebo group showed an 
increase of 0.5 ± 3.2 min in intervening wakeful-
ness. The difference between the two groups is 
j ust short of statistical significance (t = 1.86, 
P = 0.052). 
The analysis o f the blood samples is not yet 
complete. Three nights' samples of different 
subjects have been assayed for restrogens and 
free and total plasma tryptophan. A significant 
positive correlation between total plasma restro-
gen concentration and concentration of free 
p lasma tryptophan, and a lso between total 
restrogen concentration and percentage free 
plasma tryptophan, has been found in all cases 
(to be published elsewhere). 
Discussion 
These results do not so far show that a:strogen is 
significantly better than placebo in rel ieving 
depression, anxiety and hot flushes in peri-
menopausal women. This may be due to the small 
numbers studied o r to the pronounced placebo 
effect on menopausal symptoms (Coope et a!. 
1975, Donovan 1951). 
We have shown that restrogen produces a 
s ignificant increase in sleep duration, and a 
decrease in intervening wakefulness in the fi rst 6 
hours of s leep that borders on statistical signifi-
cance. We have also found a significant positive 
18 
correlation between plasma restrogen concentra-
tion and free plasma tryptophan levels. The level 
of free plasma tryptophan has been showh to 
affect the rate of synthesis and turnover of 
serotonin in the brain (Fernstrom & Wurtman 
1971, Gessa eta/. 1972, Knott & Curzon 1972). 
T here is evidence from animal studies (Jouvet 
1969) that cerebral serotonin is involved in the 
maintenance of sleep. It is possible that insomnia 
in menopausal women is due to fall ing cestrogen 
levels producing a fall in free plasma tryptophan, 
which then influences cerebral serotonin metabol-
ism. The increase in sleep duration with therapy 
may be due to exogenous restrogen causing an 
increase in free plasma tryptophan. 
Coppen eta/. (1972) reported that free plasma 
tryptophan levels were low in depressed women, 
but other workers (Niskanen et a/. 1976, Peel 
et a/. 1976) have produced conflicting results. 
Aylward (1973) found that free plasma tryptophan 
concentrations were low in depressed meno-
pausal women, but that restrogen therapy both 
relieves the depression and increases the free 
plasma tryptophan levels. The possibili ty that 
free plasma tryptophan concentration falls in 
parallel with rest rogen levels at the time of the 
menopause, and that this causes the depression 
which is so common at this time, requires further 
investigation. 
Acknowledgment: I am grateful to Mrs M Gray 
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and to Abbott Laboratories for their support. 
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Effect of oestrogen on the sleep, 
mood, and anxiety of 
menopausal women 
JOAN THO~SON, IAN OSWALD 
/Jri1ish ,\lfdir<Jl } ournal, 1977,2, 1317-1319 
Summary 
A double-blind controlled study of the effect of piperazine 
oestrone sulphate on sleep, depression, anxiety, and hot 
flushes was performed in 34 perimenopausal women. 
Half of the patients were given six weeks' placebo followed 
by eight weeks' oestrogen, and half remained on placebo 
throughout. Sleep was recorded electrophysiologically 
every week, and mood and anxiety were rated daily by 
means of visual analogue scales. Hot flushes were 
counted daily. Observer rating scales of anxiety and 
depression were completed at intervals. 
During the first month of active treatment the amount 
of intervening wakefulness in the first six hours of sleep 
decreased significantly more in the oestrone group than 
in those on placebo. Between the baseline period and the 
second treatment month the oestrone group showed a 
significantly greater decrease in the total amount of 
intervening wakefulness and in the frequency of awaken-
ings. Their total amount of rapid eye movement sleep 
increased. Mood and anxiety improved and the number 
of hot flushes decreased to a similar degree in both 
groups. 
Although oestrogen did reduce the number of episodes 
of wakefulness in perimenopausal women complaining 
of insomnia, its effects on their psychological symptoms 
were little different to those of placebo. 
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Introduction · 
The perimenopausal period has long been considered to be a time 
of increased morbidity, and various epidemiological surveys1• 3 
have shown that complaints of hot flushes, insomnia, depression, 
and anxiety are especially common at this time. The symptoms 
may be due to hormonal changes, but it is also possible that the 
psychological symptoms might be due to fear of aging or to the 
social changes of middle age. }aszman' and Ballinger• have 
inferred that insomnia is due to hormonal changes, since their 
surveys have shown that the incidence of the complaint rises as 
oestrogen levels fall in the perimenopausal period. Other 
possible causes are aging, anxiety, and depression, all of which 
arc associated with sleep disturbance. •· ' 
Hormone replacement therapy has been used to treat meno-
pausal symptoms since 1896 but remains controversial. McKinlay 
and McKinlay" reviewed the many studies of hormone replace-
ment therapy but found that results were conflicting and that 
studies lacked consistency in defining the menopause, the 
symptoms associated with it, and the age group to be studied. 
W c therefore carried out a double-blind controlled study of the 
effect of oestrogen therapy on sleep, mood, anxiety, and hot 
flushes in perimenopausal women. 
Patients and methods 
Patients were referred by local general practitioners. All were aged 
45-55 and had had amenorrhoea for at least three months and symptoms 
of insomnia, depression, anxiety, and hot flushes. They received no 
other medication, had no contraindications to oestrogen therapy, and 
were asked to abstain from alcohol for the duration of the study. 
Each patient was studied for 14 weeks, and throughout this time 
they attended the sleep laboratory in pairs on one night each week for 
electrophysiological recording of sleep. In the first six weeks all 
patients received a placebo. In the remaining eight weeks one of each 
pair received piperazine oestrone sulphate in a dose of 1·5 mg twice 
daily while the other remained on placebo. All patients were warned 
that the pills they received might be blanks. 
The first two nights spent in the sleep laboratory were for adaptation 
purposes only, and the next four were for baseline recordings. The 
subsequent four nights were in the first treatment month and the final 
four in the second treatment month. Ultimately the sleep records were 
scored blind according to standard criteria. t 
Each day throughout the study patients rated their mood and 
anxiety, using 100-mm visual analogue scales, and they noted the 
number of hot flushes they experienced. Hamilton observer rating 
scales of anxiety'" and depression" were completed at the beginning 
and end of the baseline placebo period, at the end of the first treatment 
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month, and at the end of the second treatment month. 
Statistics-Intragroup changes in the different periods of the experi-
ment were compared by t tests for paired otservations. The changes 
between the baseline period and first treatment month and between 
the baseline and second treatment month were also examined for 
each group, and the magnitude of change in the two groups was then 
compared using Student's t test. A one-tailed test was used for inter-
vening wakefulness and frequency of arousals, which we had predicted 
would decrease with oestrogen treatment, and a two-tailed test in all 
other cases. 
Results 
Thirty-four patients completed the study. Eight others had started 
but failed to complete the study, seven dropping out in the first week, 
and one in the eighth week because of urinary tract infection. The 
mean age was 49·7 years in the oestrogen group (n = 17) and 48·5 years 
in the placebo group (n = 17). The two groups were comparable in 
terms of menstrual age. 
SLEEP DURATION 
The duration of sleep increased in both groups. In the oestrogen 
group mean sleep duration ( ± SE) increased from a baseline value of 
423·2 ±8·2 minutes to 442·2± 7·7 minutes in the first treatment month 
(t = 3· 305; P < 0·0 I) and rose to 446·5 ± 7 ·2 minutes in the second 
treatment month (t = 2·939; P < O·Ol). In the placebo group the 
increase from the baseline duration of 418·2 ± 7·2 minutes to 424·3±8·2 
minutes in the first treatment month was not significant, but the 
increase from the baseline value to 429·4 ± 7·2 minutes in the second 
treatment month was significant (t"' 2·735; P < 0·02). The difference 
between the two groups was not significant. 
INTERVENING WAKEFULNESS 
A measure of the brokenness of sleep is provided by the amount of 
time awake that intervenes between periods of sleep. Comparing the 
baseline period and the first treatment month, the oestrone group 
showed a decrease in the amount of intervening wakefulness during 
the whole of sleep of 14·4±5·1 minutes, and the placebo group 
showed a decrease of 4·7 ±4·5 minutes. The difference between the 
two groups was just short of significance (t = 1·454). In the second 
treatment month the oestrone group had 15·8 ± 5·8 minutes less 
intervening wakefulness than in the baseline period and the placebo 
group 2 ·1 ±2·2 minutes less. The difference between the two groups 
was significant ( r = 2·176; P < 0·025). 
4 
The oestrone-treated group also woke less often. In the second 
treatment month they showed a decrease in the number of arousals 
from sleep to wakefulness of 0·9 ± 0·4 compared with the baseline 
period, whereas the placebo group showed a small mean increase of 
0·1 ±0-4. The difference between the two groups was significant 
(t= 1·717; p < 0·05). 
The results were also analysed in terms of the first six hours of 
accumulated sleep to keep the sleep duration constant among subjects 
and nights. The mean cumulative intervening wakefulness in the first 
six hours of sleep in oestrone and placebo groups is shown in fig 1. 
The mean value during the baseline period was higher in those who 
later received oestrone, but not significantly so (t = 1·140; NS). 
Between the baseline period and first treatment month the oestrone 
group showed a decrease in intervening wakefulness of 17·2±6·6 
minutes and the placebo group a decrease of 2·6 ±4·6 minutes 
(. = 1·816; P < 0·05). When the baseline value was compared with that 
in the second month of treatment the oestrone group showed a 
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fiG 1-Mean cumulative wakefulness intervening during accumulation of 
first six hours of sleep in oestrone and placebo groups in baseline period, 
first treatment month, and second treatment month. 
decrease of 18·0±7·3 minutes and the placebo group a decrease of 
only 1·0 ±2·4 minutes, the difference between the two groups again 
being significant (I= 2·205; P < 0·025). 
The number of arousals to wakefulness in the first six hours of 
sleep in the two groups is shown in fig 2. The oestrone group showed 
a decrease in the number of awakenings of 1·1 ±0·5 between the 
baseline and second treatment months, while the placebo group 
showed an increase of 0·2 ±0·3. The difference between the two 
groups was significant (t = 2·260; P < 0·025). 
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FIG 2-Cumulativc mean number of awakenings in first six hours of sleep in 
o<!strone and placebo groups in baseline period, first treatment month, and 
second treatment month. 
SLEEI' STAGES 
The total amount of rapid eye movement (REM) sleep in the 
oestrone group increased throughout the study. Between the baseline 
month and first treatment month the difference between the groups 
was not significant, but between the baseline and second treatment 
months the oestrone group showed an increase in REM sleep of 
13·3±4·7 minutes and the placebo group of 2·3±2·0 minutes: the 
difference between the groups was significant ( t "" 2·184; P < 0·05). 
There was no increase in REM sleep in the first six hours of sleep in 
either group. . 
No significant changes in stage l , stage 2, or slow-wave sleep were 
observed. 
MOOD 
Both oestrone and placebo groups showed an improvement in mood 
throughout the study, as shown by Hamilton rating scales and visual 
analogue scales. The mean Hamilton depression score of the oestrone 
group was 16·3 ± 1·9 atthe start of the study, 7·9 ± 1·2 at the end of the 
baseline period, 7 · 3 ± 1· 3 at the end of the first treatmen~ month, and 
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5·9 ± 1·8 at the end of the second treatment month. Over the same 
period the scores of the placebo group fell from 18·2 ± 2·0 to 10·1 ± 1·5, 
to 6·2±1·3, and finally to 4·5±0·7. 
In both groups the difference in values between the start and end of 
the baseline period was significant (oestrone group: 1 = 4·465, P < 0·00 I ; 
placebo group: z = 6·125; P < 0·001). In the placebo group there was a 
significant decrease from the end of the baseline period tO the end of 
the first treatment month (1= 2·810; P < 0·02) and to the end of the 
second treatment month ( I = 3·301; P < 0·01), but in the oestrone 
group these changes did not reach significance (1 = 0·997 and 1·552). 
There were no significant differences between the two groups. 
ANXIETY 
Both oestrone and placebo groups showed a steady improvement in 
anxiety as measured by Hamilton anxiety rating scales and visual 
analogue scales throughout the study. The Hamilton anxiety score of 
the oestrone group fell from 17·2 ± 1·8 at the start of the study to 
9·7 ± 1·3 at the end of the baseline period, 7·7 ± 1·2 at the end of the 
first treatment month, and 5·6 ± 1·4 at the end of the second treatment 
month. The scores of the placebo group fell from 20·1 ± 2·1 to 
11·4±1·3, to 6·5±1·1, and to 5·4±0·7 at the end of the study. 
In both groups the difference in values between the start of the 
study and the end of the baseline period was significant (oestrone 
group: 1=5·455, P < O·OO l ; placebo group: 1=5·605, P < O·OOl ). The 
decrease from the end of the baseline period to the end of the first 
treatment month was significant for the placebo group (1 = 4· 363; 
P < 0·001) but not for <he oestrone group (1 = 1·748), and the decrease 
from the end of the baseline period to the end of the study was 
significant in both groups (oestrone group: 1 = 3·422, P < 0·01; placebo 
group: 1 = 4· 348, P < 0·001 ). There were no significant differences 
between the two groups. 
HOT FLUSHES 
The mean hot flush count of both groups fell steadily throughout the 
study, from a mean of 14·4±4·4 pP.r week at the outset to 8·:>±3·3 in 
the 14th week in the placebo group and from 13·3±3·6 to 5·9±2·2 in 
the case of the oestrone group. There were no significant differences 
between the two groups. 
Discussion 
We have shown that oestrogen treatment diminishes the 
number and duration of episodes of wakefulness that interrupt 
sleep in perimenopausal women complaining of insomnia. The 
patients treated with oestrogen also showed an increase in the 
duration of sleep, but this did not reach significance when 
oestrone and placebo groups were compared. The increase in 
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REM sleep shown by the oestrogen group in the second treat-
ment month was probably due to the increase in sleep duration, 
since no changes in REM sleep were found in the first six hours 
of sleep, and it is known that REM periods become more 
frequent and prolonged towards the end of the night. 
We have previously reported a highly positive correlation 
between nocturnal plasma oestrogen and free plasma tryptophan 
concentrations in perimenopausal women,'~ and Aylward" has 
reported that oestrogen treatment increases free plasma trypto-
phan concentrations in perimenopausal women. Free plasma 
tryptophan is the precursor of the cerebral neurotransmitter 
serotonin, and Jouvet•• has proposed that serotonin depletion 
by pharmacological means leads to insomnia. Falling oestrogen 
levels at the time of the menopause may lead to a fall in free 
plasma tryptophan concentrations, which is reversed by 
oestrogen therapy, and the effect of oestrogen in sleep may be 
mediated through changes in plasma tryptophan influencing 
cerebral serotonin metabolism. 
We found that depression, anxiety, and hot flushes in these 
perimenopausal women responded strongly to placebo. Donovan" 
reported that in 95°, of cases menopausal symptoms could be 
relieved by history-taking alone, while an injection of saline 
relieved symptoms in the remainder. Pratt and Thomas'6 also 
observed a pronounced placebo effect in their blind controlled 
study and found no significant difference between oestrogen 
and placebo in relieving either physical or psychological symp-
toms. 
Subjective rating methods for measuring such factors as mood 
are less precise and less suitable for studying small groups than 
the objective, electrophysiological measures. This may have 
contributed to our failure to find that oestrogen was significantly 
more effective than placebo in relieving depression and anxiety 
in menopausal women. Our findings contrasted with those of 
Aylward,' 3 who found in a double-blind study using the same 
dose and type of oestrogen that we used that oestrogen did 
relieve depression. His patients, however, had undergone 
oophorectomy and may therefore have differed from women 
who have experienced a physiological menopause, since the 
postmenopausal ovary secretes androgenic hormones.'' 1 • 
Utian•• and George et al"" also carried out controlled studies of 
the effect of conjugated equine oestrogens on the psychological 
symptoms of women who had undergone oophorectomy. Urian 
reported that oestrogen had a mental t<>nic effect, but George, 
who used a smaller dose of oestrogen, found that oestrogen was 
not significantly more effective than placebo in relieving 
psychological symptoms and suggested that the mental tonic 
effect might be dose-related. 
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We found a marked placebo effect on hot flushes, similar to 
that described by Coope ez a/~' and Pratt and Thomas," and it 
was not possible to predict on the basis of changes in hot flush 
count or severity which patients were receiving oestrogen 
therapy. 
In conclusion, whereas we found only placebo effects on 
depression, anxiety, and hot flushes, oestrogen treatment 
produced an objective decrease in the brokenness of sleep in 
perimenopausal women complaining of insomnia. 
We thank the many local general practitioners for their help in 
referring patients; our colleague, Kirstine Adam, for her help; Mrs 
M Gray for technical help; and Abbott Laboratories Ltd for their 
support. 
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The secretion of several hormones increases during the night and this is sometimes 
due to a circadian rhythm (e.g. corticosteroids) and sometimes contingent on sleep 
(e.g. growth hormone, prolactin). It has been postulated that sleep is a time that 
facilitates growth and restorative processes. Growth hormone secretion during sleep 
is increased when greater restorative processes may be presumed, e.g. after exercise 
or sleep deprivation. Luteinizing hormone and testosterone are sleep-dependent at 
the time of puberty. A study is currently being carried out to investigate the re-
lationship between sleep and oestrogen at the menopause. A double-blind, controlled 
study of the effect of piperazine oestrone sulphate (1 .5 mg b.d.) on sleep, mood, 
anxiety levels and hot flushes in menopausal women is described. Preliminary results 
on 16 subjects show a significant increase in sleep duration in patients on oestrogen 
(p<0.04) with a decrease in intervening wakefulness on the border of significance 
(p<0.06). Blood studies during sleep show a highly significant positive correlation 
between total plasma oestrogen concentration (unconjugated oestrone and oestradiol) 
and both free plasma tryptophan concentration and % free plasma tryptophan. 
This suggests a means by which plasma oestrogen may influence cerebral serotonin 
metabolism, and hence mood, in menopausal women. 
Key words: Piperazine oestrone sulphate - sleep - menopause 
Introduction 
Bodily functions change during sleep and since the central nervous system and the 
endocrine system always co-operate in the regulation of bodily function, it is not 
surprising that sleep has many relationships with the endocrines. The relationships 
between sleep and hormones are studied by sampling blood during sleep. Electrodes 
attached to the head are used to record brain electrical rhythms, muscle tone and eye 
movements. A catheter is inserted into the forearm vein before the patient or volun-
teer goes to bed and an extension to the catheter passes through the bedroom wall and 
allows blood samples to be taken through the night without disturbing the sleeper. 
The levels of many hormones rise at night. In some cases the24-hourriseandfall is 
a manifestation of a circadian rhythm and is not dependent on sleep. Corticosteroids, 
for example, rise towards the end of the night, whether the individual has slept or 
been kept awake. However, in 1968 Japanese workers showed that there was 
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increased secretion of human growth hormone during the night14,28 and this rise is 
dependent on sleep. 25 Sleep-dependent secretion does not take place at the usual time 
if the individual stays awake but instead is delayed until he has gone to sleep. 
Growth hormone increases the rate of synthesis of protein and enhances the 
burning of fat as fuel, so sparing amino acids. The sleep-dependent rise in growth 
hormone lends support to the view that sleep enhances growth and restorative 
processes., Re-growth of skin occurs especially during the sleep period in humans1 0 
and the mitotic index has been reported to rise during the sleep period in a wide 
variety of the ectodermal tissues of rodents which sleep during the day and are awake 
at night. In other ectodermal tissues in which mitoses do not occur, such as the brain, 
there is greatly increased protein synthesis during sleep.21 The same is true of meso-
dermal tissues such as muscle22 and cartilage.27 Endodermal tissues also show more 
mitoses during the sleep period, gastric epithelium being an example. 6 
In man, the metabolic conditions peculiar to sleep mean that growth hormone is 
more effective in promoting protein synthesis if given at the beginning of sleep. 
Rudman eta!. 23 showed that nitrogen retention, an index of protein synthesis, was 
significantly greater when growth hormone was injected just prior to sleep than when 
it was injected in the morning. The secretion of growth hormone is greater under 
conditions when greater restoration is needed. Thus, monkeys deprived of sleep for 
3 days and nights secrete significantly more growth hormone when they are allowed 
to sleep.15 At Edinburgh, it was demonstrated that heavy exercise during the day 
significantly increases the secretion of nocturnal growth hormone. 2 Other hormones 
have since been found to be sleep-dependent for their main secretion of the 24 hours. 
The large nocturnal secretion of prolactin is sleep-dependent24 and children in early 
puberty secrete more luteinizing hormone and more testosterone duriDg their sleep. 4 
The brain electrical rhythms of sleep can be categorized into stages, and it has 
been observed that the stage in which growth hormone is secreted - Stage 4 or slow 
wave sleep- is enhanced under conditions when one could expect a greater need for 
restorative processes. Whereas Stage 4 sleep is absent in hypothyroid middle-aged 
patients, a group of hyperthyroid patients studied at Edinburgh had abnormally 
large amounts of Stage 4 sleep.e A further example of the interaction between 
hormone status by day and sleep by night is provided by the findings of Johns 
et al., 17 who studied the day-to-day fluctuations in thyroxine secretion and found 
that after days when normal men had higher thyroxine secretion they had more 
Stage 4 sleep at night. 
Recent work at Edinburgh has been designed to see whether there are other 
connections between hormone status, sleep and the menopause. The menopause is 
associated with a decline in oestrogen production, and also with a high incidence of 
insomnia. Jaszmann et a/.16 surveyed 2933 women aged 40 to 60 years, and found 
that 20% of pre-menopausal women complained of insomnia, rising to 40% 2 to 5 
years after the menopause, and falling to 30% 10 years after the menopause. Sherman 
et a/.26 found that oestradiol levels fall before the menopause, while Chakravarti 
eta/. 5 found that oestrogen levels fell to 20% of normal levels within I year of the 
menopause, remaining low for 10 years but rising thereafter. This suggests a relation-
ship between oestrogen levels and insomnia. However, other causes of insomnia have 
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been suggested. Thompson et a/. 29 suggested that insomnia at the menopause may 
be due to night sweats. Williams et a/.31 showed that there is an increase in the fre-
quency and duration of episodes of wakefulness in the sleep of older people, and 
this may contribute to the insomnia of post-menopausal women. The insomnia may 
also be due to depression or anxiety, which are common symptoms at this stage 
in life. 
Oestrogens and sleep at the menopause 
To determine the relationship between oestrogens and sleep at the menopause, we 
are currently conducting a double-blind controlled trial of the effect of oestrogen 
therapy on the sleep, mood and anxiety levels of menopausal women. Local general 
practitioners refer suitable patients, who must be aged 45 to 55 years old, with at 
least 3-months' amenorrhoea and symptoms of insomnia, hot flushes, anxiety and 
depression. They should not be on any other medication, and must abstain from 
alcohol throughout the study. Patients with a history of jaundice, malignancy and 
thrombo-embolic phenomena are excluded. A total of 40 patients will be studied. 
The study lasts 14 weeks for each patient. The first 6 weeks are termed the base-
line period, when all patients are on placebo. The next 4 weeks are termed the 
transition period, and the remaining 4 the final month. Patients attend the sleep 
laboratory in pairs. For the first 6 weeks both take a placebo, but during the transi-
tion period and final month, one of the pair receives piperazine oestrone sulphate 
in a dose of 1.5 mg b. d. The other patient remains on placebo throughout, to control 
for the effect of time, placebo, and the attention of the researchers. All are warned 
that the pills may be blanks. 
Patients attend the sleep laboratory I night per week for electrophysiological 
recording of sleep. The first 2 nights are for adaptation purposes only, the next 4 
are in the baseline period, the next 4 in the transition period, and the remaining 4 
in the final month. The sleep records are scored according to international criteria. 2o 
Patients rate their sleep quality, mood and anxiety daily using 100 mm visual 
analogue scales, and also note the number of hot flushes they have had each day. 
Observer rating scales of anxiety1 2 and depression 1 3 are completed at the beginning 
and end of the baseline placebo period, at the end of the transition period, and the 
end of the final month. 
The study has not yet been completed. The results of 16 patients have so far been 
analysed. The oestrone group (n=8) had a mean age of 50. I years, the placebo 
group (n= 8) had a mean age of 48.8 years. In each group there were 3 patients with 
amenorrhoea lasting between 3 and 12 months, 3 patients with 2 to 5 years of 
amenorrhoea, and 2 patients who were more than 5 years post-menopausal. 
Both groups showed a steady improvement in sleep quality, mood and anxiety 
levels, and a fall in the number of hot flushes. At this early stage there is no signifi-
cant difference between the two groups in respect of such symptoms. At present, 
only objective measures of sleep have shown a significant difference between the 
two groups. 
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No significant difference between the baseline period and the transition period 
was found. However, comparing the baseline period and the final month, the 
oestrone group showed a mean increase in sleep duration of 24.1 ± 7.7 min. The 
placebo group had a mean increase of 3.7 ± 5.2 min. Using a Student's t-test the 
difference between the two groups is significant (t= 2.2, p<0.04). A one-tailed t-test 
was used since this difference had been predicted. 
A measure of the brokenness of sleep, or intervening wakefulness, is the amount 
of time spent awake between going to sleep and accumulating 6 hours of sleep. 
The oestrone group showed a mean decrease of intervening wakefulness of 9.6 
±4.4 min between the baseline period and the final month. The placebo group 
showed a mean increase of 0.5 ±3.2 min in intervening wakefulness in the same 
period. The difference between the two borders on significance, t= 1.86, p = 0.052. 
Patients may also attend the sleep laboratory for blood studies on 2 extra nights, 
1 in the baseline period and 1 in the final month. Sleep is recorded as usual on those 
nights, and blood samples are taken at 20 min intervals throughout the night. 
Blood samples are centrifuged immediately and plasma stored at - 20°C. Each 
sample is assayed for oestrone, oestradiol, free and total plasma tryptophan, 
prolactin and magnesium. Three night samples of different subjects on placebo 
have been analyzed so far. A significant positive correlation between total plasma 
oestrogen concentration (unconjugated oestrone+ oestradiol) and free plasma 
tryptophan concentration, and also between total oestrogen concentration and 
percentage free plasma tryptophan has been found.3o 
The relationship between plasma oestrogen concentration and free plasma tryp-
tophan provides a link between oestrogens in plasma and cerebral serotonin meta-
bolism. The concentration of free plasma tryptophan has been shown to affect the 
rate of synthesis and turnover of serotonin in the brain. 9.11 •19 Jouvet1B has pro-
posed that cerebral serotonin is concerned in the maintenance of sleep and, if so, 
falling oestrogen levels at the menopause might produce insomnia by decreasing 
free plasma tryptophan concentration and thus influencing brain serotonin meta-
bolism. The increase in sleep duration, and decrease in intervening wakefulness, 
could then be due to oestrogen therapy reversing this fall in free plasma tryptophan 
levels. Coppen et a/. 7 have reported a fall in free plasma tryptophan in depressed 
women and Aylward3 has reported that oestrogen therapy both increased free 
plasma tryptophan levels and relieved depression in menopausal women. The 
possibility that falling levels may cause depression by producing a parallel fall in 
free plasma tryptophan levels requires further investigation. 
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Discussion 
Dr. S. Contractor (Choring Cross Hospital, London): There is another possible explanation, isn't 
there, of the mechanism of action of oestrogen on sleep and that is that oestradiol is known to act 
on the tryptophan -xanthurenic acid pathway and, therefore, it may be removing the tryptophan 
available for your SHT pathway. 
Dr. J. Thomson: That is a possible explanation, but it really needs further investigation. 
Dr. M. Aylward (Giamorgan, S Wales): May I make a comment on the last suggestion. In fact, 
oestradiol or oestrone administered to menopausal patients do not increase the excretion of 
tryptophan metabolites in urine. It is unlikely, therefore, that the data quoted by Dr. Thomson 
could be explained by induction of hepatic tryptophan metabolizing enzymes by oestrogens. 
©1977. Clayton-Wray Publications Limited. Reproduction of this paper in whole or in part is not 
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RELATIONSHIP BETWEEN NOCTURNAL PLASMA OESTROGEN CONCENTRATION 
AND FREE PLASMA TRYPTOPHAN IN PERIMENOPAUSAL WOMEN 
JOAN THOMSON, J. MADDOCK*, M. AYLWARD* AND I. OSWALD 
University Department of Psychiatry, Royal Edinburgh Hospital, /::,ainburgh, EHJO 5HF, 
and *Simbec Research Laboratory, Cefn Coed, Merthyr Tydji'l, Mid_-Glamorgan, CF48 2PH 
(Received 12 July 1976) 
~ study of the relationship between nocturnal endogenous plasma oestrogen and free plasma 
ryptophan levels in perimenopausal women is reported. The study was approved by the Royal 
:din burgh Hospital Ethics Committee, and all subjects gave informed consent. 
The three subjects in the study had symptoms associated with the climacterium, including 
tot flushes, insomnia, and depression. Case I was 5 years post-menopausal, Case 2 hact 
:months amenorrhoea, and Case 3 had only 6 months amenorrhoea. 
Blood was sampled during sleep from 22.30 to 07.00 h at 20 min intervals by means of an 
~dwelling catheter as described by Ogunremi, Adamson, Brezinova, Hunter, MacLean, Oswald 
~ Percy-Robb (I 973). It was centrifuged immediately and the plasma deep frozen. 
Total plasma tryptophan was measured by the method of Wapnir & Stevenson (I 969). 
'lasma was centrifuged in Centriflo membrane cones (Ami con Ltd) for 30 min at 1000 g and 
ree plasma tryptophan assayed in the ultrafiltrate as described by Wapnir & Stevenson (I 969) 
nd Denckla & Dewey ( 1967). 
Oestrogens were extracted from plasma with diethyl ether and separated by LH-20 Sephadex 
olumn chromatography. Oestrone and oestradiol concentrations were then measured by radio-
nmunoassay using standard antisera (New England Nuclear) p repared in sheep against 
estradiol-1713-succinyl-albumin. This has 50% cross-reactivity with oestrone, but since the 
estrogens were separated before assay, each oestrogen could be measured against this same 
ntiserum, using appropriate standards. 
Total plasma oestrogen (unconjugated oestrone+ oestradiol) concentration fluctuated during 
:te night without relation to changes in total plasma tryptophan levels. There was, however, a 
ignificant positive correlation between total plasma oestrogen concentration and the concen-
rat ion of free plasma tryptophan. The correlations between total plasma oestrogen and con-
entration of free plasma tryptophan were: Case 1, r=0·875, P<O·OOl; Case 2, r=0·867, 
<0·001; Case 3, r=0-483,P<0·005. 
The correlations between total plasma oestrogen concentration and % free plasma trypto-
han were higher (see Fig. I): Case l,r=0·997,P<O·OOJ;Case 2,r=0·995,P<0·001;Case 3, 
=0·810, P<O·OOI. There was no correlation between free and total plasma tryptophan 
oncentration in Cases 2 and 3, but for Case 1, r= 0-403, P<0·05. 
The mean plasma oestrogen levels were: Case I , 71·2ng/l; Case 2, 225·9ng/l; Case 3, 
76·7 ng/1. The oestrone: oestradiol ratio in Case I was 3·8: I, in Case 2 was 2·3: 1, and in 
ase 3 was 3·1: 1. The mean free plasma tryptophan concentrat i~ns were: Case 1, 0·90mg/l 
5·6 %); Case 2, I ·83 mg/1 (12·2 %); Case 3, I ·43 mg/1 (1 0·5 %). 
The correlation, for the three women, between mean plasma oestrogen concentration and 
tean % free plasma tryptophan was significant (r=0·9995: n=3, P<0·05). The mean total 
yptophan concentration in Case I was 13·7mg/l, Case 2 was 14·8mg/l, and Case 3 was 
3·4 mg/1. 
We have shown fluctuations in the concentrations of oestrogen and free plasma tryptophan 
1 plasma from perimenopausal women during the night. There was a significant positive 
>rrelation between total oestrogen concentration and concentration and %free plasma trypto-
1an. The majority of tryptophan in plasma is bound to albumin (McNenamy & Oncley, 
396 .lOAN TI!OMSON, J. MADDOCK, M. AYLWARD AND I. OSWALD 
300 (l) 
200 
100 - /X\ 
\ 













'r"',,/~ X X 
23.00 01.00 03.00 05.00 07.00 





Fig. 1. Relationships between nocturnal plasma oestrogen (unconjugated oestrone and 
oestradiol) (X) and% free tryptophan (• ) in three perimenopausal women. 
1958). Oestrogens in plasma bind with high affinity to a specific binding globulin present i1 
low concentrations in plasma, but they can also bind, though with lower affinity, to albumi1 
(Burton & Westphal, 1972). Because of this, it seems likely that the relationship betwee1 
oestrogen concentration and free plasma tryptophan level is due to a direct action of oestro 
gen on the tryptophan binding site of albumin. Since the metabolism of brain serotoni• 
depends partly on the concentration of free plasma tryptophan (Fernstrom & Wurtman, 1971 
Knott & Curzon, 1972; Gessa & Tagliamonte, 1974) these results suggest a possible means b 
which oestrogens might influence cerebral serotonin metabolism and perhaps mood in peri 
menopausal women. 
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